US8221768B2 - Chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence - Google Patents

Chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence Download PDF

Info

Publication number
US8221768B2
US8221768B2 US12/580,080 US58008009A US8221768B2 US 8221768 B2 US8221768 B2 US 8221768B2 US 58008009 A US58008009 A US 58008009A US 8221768 B2 US8221768 B2 US 8221768B2
Authority
US
United States
Prior art keywords
virus
protein
flavivirus
antigen
prm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US12/580,080
Other versions
US20100040643A1 (en
Inventor
Gwong-Jen J. Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centers of Disease Control and Prevention CDC
Original Assignee
Centers of Disease Control and Prevention CDC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/012298 external-priority patent/WO1999063095A1/en
Application filed by Centers of Disease Control and Prevention CDC filed Critical Centers of Disease Control and Prevention CDC
Priority to US12/580,080 priority Critical patent/US8221768B2/en
Assigned to THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION reassignment THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHANG, GWONG-JEN J.
Publication of US20100040643A1 publication Critical patent/US20100040643A1/en
Application granted granted Critical
Publication of US8221768B2 publication Critical patent/US8221768B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the vaccines are recombinant nucleic acids which contain genes for structural proteins of flaviviruses, such as Japanese encephalitis virus (JEV), West Nile virus (WNV) or related flaviviruses. These vaccines serve as a transcriptional unit for the biosynthesis of the virus protein antigens when administered in vivo.
  • the diagnostics are compositions containing antigens produced from the recombinant nucleic acids that can be used to detect flavivirus infection.
  • Flaviviruses are members of the genus Flavivirus , which is classified within the family Flaviviridae. The flaviviruses are largely pathogenic to humans and other mammals. Flaviviruses that inflict disease upon humans and animals include Alfuy, acea, Aroa, Bagaza, Banzi, Batu Cave, Bouboui, Bukalasa bat, Bussuquara, Cacipacore, Carey Island, Cowbone Ridge, Dakar bat, Dengue (serotypes 1, 2, 3 and 4), Edge Hill, Entebbe bat, Gadgets Gully, Iguape, Ilheus, Israel turkey meningoencephalitis, Japanese encephalitis, Jugra, Jutiapa, Kadam, Karshi, Kedougou, Kokobera, Koutango, Kunjin, Kyasanur Forest disease, Langat, Meaban, Modoc, Montana myotis leukoencephalitis, Murray Valley encephalitis, Naranjal, Negishi, Nt
  • the flaviviruses contain the following three structural proteins: prM/M, the premembrane and membrane protein; E, the envelope protein; and C, the capsid protein.
  • prM/M the premembrane and membrane protein
  • E the envelope protein
  • C the capsid protein.
  • M has a molecular weight (MW) of about 7-8 kilodaltons (kDa)
  • E has a MW of about 55-60 kDa.
  • M is synthesized as a larger precursor termed prM.
  • the pr portion of prM is removed when prM is processed to form M protein in mature virions.
  • M and E are located in the membrane of the flavivirus particle, and so have long been considered to constitute important immunogenic components of the viruses.
  • the flaviviruses are RNA viruses comprising single stranded RNA having a length, among the various species, of about 10 kilobases (kb).
  • the C protein with a MW of 12-14 kDa, complexes with the RNA to form a nucleocapsid complex.
  • Several nonstructural proteins are also encoded by the RNA genome which are termed NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5.
  • the genome is translated within the host cell as a polyprotein, then processed co- or post-translationally into the individual gene products by viral- or host-specific proteases ( FIG. 1 ).
  • the nucleotide sequences of the genomes of several flaviviruses are known, as summarized in U.S. Pat. No. 5,494,671. That for JEV is provided by Sumiyoshi et al. ( Virology 161: 497-510 (1987)) and Hashimoto et al. ( Virus Genes 1: 305-317 (1988)).
  • the nucleotide sequences of the virulent strain SA-14 of JEV and the attenuated strain SA-14-14-2, used as a vaccine in the People's Republic of China, are compared in the work of Nitayaphan et al. ( Virology 177: 541-552 (1990)).
  • Nucleotide sequences encoding the structural proteins of other flavivirus species are also known. In many cases, the sequences for the complete genomes have been reported. The sequences available include dengue serotype 1 virus, dengue serotype 2 virus (Deubel et al., Virology 155: 365-377 (1986); Gruenberg et al., J. Gen. Virol. 69: 1391-1398 (1988); Hahn et al.
  • Virology 162 167-180 (1988)
  • dengue serotype 3 virus Osatomi et al., Virus Genes 2: 99-108 (1988)
  • dengue serotype 4 virus Mackow et al., Virology 159: 217-228 (1987), Zhao et al., Virology 155: 77-88 (1986)
  • West Nile virus Lanciotti et al., Science 286: 2331-2333 (1999)
  • Powassan virus Mandl et al., Virology 194: 173-184 (1993)
  • yellow fever virus YFV
  • SLEV St. Louis encephalitis virus
  • WNV St. Louis encephalitis virus
  • JEV JEV
  • West Nile fever is a mosquito-borne flaviviral infection that is transmitted to vertebrates primarily by various species of Culex mosquitoes.
  • JE Japanese encephalitis
  • MVE Murray Valley encephalitis
  • WNV is maintained in a natural cycle between arthropod vectors and birds.
  • the virus was first isolated from a febrile human in the West Nile district of Kenya in 1937 (Smithburn et al., Am. J. Trop. Med. Hyg. 20: 471-492 (1940)). It was soon recognized as one of the most widely distributed flaviviruses, with its geographic range including Africa, the Middle East, Western Asia, Europe and Australia (Hubalek et al., Emerg.
  • the outbreak was subsequently shown to be caused by WNV, based on monoclonal antibody (Mab) mapping and detection of genomic sequences in human, avian and mosquito specimens (Anderson et al., Science 286: 2331-2333 (1999); Jia et al., Lancet 354: 1971-1972 (1999); Lanciotti et al., Science 286: 2333-2337 (1999)).
  • Virus activity detected during the ensuing winter months indicated that the virus had established itself in North America ( Morb. Mortal. Wkly. Rep. 49: 178-179 (2000); Asnis et al., Clin. Infect. Dis. 30: 413-418 (2000); Garmendia et al., J. Clin. Micro.
  • JEV Japanese encephalitis virus
  • Vaccines Plotkin, ed.
  • W.B. Saunders Philadelphia, Pa., 1999, pp. 672-710
  • JEV has been largely controlled by use of a vaccine of inactivated JEV. Nevertheless, it is still prevalent in other countries of the region.
  • Vaccines available for use against JEV infection include live virus inactivated by such methods as formalin treatment, as well as attenuated virus (Tsai et al., in Vaccines (Plotkin, ed.) W.B. Saunders, Philadelphia, Pa., 1994, pp. 671-713).
  • Whole virus vaccines although effective, do have certain problems and/or disadvantages.
  • the viruses are cultivated in mouse brain or in cell culture using mammalian cells as the host. Such culture methods are cumbersome and expensive.
  • antigens from the host cells i.e., the brain or other host
  • the final vaccine product potentially leading to unintended and undesired allergic responses in the vaccine recipients.
  • the risk of inadvertent infection among workers involved in vaccine production There is also the risk that the virus may not be fully or completely inactivated or attenuated and thus, the vaccine may actually cause disease.
  • Dengue fever and dengue hemorrhagic fever are caused by dengue virus, which is also a mosquito-borne flavivirus.
  • dengue virus serotypes There are four antigenically related, but distinct, dengue virus serotypes, (DEN-1, DEN-2, DEN-3 and DEN-4), all of which can cause DF/DHF.
  • Symptoms of DF the mild form of dengue-related disease, include fever, rash, severe headache and joint pain. Mortality among those subjects suffering from DF is low; however, among those subjects suffering from DHF, mortality can be as high as 5%.
  • a recombinant flavivirus which is a chimera between two flaviviruses is disclosed in PCT publication WO 93/06214.
  • the chimera is a construct fusing non-structural proteins from one “type,” or serotype, of dengue virus or a flavivirus, with structural proteins from a different “type,” or serotype, of dengue virus or other flavivirus.
  • U.S. Pat. No. 4,810,492 describes the production of the E glycoprotein of JEV for use as the antigen in a vaccine.
  • the corresponding DNA is cloned into an expression system in order to express the antigen protein in a suitable host cell such as E. coli , yeast, or a higher organism cell culture.
  • U.S. Pat. No. 5,229,293 discloses recombinant baculovirus harboring the gene for JEV E protein. The virus is used to infect insect cells in culture such that the E protein is produced and recovered for use as a vaccine.
  • U.S. Pat. No. 5,021,347 discloses a recombinant vaccinia virus genome into which the gene for JEV E protein has been incorporated.
  • the live recombinant vaccinia virus is used as the vaccine to immunize against JEV.
  • Recombinant vaccinia viruses and baculoviruses in which the viruses incorporate a gene for a C-terminal truncation of the E protein of dengue serotype 2, dengue serotype 4 and JEV are disclosed in U.S. Pat. No. 5,494,671.
  • U.S. Pat. No. 5,514,375 discloses various recombinant vaccinia viruses which express portions of the JEV open reading frame extending from prM to NS2B.
  • HeLa cells infected with recombinant vaccinia virus bearing genes for prM and E from JEV were shown to produce subviral particles (Konishi et al., Virology 188: 714-720 (1992)).
  • Dmitriev et al. reported immunization of mice with a recombinant vaccinia virus encoding structural and certain nonstructural proteins from tick-borne encephalitis virus ( J. Biotechnology 44: 97-103 (1996)).
  • Recombinant virus vectors have also been prepared to serve as virus vaccines for dengue fever. Zhao et al. ( J. Virol. 61: 4019-4022 (1987)) prepared recombinant vaccinia virus bearing structural proteins and NS1 from dengue serotype 4 and achieved expression after infecting mammalian cells with the recombinant virus. Similar expression was obtained using recombinant baculovirus to infect target insect cells (Zhang et al., J. Virol. 62: 3027-3031 (1988)). Bray et al. ( J. Virol.
  • mice that received three intradermal injections of recombinant dengue-2 plasmid DNA containing prM 100% developed anti-dengue-2 neutralizing antibodies and 92% of those receiving the corresponding E gene likewise developed neutralizing antibodies (Kochel et al., Vaccine 15: 547-552 (1997)).
  • Challenge experiments using a two-dose schedule failed to protect mice against lethal dengue-2 virus challenge.
  • the vaccines developed to date for immunizing against infection by JEV, SLEV, dengue virus and other flaviviruses have a number of disadvantages and problems attending their use. Inactivated vaccine is costly and inconvenient to prepare. In addition, any such vaccine entails the risk of allergic reaction originating from proteins of the host cell used in preparing the virus. Furthermore, such vaccines present considerable risk to the workers employed in their production.
  • Candidate attenuated JEV vaccines are undergoing clinical trials, but as of 1996 have not found wide acceptance outside of the People's Republic of China (Hennessy et al., Lancet 347: 1583-1586 (1996)).
  • Recombinant vaccines based on the use of only certain proteins of flaviviruses, such as JEV, produced by biosynthetic expression in cell culture with subsequent purification or treatment of antigens, do not induce high antibody titers. Also, like the whole virus preparations, these vaccines carry the risk of adverse allergic reaction to antigens from the host or to the vector. Vaccine development against dengue virus and WNV is less advanced and such virus-based or recombinant protein-based vaccines face problems similar to those alluded to above.
  • the present invention meets these needs by providing highly immunogenic recombinant antigens for use in diagnostic assays for the detection of antibodies to selected flaviviruses.
  • the present invention further provides for the use of recombinant antigens derived from flaviviruses, flavivirus genes or mimetics thereof in immunodiagnostic assays for the detection of antibodies to flavivirus proteins.
  • the present invention provides a nucleic acid molecule which contains a transcriptional unit (TU) for an immunogenic flavivirus antigen.
  • the TU directs a host cell, after being incorporated within the cell, to synthesize the antigen.
  • the flavivirus can be yellow fever virus (YFV), dengue serotype 1 virus (DEN-1), dengue serotype 2 virus (DEN-2), dengue serotype 3 virus (DEN-3), dengue serotype 4 virus (DEN-4), St. Louis encephalitis virus (SLEV), Japanese encephalitis virus (JEV), West Nile virus (WNV), Powassan virus or any other flavivirus.
  • the antigen can be the flavivirus prM/M protein, the E protein, or both. In important embodiments of the present invention, the antigen can be a chimeric flavivirus protein.
  • the TU includes both the prM/M and E proteins, the host cell secretes subviral particles containing the prM/M and E antigens.
  • the nucleic acid is a DNA molecule.
  • the nucleic acid TU includes a control sequence disposed appropriately such that it operably controls the expression of the prM/M and E antigens and this control sequence can be the cytomegalovirus immediate early promoter.
  • the nucleotide sequence of the TU is engineered to optimize eukaryotic translation by minimizing large hairpin structures in the 5′-end untranslated region of an mRNA produced by the TU and/or the inclusion of a Kozak consensus sequence at the translational start site of an mRNA produced by the TU.
  • the transcriptional unit also includes a poly-A terminator.
  • the present invention further provides a host cell comprising a nucleic acid molecule which includes a transcriptional unit for an immunogenic flavivirus antigen that directs the host cell to synthesize the immunogenic antigen.
  • the flavivirus may be YFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flavivirus.
  • the antigen may be the prM/M protein, the E protein, or both the prM/M and the E proteins. In the latter case, the cell secretes subviral particles containing the prM/M and E antigens.
  • the invention provides a composition for vaccinating a subject against a flavivirus containing a nucleic acid molecule that includes a transcriptional unit for an immunogenic flaviviral antigen.
  • the transcriptional unit directs a cell within the body of the subject, after being incorporated therein, to synthesize the immunogenic antigen.
  • the composition further includes a pharmaceutically acceptable carrier.
  • the flavivirus may be YFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flavivirus.
  • the antigen may be the prM/M protein, the E protein, or both the prM/M and the E proteins.
  • the cell secretes subviral particles comprising the flavivirus prM/M and E antigens. These subviral particles are also referred to as noninfectious recombinant antigen (NRA).
  • the nucleic acid molecule is a DNA molecule.
  • the transcriptional unit additionally contains a control sequence disposed appropriately such that it operably controls the synthesis of the prM/M and E antigens when the nucleic acid is introduced into the cell of the subject. This control sequence can be the cytomegalovirus immediate early promoter.
  • the transcriptional unit can also include a poly-A terminator.
  • compositions provided by the present invention for vaccinating a subject against a flavivirus can include a nucleic acid molecule, or molecules, that include transcriptional units for more than one immunogenic flaviviral antigen.
  • the more than one immunogenic flaviviral antigen can be from different flavivirus species, strains or isolates in any combination.
  • the flaviviruses included can be two or more, three or more, four or more, five or more, or seven or more flaviviruses. Examples of such flaviviruses include, but are not limited to YFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flaviviruses.
  • Combination vaccines can be formulated to confer immunity to flavivirus disease common to particular geographical regions.
  • DEN-1, DEN-2, DEN-3, DEN-4, WN, and JE viruses can be selected.
  • DEN-1, DEN-2, DEN-3, DEN-4, WN and YF can be selected.
  • DEN-1, DEN-2, DEN-3, DEN-4, Rocio and YF viruses can be selected.
  • the invention provides still further a method of immunizing a subject against infection by a flavivirus.
  • the method involves administering to the subject an effective amount of a vaccinating composition that contains a nucleic acid molecule which includes a transcriptional unit for an immunogenic flavivirus antigen.
  • the transcriptional unit directs a cell within the body of the subject, after being taken up by the cell, to synthesize the immunogenic antigen.
  • the composition additionally includes a pharmaceutically acceptable carrier.
  • the flavivirus may be YFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flavivirus.
  • the antigen may be the prM/M protein, the E protein, or both the prM/M and the E proteins.
  • the cell within the body of the subject after incorporating the nucleic acid within it, secretes subviral particles comprising the flaviviral prM/M and E antigens.
  • the vaccinating composition is administered to the subject in a single dose, via a parenteral route.
  • the nucleic acid is a DNA molecule.
  • the transcriptional unit further includes a control sequence disposed appropriately such that it operably controls the synthesis of the prM/M and E antigens and in a significant aspect of this embodiment, the control sequence is the cytomegalovirus immediate early promoter.
  • the transcriptional unit may include a poly-A terminator.
  • nucleic acid TU-containing vaccine Being a nucleic acid construct involving only portions of the flavivirus genome rather than the sequence encompassing the complete genome, the nucleic acid TU-containing vaccine is completely nonviable. It therefore poses no danger of infection by the flavivirus to those involved in its manufacture or to subjects receiving the vaccine.
  • the nucleic acid vaccine is easy to prepare and easy to administer and is stable in storage prior to use. Unexpectedly it has been found that the nucleic acid vaccine of the invention is essentially 100% successful in conferring protective immunity in mammals after administering only a single dose.
  • nucleic acid TU is able to engender immunity to a flavivirus in a female mammal which can be transmitted to its progeny through the milk.
  • the inventor believes that a possible mechanism for the success of the nucleic acid in conferring protective immunity is that a host cell harboring the nucleic acid, such as the cell of a subject to whom the vaccine is administered, produces subviral particles containing the flaviviral prM/M and E antigens. These particles mimic the immunogenic attributes of native flavivirus virions.
  • the present invention also provides noninfectious antigenic polypeptides, antigenic polypeptide fragments and NRA comprising the prM/M and/or E proteins of flaviviruses, wherein the transmembrane signal sequence is derived from a first flavivirus and the M and/or E proteins are derived from a second flavivirus.
  • the prM/M protein can comprise amino acid sequences from both the first and the second flaviviruses.
  • the E protein can comprise amino acid sequences from both the first and second flaviviruses.
  • Chimeric as used herein means any protein or nucleic acid comprising sequence from more than one flavivirus.
  • non-virulent means the antigen or vaccine of this invention is incapable of causing disease. More particularly, the recombinant protein antigens are free of contaminating genomic material from flaviviruses that is necessary for flavivirus infection, replication and pathogenesis.
  • the polypeptides of the present invention can comprise the amino acid sequences defined herein, or that are known in the art, of the prM, M and/or E proteins of selected flaviviruses.
  • the nucleic acids of this invention can comprise nucleotide sequence that encodes the prM, M and/or E proteins of selected flaviviruses.
  • the antigens of the present invention can be unconjugated, or they can be conjugated to a carrier molecule that facilitates placement of the antigen on a solid phase.
  • a carrier molecule is one to which antigens can be conjugated and which will not react with antibodies in human serum.
  • An example of such a carrier is bovine serum albumin (BSA).
  • the antigens of the present invention can also be recombinant proteins obtained by expressing nucleic acids encoding the antigen in an expression system capable of producing the antigen.
  • the amino acid sequences of the present antigens can contain an immunoreactive portion of the prM, M and/or E antigen. These antigens may further be attached to sequences designed to provide for some additional property, such as to remove/add amino acids capable of disulfide bonding to increase the reactivity of an epitope by providing a more rigid secondary structure, to increase its bio-longevity or to alter its cytotoxicity or to prevent infection. In any case, the antigen must possess immunoreactivity and/or immunogenicity.
  • FIG. 1 is a schematic representation of flaviviral polyprotein processing.
  • the central horizontal region provides a schematic representation of the viral genome.
  • the lines denote the 5′ and 3′ non-translated regions and the boxed regions represent the open reading frame for structural (left and top) and non-structural (right and bottom) proteins.
  • Cleavage by host cell signalase occurs simultaneously with translation at the E protein C-terminus, separating structural and non-structural regions.
  • a subtilase-like cellular enzyme, furin may be responsible for prM cleavage.
  • Potential transmembrane domains of viral polyprotein are indicated by shaded areas.
  • FIG. 2 is a map of the JEV genome (top) and the DNA sequence of oligonucleotides used in a reverse transcriptase-polymerase chain reaction (RT-PCR) (center) to construct the transcription unit for the expression of prM-E protein coding regions (bottom). Potential transmembrane domains of viral polyprotein are indicated by shaded areas.
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • FIG. 3 shows a schematic representation of the plasmid vectors, pcDNA3, pCBamp, and pCIBamp, and the relationship between them.
  • These plasmids include the CMV (cytomegalovirus) promoter/enhancer element, BGHp(A) (bovine growth hormone polyadenylation signal and transcription termination sequence), ampicillin resistance gene and ColE1 origin of replication for selection and maintenance in E. coli .
  • the f1 origin of replication for single-stranded rescue in E. coli cells, SV40 origin of replication (SV40 ORI), neomycin resistance coding region and SV40p(A) sequences were deleted from pcDNA3 to generate pCBamp.
  • An intron sequence was inserted in the NcoI-KpnI site of pCBamp to generate plasmid pCIBamp.
  • FIG. 4 shows SDS-PAGE-immunoblot analyses of the sucrose gradient purified subviral particles from JE-4B COS-1 culture fluid (4B, right lane of each pair).
  • the density gradient purified JE virion from JEV infected C6/36 cell culture was used as a positive control (JEV, left lane of each pair).
  • JE RAF hyperimmune ascitic fluid
  • 4G2 anti-E monoclonal antibody
  • JM01 anti-M monoclonal antibody
  • NMAF normal mouse ascitic fluid
  • FIG. 5 shows a profile of the E antigen in a rate zonal sucrose gradient analysis prepared from the PEG precipitate of JE-4B cell culture medium with or without Triton X-100 treatment.
  • FIG. 6 shows signal peptide probability of the pCBJE1-14 (pCBJE) predicted by the SignalP-HMM program (panel A; amino acids 1-39 of SEQ ID NO: 18).
  • the signal peptide probability is improved by altering the c-region sequence at ⁇ 4 and ⁇ 2 positions (C-4G and G-2S) (panel B, JE-LSS-M; SEQ ID NO: 62), by shortening the n-region (panel C, JE-SS-ORI; SEQ ID NO: 63), or by a combination of both modifications (panel D, JE-SS-M; SEQ ID NO: 64).
  • FIG. 7 shows schematic representations of plasmid vectors pCBD2-14-16 (100% DEN-2 E), pCBD2-1J-4-3 (90% DEN-2 E: 10% JEV E), and pCB8D2-2H-2-9-1 (80% DEN-2 E: 20% JEV E).
  • These plasmids include the human cytomegalovirus (CMV) early gene promoter; JE virus signal sequence; DEN-2 virus prM and E gene region (amino terminal 100%, 90%, or 80%, respectively); JE virus E gene region (none, 10% or 20%, respectively); and bovine growth hormone poly A signal (BGH).
  • CMV human cytomegalovirus
  • FIG. 8 shows a comparison of secreted and membrane-bound recombinant protein by western blot.
  • A Analysis of secreted recombinant antigen following PEG-precipitation and ethanol extraction of culture fluid for DEN-2 plasmids pCB8D2-2J-2-9-1, pCB9D2-1J-4-3, pCBD2-14-16, and control plasmid pEGFP.
  • Lane 1(V) purified DEN-2 virus stained by Gold Blot (Owl Separation Systems, Portsmouth, N.H.).
  • the invention encompasses nucleic acid transcriptional units which encode flaviviral antigenic proteins, such as the prM/M and E protein antigens.
  • the nucleic acids function to express the prM/M and E protein antigens when the nucleic acid is taken up by an appropriate cell, especially when the cell is the cell of a subject.
  • the invention also encompasses a vaccine whose active agent is the nucleic acid transcriptional unit (TU).
  • the invention further encompasses cells containing a TU.
  • the invention in addition encompasses a method of immunizing a subject against flaviviral infection by administering to the subject an effective amount of a vaccine containing the nucleic acid TU molecules.
  • the invention provides an isolated nucleic acid comprising a transcriptional unit encoding a signal sequence of a structural protein of a first flavivirus and an immunogenic flavivirus antigen of a second flavivirus, wherein the transcriptional unit directs the synthesis of the antigen.
  • the invention further encompasses the use of the nucleic acid transcriptional unit (TU) to generate flaviviral antigens and the flaviviral antigens produced by the nucleic acid TU.
  • the flaviviral antigens encompassed by the present invention include chimeric flavivirus antigens incorporating amino acid sequence from a first flavivirus and at least one further flavivirus.
  • the invention still further encompasses the use of the flaviviral antigens encoded by the TU of the invention to produce flavivirus-specific antibodies and to detect the presence of flavivirus-specific antibodies.
  • the isolated nucleic acid of this invention can comprise a transcriptional unit encoding a Japanese encephalitis virus signal sequence.
  • the transcriptional unit of this invention can encode an immunogenic flavivirus antigen which can be from one or more of the following flaviviruses: yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, Japanese encephalitis virus, Powassan virus and West Nile virus.
  • the transcriptional unit of this invention can encode an immunogenic chimeric flavivirus antigen which can include sequence from more than one of the following flaviviruses: yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, Japanese encephalitis virus, Powassan virus and West Nile virus.
  • the nucleic acid of this invention can encode a signal sequence of Japanese encephalitis virus and an M protein and an E protein of West Nile virus, SLEV, YFV and/or Powassan virus.
  • the nucleic acid can also encode an immunogenic antigen which can be an M protein of a flavivirus, an E protein of a flavivirus, both an M protein and an E protein of a flavivirus, a portion of an M protein of a flavivirus, a portion of an E protein of a flavivirus and/or both a portion of an M protein of a flavivirus and a portion of an E protein of a flavivirus.
  • the isolated nucleic acid encodes both the M protein and the E protein of the flavivirus.
  • the nucleic acid of the invention can be DNA and can comprise nucleotide sequence SEQ ID NO:15, SEQ ID NO: 19, SEQ ID NO:21, SEQ ID NO:23 or SEQ ID NO: 42.
  • the nucleic acid of this invention can encode a signal sequence of Japanese encephalitis virus, an M protein of a second virus and a chimeric E protein formed by from substitution of a portion of the nucleic acid encoding the second virus' E protein with nucleic acid encoding the corresponding portion of the JEV E protein.
  • the portion of sequence corresponding to the deleted portion of the second virus' E protein can be substituted by other sequence selected from a third virus or it can be a non-viral sequence.
  • the second protein can be West Nile virus, SLEV, YFV, Powassan and/or a serotype of Dengue virus.
  • Chimeric E proteins can include those where the carboxy terminal portion can be from one flavivirus and the remainder of the chimeric E protein is from another flavivirus.
  • the carboxy terminal portion can be, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, or 75% of the chimeric E protein.
  • the nucleic acid of the invention can be DNA and can comprise the protein-encoding sequence from nucleotide sequence SEQ ID NO:44 or SEQ ID NO:46.
  • the nucleic acid of the invention can comprise nucleotide sequence SEQ ID NO:44 or SEQ ID NO:46.
  • the transcriptional unit of this invention can also comprise a control sequence disposed appropriately so that it operably controls the synthesis of the antigen.
  • the control sequence can be, for example, the cytomegalovirus immediate early promoter.
  • the nucleic acid of this invention can also comprise a Kozak consensus sequence located at a translational start site for a polypeptide comprising the antigen encoded by the transcriptional unit.
  • the transcriptional unit of this invention can also comprise a poly-A terminator.
  • the present invention further provides a cell comprising the nucleic acid of this invention.
  • compositions comprising a pharmaceutically acceptable carrier and nucleic acid or cell or antigen of this invention.
  • the present invention additionally provides a method of immunizing a subject against infection by a flavivirus, comprising administering to the subject an effective amount of a composition of this invention.
  • the composition used to immunize a subject directs the synthesis of both the M protein and the E protein of a flavivirus and a cell within the body of the subject, after incorporating the nucleic acid within it, secretes subviral particles comprising the M protein and the E protein.
  • the composition can comprise an M protein and/or E protein of a flavivirus or subviral particles comprising the M protein and E protein.
  • the immunizing composition can be administered to the subject in a single dose and can be administered via a parenteral route.
  • the antigen from the second flavivirus encoded by the nucleotide sequence of TU can be the M protein which can be, for example, from West Nile virus.
  • the antigen can also be protein from dengue virus, St. Louis encephalitis virus, Japanese encephalitis virus, Powassan virus and/or yellow fever virus.
  • the antigen comprises a prM/M protein comprising the transmembrane signal sequence from a first flavivirus and further amino acid sequence comprising the remainder of the prM/M protein from a second flavivirus, which can be from SLEV, JEV, YFV, WNV and/or Powassan virus.
  • the transmembrane signal sequence from a first flavivirus can be an improved or modified signal sequence wherein the signal sequence imparts desired characteristics such as a high signal sequence probability. Accomplishing these goals by design or selection can be with the use of machine-learning computer programs including, but not limited to, those using a hidden Markov model.
  • the antigen encoded by the nucleotide sequence of the TU can be West Nile virus antigen, dengue virus antigen, St. Louis encephalitis virus antigen, Japanese encephalitis virus antigen, Powassan virus antigen and/or yellow fever virus antigen.
  • the antigen encoded by the nucleotide sequence of the TU can also be the E protein, which can be the E protein from West Nile virus, dengue virus, St. Louis encephalitis virus, Japanese encephalitis virus, Powassan virus and/or yellow fever virus.
  • the antigen encoded can also be a chimeric E protein comprising amino acid sequence selected from more than one flavivirus.
  • the antigen encoded by the nucleotide sequence of the TU can be the M protein and the E protein, which can be from West Nile virus, dengue virus, St. Louis encephalitis virus, Japanese encephalitis virus, Powassan virus and/or yellow fever virus.
  • M protein or “pr/M protein” or “prM/M protein” means a flavivirus M protein or flavivirus prM protein.
  • examples include, but are not limited to, prM proteins comprising amino acid sequence from one or more flavivirus prM proteins, M proteins comprising no additional amino acid sequence and proteins comprising additional amino acid sequences which are processed in vitro or in vivo to generate the mature M protein.
  • nucleic acid transcriptional unit or “nucleic acid transcriptional unit molecule” means a nucleic acid encoding one or more specified proteins.
  • the TU has biological activity such that, after having been introduced into a suitable cell, the nucleic acid induces the synthesis of one or more specified gene products encoded by the nucleic acid.
  • the gene product(s) is (are) other biological macromolecules, such as proteins, not chemically related to the TU.
  • the nucleic acid TU induces the cell to employ its cellular components to produce the specific gene product or products encoded by the nucleic acid of the TU.
  • the TU is the DNA of a plasmid or similar vector, wherein the plasmid or vector comprises coding sequences of marker genes or other sequence constructions that facilitate use of the TU for experimentation and biosynthesis.
  • a “control sequence” is a regulatory nucleotide sequence incorporated within a TU which interacts with appropriate cellular components of the cell and leads to enhanced or activated biosynthesis of the gene products encoded by the TU.
  • a suitable control sequence is one with which the components of the cell have the capability to interact, resulting in synthesis of the gene product.
  • a control sequence When operably disposed in a nucleic acid with respect to a specified coding sequence, a control sequence effectively controls expression of the specified nucleic acid to produce the gene product.
  • a “promoter” is a nucleotide sequence in a TU which serves as a control sequence.
  • a “Kozak sequence” or “Kozak consensus sequence” is a nucleotide sequence at the translational start site which optimizes translation of eukaryotic mRNAs (Kozak, Mol. Cell. Biology 9: 5134-5142 (1989)).
  • a “terminator” is an extended nucleotide sequence which acts to induce polyadenylation at the 3′ end of a mature mRNA.
  • a terminator sequence is found after, or downstream from, a particular coding sequence.
  • a “cell” is a prokaryotic or eukaryotic cell comprising a TU coding for one or more gene products, or into which such a TU has been introduced.
  • a cell harbors a foreign or heterologous substance, the TU, which is not naturally or endogenously found in the cell as a component.
  • a suitable cell is one which has the capability for the biosynthesis of the gene products as a consequence of the introduction of the TU.
  • a suitable cell is one which responds to a control sequence and to a terminator sequence, if any, that may be included within the TU.
  • the cell is a mammalian cell.
  • the cell is a naturally occurring cell in the body of a human or nonhuman subject to whom (which) the TU has been administered as a component of a vaccine.
  • the cell may be a human or nonhuman cell cultured in vitro.
  • a “vaccine” or a “composition for vaccinating a subject” specific for a particular pathogen means a preparation, which, when administered to a subject, leads to an immunogenic response in a subject.
  • an “immunogenic” response is one that confers upon the subject protective immunity against the pathogen. Without wishing to be bound by theory, it is believed that an immunogenic response may arise from the generation of neutralizing antibodies (i.e., a humoral immune response) or from cytotoxic cells of the immune system (i.e., a cellular immune response) or both.
  • an “immunogenic antigen” is an antigen which induces an immunogenic response when it is introduced into a subject, or when it is synthesized within the cells of a host or a subject.
  • an “effective amount” of a vaccine or vaccinating composition is an amount which, when administered to a subject, is sufficient to confer protective immunity upon the subject.
  • a vaccine has been understood to contain as an active principle one or more specific molecular components or structures which comprise the pathogen, especially its surface. Such structures may include surface components such as proteins, complex carbohydrates, and/or complex lipids which commonly are found in pathogenic organisms.
  • the terms “vaccine” or “composition for vaccinating a subject” extend the conventional meaning summarized in the preceding paragraph. As used herein, these terms also relate to the TU of the instant invention or to compositions containing the TU.
  • the TU induces the biosynthesis of one or more specified gene products encoded by the TU within the cells of the subject, wherein the gene products are specified antigens of a pathogen.
  • the biosynthetic antigens then serve as an immunogen.
  • the TU, and hence the vaccine may be any nucleic acid that encodes the specified immunogenic antigens.
  • the TU of the vaccine is DNA.
  • the TU can include a plasmid or vector incorporating additional genes or particular sequences for the convenience of the skilled worker in the fields of molecular biology, cell biology and viral immunology (See Molecular Cloning: A Laboratory Manual, 2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989; and Current Protocols in Molecular Biology , Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly), which are incorporated herein by reference).
  • the TU molecules of the instant invention comprise nucleic acids, or derivatives of nucleic acids, having nucleotide sequences that encode specific gene products related to antigens of flaviviruses such as, but not limited to, WNV, JEV, dengue virus, yellow fever virus and SLEV.
  • any nucleic acid may serve as a TU, in an important embodiment, the TU is DNA.
  • the nucleic acids may be RNA molecules. They may also be any one of several derivatives of DNA or RNA having a backbone of phosphodiester bonds that have been chemically modified to increase the stability of the TU as a pharmaceutical agent. Modifications so envisioned include, but are not limited to, phosphorothioate derivatives or phosphonate derivatives. These and other examples of derivatives are well known to persons skilled in the field of nucleic acid chemistry.
  • the genome of JEV has been characterized and sequenced ( FIGS. 1 and 2 ).
  • the M structural protein is expressed as a portion of the polyprotein which includes a pre-M sequence (pr).
  • This pr sequence immediately amino terminal to the M protein sequence, prevents conformational problems in the processing of the polyprotein.
  • the presence of the pr sequence is important in preventing misfolding of the E protein.
  • the presence of prM allows for assembly of JEV particles.
  • the pr sequence can be cleaved from the prM protein to yield mature virus particles containing M proteins, although cleavage of the prM protein to yield M protein is not necessary to produce infectious particles.
  • the prM sequences from many different, related flaviviruses are cleaved to but a low extent, but the flaviviruses themselves are nonetheless, infectious.
  • Examples of such related flaviviruses with similar genomic structures and functions include, but are not limited to WNV, YFV, dengue virus and SLEV.
  • the TU encoding flaviviral M and E proteins in the instant invention is DNA.
  • this DNA comprises a nucleotide sequence which encodes the M protein, comprising the pre-M sequence, and a nucleotide sequence encoding the E protein.
  • the intended gene products are enabled to form subviral particles within the cell.
  • the pre-M sequence can then be cleaved in a fashion analogous to that which occurs with respect to replete virions.
  • a control sequence that has the effect of enhancing or promoting the transcription of the nucleotide sequences encoding the antigens.
  • Use of such promoters is well known to those of skill in the fields of molecular biology, cell biology and viral immunology (See Molecular Cloning: A Laboratory Manual, 2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989; and Current Protocols in Molecular Biology , Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly)).
  • the promoter to be employed is preferably one which operates effectively in mammalian cells.
  • a promoter is disposed with respect to the coding sequences from which transcription is to be promoted, at a position at which it may operably promote such transcription.
  • this promoter is the cytomegalovirus early promoter.
  • the coding sequences are followed, in the TU nucleic acid, by a terminator sequence (Sambrook et al.).
  • a terminator sequence (Sambrook et al.).
  • Particular embodiments of the invention relate to both prokaryotic and eukaryotic cells. Many promoter sequences are known that are useful in either prokaryotic or eukaryotic cells. (See Sambrook et al.)
  • the nucleic acids of the invention may further include DNA sequences known to those of skill in the art to act as immunostimulatory elements.
  • immunostimulatory elements include, but are not limited to, certain CpG motifs in bacterial DNA (Sato et al., Science 273: 352-354 (1996); Klinman et al., Vaccine 17: 19-25 (1998)).
  • RNA molecule may be isolated from a sample of live virus by methods widely known among virologists familiar with flaviviruses, for example, and with other groups of viruses as well. Methods used with JEV are summarized in Kuno et al. ( J. Virol.
  • RNA is used as a template for the synthesis of cDNA using reverse transcriptase.
  • a fragment containing the pre-M through E coding region ( FIG. 2 ) is obtained by digestion with restriction nucleases known to cleave the cDNA appropriately to provide such fragments. Examples of restriction digestion of JEV are provided in Nitayaphan et al. (1990) and Konishi et al. (1991).
  • Examples of these methods include incorporation of the nucleic acid into a plasmid for replication by culturing in a cell such as a prokaryotic cell and harvesting the plasmid after completing the culture, as well as amplification of the nucleic acid by methods such as PCR and other amplification protocols, as are well known in the art. These examples are not intended to limit the ways in which the nucleic acid containing the TU may be obtained.
  • the TU-containing nucleic acid molecules of the instant invention may be introduced into appropriate cells in many ways well known to skilled workers in the fields of molecular biology and viral immunology.
  • these include, but are not limited to, incorporation into a plasmid or similar nucleic acid vector which is taken up by the cells, or encapsulation within vesicular lipid structures such as liposomes, especially liposomes comprising cationic lipids, or adsorption to particles that are incorporated into the cell by endocytosis.
  • a cell of this invention is a prokaryotic or eukaryotic cell comprising a TU, or into which a TU has been introduced.
  • the TU of the present invention induces the intracellular biosynthesis of the encoded prM/M and E antigens.
  • a suitable cell is one which has the capability for the biosynthesis of the gene products as a consequence of the introduction of the nucleic acid.
  • a suitable cell is one which responds to a control sequence and to a terminator sequence, if any, which may be included within the TU. In order to respond in this fashion, such a cell contains within it components which interact with a control sequence and with a terminator and act to carry out the respective promoting and terminating functions.
  • the cell When the cell is cultured in vitro, it may be a prokaryote, a single-cell eukaryote or a multicellular eukaryote cell.
  • the cell In particular embodiments of the present invention, the cell is a mammalian cell.
  • the synthesized prM/M and E protein gene products are available for use in analytical, or diagnostic applications, including preparation of antigen for use as a vaccine or in immunodiagnostic assays, or for demonstrative purposes.
  • the prM/M and E antigens are secreted in the form of subviral particles. These are aggregates of prM/M and E proteins resembling live virus in surface ultrastructural morphology and immunogenic properties. Since the TU of the invention does not include the remainder of the flaviviral genome, however, there is no capsid incorporated, and most importantly, no infectious viral RNA.
  • the cell is a natural cellular component of the subject to whom the TU has been administered as a vaccine.
  • the TU when administered to the subject, is taken up by the cells of the subject.
  • the subject's cells have the capability of responding to any promoter sequences, and terminator, if present.
  • the TU induces the subject's cells to synthesize flaviviral prM/M and E gene products.
  • the subject's cells produce subviral particles in vivo consisting of the prM/M and E antigens, just as has been found to occur with cultured mammalian cells in vitro.
  • Such subviral particles serve as the in vivo immunogen, stimulating the immune system of the subject to generate immunological responses which confer protective immunity on the subject.
  • the resulting protective immunity may arise via either humoral or cellular immunity, i.e., via either an MHC class II- or class I-restricted mechanism, respectively, or by both mechanisms.
  • subjects are immunized against infection by flaviviruses, such as JEV, YFV, dengue virus, SLEV, WNV or other flaviviruses by administering to them an effective amount of a TU comprising nucleic acid which encodes the prM and/or E antigens.
  • flaviviruses such as JEV, YFV, dengue virus, SLEV, WNV or other flaviviruses
  • the nucleic acid after being incorporated into the cells of the subject, leads to the synthesis of the flaviviral prM/M and/or E antigens.
  • composition which comprises a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable means a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an subject along with the immunogenic material (i.e., recombinant flavivirus protein antigens or portions thereof) without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the vaccine in which it is contained.
  • examples of pharmaceutically acceptable carriers, or components thereof include water, physiological saline and common physiological buffers (for further examples, see Amon, R. (Ed.) Synthetic Vaccines I : pp. 83-92, CRC Press, Inc., Boca Raton, Fla., 1987).
  • the critical value in describing a vaccination dose is the total amount of immunogen needed to elicit a protective response in a host which is subject to infectious disease caused by virulent or wild-type flavivirus infection.
  • the number and volume of doses used can be varied and are determined by the practitioner based on such parameters as, age, weight, gender, species, type of vaccine to be administered, mode of administration, overall condition of the subject, et cetera, as well as other important factors recognized by those of skill in the art.
  • the TU may be administered to a subject orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, intranasally, topically or the like. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation.
  • parenterally e.g., intravenously
  • intramuscular injection e.g., intraperitoneal injection
  • transdermally e.g., extracorporeally, intranasally, topically or the like. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation.
  • the exact amount of the TU required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the immunogenicity of the vaccine used, the strain or species of flavivirus against which the subject is being immunized, the mode of administration and the like. Thus, it is not possible to specify an exact amount for every embodiment of
  • Parenteral administration of the vaccine of the present invention is generally characterized by injection.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
  • a more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Pat. No. 3,610,795, which is incorporated by reference herein.
  • conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • the TU of this invention can be administered to the subject by the use of electrotransfer mediated in vivo gene delivery, wherein immediately following administration of the TU to the subject, transcutaneous electric pulses are applied to the subject, providing greater efficiency and reproducibility of in vivo nucleic acid transfer to tissue in the subject (Mir et al., Proc. Nat. Acad. Sci USA 96: 4262-4267 (1999)).
  • the efficacy of the immunization can be monitored according the clinical protocols well known in the art for monitoring the immune status of a subject.
  • An effective amount of a vaccinating composition is readily determined by those of skill in the art to be an amount which, when administered to a subject, confers protective immunity upon the subject.
  • the skilled artisan can assess the ability to induce flaviviral prM/M- and E-specific antibodies and/or flaviviral prM/M- and E-specific cytotoxic T lymphocytes present in the blood of a subject to whom the vaccine has been administered.
  • One can also determine the level of protective immunity conferred upon an experimental subject by challenge with live flavivirus corresponding to the antigenic composition used to immunize the experimental subject. Such challenge experiments are well known to those of skill in the art.
  • TUs employed in such methods may have differing overall sizes
  • doses ranging from about 0.1 ⁇ g/kg body weight to about 50 ⁇ g/kg body weight can be used.
  • a TU of the present invention which is a DNA confers protective immunity at a level of effectiveness approximating 100% after administration of only a single effective dose of the TU by i.m. injection or by electrotransfer. This is in contrast to many immunization methods carried out using conventional vaccines (as described above), which require one or more booster vaccinations and which may not confer protective immunity to an effectiveness near 100%.
  • protective immunity may be transmitted from a vaccinated female subject to the offspring of the subject.
  • a significant proportion of neonatal mice was shown to be protected against viral challenge after the mothers were vaccinated using the TU DNA of the invention.
  • passive immunity may be conferred on neonatal mammals due to the presence in maternal milk of neutralizing antibodies specific for various pathogens. It is possible that the protective immunity against JEV found within the neonates was transmitted to them in this way.
  • the TU encodes a signal sequence of a structural protein of a first flavivirus and an immunogenic flavivirus antigen of a second flavivirus.
  • the signal sequence of structural protein of a first flavivirus is replaced by a signal sequence of structural protein of a second flavivirus, which results in proper folding of the nascent polypeptide, proper processing in a host, and/or proper folding of the processed protein.
  • the TU may encode an immunogenic flavivirus antigen wherein the antigen comprises sequence from one or more than one flavivirus.
  • the signal sequence can be an improved signal peptide. Improvement of signal sequences, or selection of more optimal signal sequences, can be accomplished by application of the principles and techniques taught in Example 18 and references cited therein, each of which are incorporated herein by reference for the express teachings in each related to the selection, identification and design of signal sequences with desired properties and functions. Generally, these desired properties and functions will include a high signal sequence probability.
  • a TU can encode a nascent polypeptide or polypeptides that are processed into proteins from more than one flavivirus.
  • the processed proteins form subviral particles that elicit an immunological response against the proteins.
  • the subviral particles can be formed from processed proteins derived from the sequence of the same flavivirus, a combination of flaviviruses, or chimeric flavivirus proteins.
  • Combination vaccines comprising more than one TU or a TU encoding an immunogenic flavivirus antigen from more than one flavivirus can be tailored for use in particular geographical regions by inclusion of proteins from flaviviruses endemic to the region or otherwise likely to be encountered.
  • a vaccine for tropical and subtropical Asia can include TU(s) that encode proteins from the four serotypes of DEN, WN and JE virus vaccines.
  • useful vaccines for Africa and Latin America could include TU(s) that encode proteins from the four serotypes of DEN, WN and YF viruses and the four serotypes of DEN, Rocio and YF viruses, respectively.
  • the TU encodes a signal sequence of a structural protein of a first flavivirus and an immunogenic chimeric flavivirus antigen that includes amino acid sequence from more than one flavivirus.
  • the signal sequence can be a Japanese encephalitis virus signal sequence.
  • the chimeric flavivirus antigen can include sequence from a Japanese encephalitis virus antigen.
  • the chimeric antigen is an E protein.
  • the carboxy terminal portion of the E protein can be E protein sequence from the Japanese encephalitis virus.
  • the carboxy terminal portion can be, for example, 5, 10, 15, 20, 25, 30, 40, 50 or 75% of the chimeric E protein.
  • the TU encodes a signal sequence of a structural protein of Japanese encephalitis virus, a prM protein of a Dengue virus and a chimeric E protein containing sequence from both the Japanese encephalitis virus and the Dengue virus.
  • the chimeric protein can be an E protein wherein the carboxy terminal portion comprises Japanese encephalitis virus sequence.
  • Examples of TUs include nucleic acid sequences shown in SEQ ID NO:44 and SEQ ID NO:46 that can direct the synthesis of flavivirus antigens such as those shown in SEQ ID NO:45 and SEQ ID NO:47.
  • the present invention further provides immunogenic compositions comprising the polypeptides of this invention in a pharmaceutical acceptable carrier for use as a protein vaccine.
  • Antigens produced from the transcriptional units of the present invention can be used to elicit effective immune responses in a subject.
  • Antigens for this purpose can comprise flavivirus prM protein, flavivirus M protein, flavivirus E protein or any combination thereof, including immunogenic fragments of the proteins.
  • a particularly preferred embodiment is the use of the NRA described herein.
  • a further preferred embodiment is a chimeric protein comprising the signal sequence of one flavivirus and the structural protein(s) of one or more different flaviviruses.
  • the signal sequence of the antigen is the Japanese encephalitis virus signal sequence.
  • the signal sequence is a an improved signal peptide. Improvement of signal sequences, or selection of more optimal signal sequences, can be accomplished by application of the principles and techniques taught in Example 18 and references cited therein each of which are incorporated herein by reference for the express teachings in each related to the selection, identification and design of signal sequences with desired properties and function. Generally, these desired properties and function will include a high signal sequence probability.
  • the protein vaccine of this invention further comprises a suitable adjuvant.
  • an “adjuvant” is a potentiator or enhancer of the immune response.
  • suitable is meant to include any substance which can be used in combination with the vaccine immunogen (i.e., flavivirus prM protein, flavivirus M protein, flavivirus E protein, or any combination thereof) to augment the immune response, without producing adverse reactions in the vaccinated subject.
  • Effective amounts of a specific adjuvant may be readily determined so as to optimize the potentiation effect of the adjuvant on the immune response of a vaccinated subject.
  • adjuvanting of the vaccines of this invention is a 2-stage process, utilizing first a 2% aluminum hydroxide solution and then a mineral oil.
  • suitable adjuvants can be chosen from the following group: mineral, vegetable or fish oil with water emulsions, incomplete Freund's adjuvant, E.
  • coli J5 dextran sulfate, iron oxide, sodium alginate, Bacto-Adjuvant, certain synthetic polymers such as Carbopol (BF Goodrich Company, Cleveland, Ohio), poly-amino acids and co-polymers of amino acids, saponin, carrageenan, REGRESSIN (Vetrepharm, Athens, Ga.), AVRIDINE (N,N-dioctadecyl-N′,N′-bis(2-hydroxyethyl)-propanediamine), long chain polydispersed ⁇ (1,4) linked mannan polymers interspersed with O-acetylated groups (e.g.
  • ACEMANNAN deproteinized highly purified cell wall extracts derived from non-pathogenic strain of Mycobacterium species (e.g. EQUIMUNE, Vetrepharm Research Inc., Athens Ga.), Mannite monooleate, paraffin oil and muramyl dipeptide.
  • this invention provides a method for immunizing subjects with immunogenic amounts of the protein vaccine of the invention to elicit an effective immune response in the subject.
  • Immunization can be carried out orally, parenterally, intranasally, intratracheally, intramuscularly, intramammarily, subcutaneously, intravenously and/or intradermally.
  • the vaccine containing the flavivirus prM protein, flavivirus M protein and/or the flavivirus E protein can be administered by injection, by inhalation, by ingestion, or by infusion.
  • a single dose can be given and/or repeated doses of the vaccine preparations, i.e. “boosters,” can be administered at periodic time intervals to enhance the initial immune response or after a long period of time since the last dose.
  • the time interval between vaccinations can vary, depending on the age and condition of the subject.
  • immunogenic amount means an amount of an immunogen, or a portion thereof, which is sufficient to induce an immune response in a vaccinated subject and which protects the subject against disease caused by wild-type or virulent flavivirus infections upon exposure thereto or which has a therapeutic or commercially beneficial effect that lessens the effect of flavivirus infection on the vaccinated subject.
  • the invention further provides an antibody produced in response to immunization by the antigen of this invention.
  • the antibodies of the present invention can include polyclonal and monoclonal antibodies which can be intact immunoglobulin molecules, chimeric immunoglobulin molecules, “humanized antibodies,” or Fab or F(ab′) 2 fragments. Such antibodies and antibody fragments can be produced by techniques well known in the art which include those described in Harlow and Lane ( Antibodies: A Laboratory Manual . Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989) and Kohler et al. ( Nature 256:495-97, 1975) and U.S. Pat. Nos. 5,545,806, 5,569,825 and 5,625,126, incorporated herein by reference.
  • the antibodies can be of any isotype IgG, IgA, IgD, IgE and IgM.
  • the present invention can also include single chain antibodies (ScFv), comprising linked V H and V L domains and which retain the conformation and specific binding activity of the native idiotype of the antibody.
  • Single chain antibodies are well known in the art and can be produced by standard methods. (see, e.g., Alvarez et al., Hum. Gene Ther. 8: 229-242 (1997)).
  • Antibodies can be produced against the antigens of this invention which are synthesized from nucleic acid sequences encoding immunogenic amino acid sequences of the prM, M and/or E antigens of one or more flaviviruses and the signal sequence of a different flavivirus (e.g., JEV). Immunogenic peptides synthesized from the use of these chimeric constructs can easily be identified by use of methods well known in the art for identifying immunogenic regions in an amino acid sequence and used to produce the antibodies of this invention.
  • an antigen/antibody complex can form, as well as assays for the detection of the formation of an antigen/antibody complex and quantitation of the detected protein, are standard in the art.
  • assays can include, but are not limited to, Western blotting, immunoprecipitation, immunofluorescence, immunocytochemistry, immunohistochemistry, fluorescence activated cell sorting (FACS), fluorescence in situ hybridization (FISH), immunomagnetic assays, ELISA, ELISPOT (Coligan et al., eds. 1995. Current Protocols in Immunology. Wiley, New York.), agglutination assays, flocculation assays, cell panning, etc., as are well known to the artisan.
  • bind means the well characterized binding of antibody to antigen as well as other nonrandom association with an antigen.
  • Specifically bind as used herein describes an antibody or other ligand that does not cross react substantially with any antigen other than the one specified, which in this case, is an antigen of this invention.
  • the antibody or ligand of this invention can be bound to a substrate (e.g., beads, tubes, slides, plates, nitrocellulose sheets, etc.) or conjugated with a detectable moiety or both bound and conjugated.
  • the detectable moieties contemplated for the present invention can include, but are not limited to, an immunofluorescent moiety (e.g., fluorescein, rhodamine), a radioactive moiety (e.g., 32 P, 125 I, 35 S), an enzyme moiety (e.g., horseradish peroxidase, alkaline phosphatase), a colloidal gold moiety and a biotin moiety.
  • an immunofluorescent moiety e.g., fluorescein, rhodamine
  • a radioactive moiety e.g., 32 P, 125 I, 35 S
  • an enzyme moiety e.g., horseradish peroxidase, alkaline phosphatase
  • the present invention further provides a method of detecting flavivirus antibody in a sample, comprising contacting the sample with the flavivirus antigen of the present invention, under conditions whereby an antigen/antibody complex can form; and detecting formation of the complex, thereby detecting flavivirus antibody in the sample.
  • the present invention further provides a method of detecting flavivirus antigen in a sample, comprising contacting the sample with an antibody of this invention under conditions whereby an antigen/antibody complex can form; and detecting formation of the complex, thereby detecting flavivirus antigen in the sample.
  • the method of detecting flavivirus antigen in a sample can be performed, for example, by contacting a fluid or tissue sample from a subject with an antibody of this invention and detecting binding of the antibody to the antigen. It is contemplated that the antigen will be on an intact flavivirus virion, will be a flavivirus-encoded protein displayed on the surface of a flavivirus-infected cell expressing the antigen, or will be a fragment of the antigen.
  • a fluid sample of this method can comprise any biological fluid which could contain the antigen or a cell containing the antigen, such as cerebrospinal fluid, blood, bile, plasma, serum, saliva and urine. Other possible examples of body fluids include sputum, mucus and the like.
  • the method of detecting flavivirus antibody in a sample can be performed, for example, by contacting a fluid or tissue sample from a subject with an antigen of this invention and detecting the binding of the antigen to the antibody.
  • a fluid sample of this method can comprise any biological fluid which could contain the antibody, such as cerebrospinal fluid, blood, bile, plasma, serum, saliva and urine. Other possible examples of body fluids include sputum, mucus and the like.
  • Enzyme immunoassays such as immunofluorescence assays (IFA), enzyme linked immunosorbent assays (ELISA) and immunoblotting can be readily adapted to accomplish the detection of flavivirus antibodies according to the methods of this invention.
  • An ELISA method effective for the detection of the antibodies can, for example, be as follows: (1) bind the antigen to a substrate; (2) contact the bound antigen with a fluid or tissue sample containing the antibody; (3) contact the above with a secondary antibody bound to a detectable moiety which is reactive with the bound antibody (e.g., horseradish peroxidase enzyme or alkaline phosphatase enzyme); (4) contact the above with the substrate for the enzyme; (5) contact the above with a color reagent; and (6) observe/measure color change or development.
  • IFA immunofluorescence assays
  • ELISA enzyme linked immunosorbent assays
  • An ELISA method effective for the detection of the antibodies can, for example, be as follows: (1) bind the antigen to a substrate
  • MAbs monoclonal antibodies
  • sample is contacted with an antigen of this invention which is bound to a substrate (e.g., an ELISA 96-well plate). Excess sample is thoroughly washed away.
  • a labeled (e.g., enzyme-linked, fluorescent, radioactive, etc.) monoclonal antibody is then contacted with any previously formed antigen-antibody complexes and the amount of monoclonal antibody binding is measured. The amount of inhibition of monoclonal antibody binding is measured relative to a control (no antibody), allowing for detection and measurement of antibody in the sample.
  • the degree of monoclonal antibody inhibition can be a very specific assay for detecting a particular flavivirus variety or strain, when based on monoclonal antibody binding specificity for a particular variety or strain of flavivirus.
  • MAbs can also be used for direct detection of flavivirus antigens in cells by, for example, immunofluorescence assay (IFA) according to standard methods.
  • IFA immunofluorescence assay
  • a micro-agglutination test can be used to detect the presence of flavivirus antibodies in a sample. Briefly, latex beads, red blood cells or other agglutinable particles are coated with the antigen of this invention and mixed with a sample, such that antibodies in the sample that are specifically reactive with the antigen crosslink with the antigen, causing agglutination. The agglutinated antigen-antibody complexes form a precipitate, visible with the naked eye or measurable by spectrophotometer. In a modification of the above test, antibodies of this invention can be bound to the agglutinable particles and antigen in the sample thereby detected.
  • the present invention further provides a method of diagnosing a flavivirus infection in a subject, comprising contacting a sample from the subject with the antigen of this invention under conditions whereby an antigen/antibody complex can form; and detecting antigen/antibody complex formation, thereby diagnosing a flavivirus infection in a subject.
  • the present invention further provides a method of diagnosing a flavivirus infection in a subject, comprising contacting a sample from the subject with the antibody of this invention under conditions whereby an antigen/antibody complex can form; and detecting antigen/antibody complex formation, thereby diagnosing a flavivirus infection in a subject.
  • the antigen of this invention can be bound to a substrate and contacted with a fluid sample such as blood, serum, urine or saliva.
  • a fluid sample such as blood, serum, urine or saliva.
  • This sample can be taken directly from the patient or in a partially purified form.
  • antibodies specific for the antigen (the primary antibody) will specifically react with the bound antigen.
  • a secondary antibody bound to, or labeled with, a detectable moiety can be added to enhance the detection of the primary antibody.
  • the secondary antibody or other ligand which is reactive, either specifically with a different epitope of the antigen or nonspecifically with the ligand or reacted antibody, will be selected for its ability to react with multiple sites on the primary antibody.
  • several molecules of the secondary antibody can react with each primary antibody, making the primary antibody more detectable.
  • the detectable moiety allows for visual detection of a precipitate or a color change, visual detection by microscopy, or automated detection by spectrometry, radiometric measurement or the like.
  • detectable moieties include fluorescein and rhodamine (for fluorescence microscopy), horseradish peroxidase (for either light or electron microscopy and biochemical detection), biotin-streptavidin (for light or electron microscopy) and alkaline phosphatase (for biochemical detection by color change).
  • Genomic RNA was extracted from 150 ⁇ L of JEV strain SA 14 virus seed grown from mouse brain using a QIAampTM Viral RNA Kit (Qiagen, Santa Clarita, Calif.). RNA, adsorbed on a silica membrane, was eluted in 80 ⁇ L of nuclease-free water, and used as a template for the amplification of JEV prM and E gene coding sequences. Primer sequences were obtained from the work of Nitayaphan et al. ( Virology 177: 541-552 (1990)). A single cDNA fragment containing the genomic nucleotide region 389-2478 was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR).
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • Restriction sites KpnI and XbaI, the consensus Kozak ribosomal binding sequence, and the translation initiation site were engineered at the 5′ terminus of the cDNA by amplimer 14DV389 (nucleotide sequence, SEQ ID NO: 1; amino acid sequence, SEQ ID NO:2).
  • One-tube RT-PCR was performed using a Titan RT-PCR Kit (Boehringer Mannheim, Indianapolis, Ind.).
  • reaction mix [20 ⁇ L 5 ⁇ buffer, 2 ⁇ L of dNTP mixture (10 mM each), 5 ⁇ L of dithiothreitol (0.1 mM), 0.5 ⁇ L of RNasinTM (40 U/ ⁇ L, Boehringer Mannheim), 2 ⁇ L of polymerase mixture, and 45.5 ⁇ L of nuclease-free water] was added and RT-PCR performed as follows: 1 cycle (50° C. for 30 min, 94° C. for 3 min, 50° C. for 30 s, 68° C. for 2.5 min), 9 cycles (94° C. for 30 s, 50° C. for 30 s, 68° C. for 2.5 min), 20 cycles (94° C.
  • the RT-PCR product was purified by a QIAquickTM PCR Purification Kit (Qiagen) and eluted with 50 ⁇ L of 1 mM Tris-HCl, pH 7.5.
  • the fragment of plasmid pcDNA3 (Invitrogen, Carlsbad, Calif.) from nucleotide (nt) 1289 to nt 3455, containing f1 ori, SV40 ori, the neomycin resistance gene, and SV40 poly(A) elements was deleted by PvuII digestion and then ligated to generate the pCBamp plasmid.
  • the vector pCIBamp, containing a chimeric intron insertion at the NcoI/KpnI site of the pCBamp was constructed by excising the intron sequence from pCI (Promega, Madison, Wis.) by digestion with NcoI and KpnI.
  • FIG. 3 presents the relationships between the plasmids pCDA3, pCBamp, and pCIBamp.
  • Plasmids containing the transcriptional unit encoding JEV prM and E proteins were prepared from these plasmids.
  • the cDNA fragment containing the JEV prM and E coding regions in the recombinant plasmid pCDJE2-7 (nucleotide sequence, SEQ ID NO: 10; amino acid sequence, SEQ ID NO: 11), derived from the pcDNA3 vector, was excised by digestion with NotI and KpnI or XbaI and cloned into the KpnI-NotI site of pCBamp, pCIBamp, pCEP4 (Invitrogen, Carlsbad, Calif.), or pREP4 (Invitrogen, Carlsbad, Calif.), or into the SpeI-NotI site of pRc/RSV (Invitrogen, Carlsbad, Calif.) expression vector to create pCBJE1-14 (nucleotide sequence, SEQ ID NO: 17; amino acid sequence, SEQ ID NO
  • Plasmid DNA for use in the in vitro transformation of mammalian cells or mouse immunization experiments was purified by anion exchange chromatography using an EndoFreeTM Plasmid Maxi Kit (Qiagen).
  • JEV specific gene products by the various recombinant expression plasmids was evaluated in transiently transfected cell lines of COS-1, COS-7 and SV-T2 (ATCC, Rockville Md.; 1650-CRL, 1651-CRL, and 163.1-CCL, respectively) by indirect immunofluorescent antibody assay (IFA).
  • IFA indirect immunofluorescent antibody assay
  • the SV-T2 cell line was excluded from further testing since a preliminary result showed only 1-2% of transformed SV-T2 cells were JEV antigen positive.
  • cells were grown to 75% confluence in 150 cm 2 culture flasks, trypsinized, and resuspended at 4° C.
  • plasmid DNA was electroporated into 300 ⁇ L of cell suspension using a BioRad Gene PulseTM (Bio-Rad) set at 150 V, 960 ⁇ F and 100 ⁇ resistance.
  • Bio-Rad Bio-Rad Gene PulseTM
  • IFA was performed with acetone-fixed plasmid-transformed cells using fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin G (Sigma Chemical Co.) and JEV HIAF.
  • COS-1 and COS-7 cell lines were transiently transformed by an equal amount of pCDJE2-7 (SEQ ID NO: 10), pCEJE, pREJE, or pRCJE plasmid DNA. JEV antigens were expressed in both cell lines transformed by all four recombinant plasmids, thus confirming that the CMV or RSV (rous sarcoma virus) promoter and BGH or SV40 poly(A) elements were functionally active.
  • pCDJE2-7 SEQ ID NO: 10
  • pCEJE pCEJE
  • pREJE pREJE
  • pRCJE plasmid DNA JEV antigens were expressed in both cell lines transformed by all four recombinant plasmids, thus confirming that the CMV or RSV (rous sarcoma virus) promoter and BGH or SV40 poly(A) elements were functionally active.
  • the plasmid pCBJE1-14 (SEQ ID NO: 17) was constructed so that a 2166-bp fragment, containing f1 ori, SV40 ori, the neomycin resistance gene and SV40 poly(a) elements from pCDJE2-7, was deleted. A chimeric intron was then inserted into pCBJE1-14 to generate pCIBJES14. The pCIBJES14 plasmid was used to determine if the expression of JEV proteins could be enhanced by the intron sequence.
  • COS-1 cells were transformed with 10 ⁇ g of pCDJE2-7 DNA by electroporation as described in the previous example. After a 24 hr incubation in non-selective culture medium, cells were treated with neomycin (0.5 mg/mL, Sigma Chemical Co.). Neomycin-resistant colonies, which became visible after 2-3 weeks, were cloned by limited dilution in neomycin-containing medium. Expression of vector-encoded JEV gene products was initially screened by IFA using JEV HIAF. One JEV-IFA positive clone (JE-4B) and one negative clone (JE-SA) were selected for further analysis and maintained in medium containing 200 ⁇ g/nL neomycin.
  • JE-4B JEV-IFA positive clone
  • JE-SA negative clone
  • JEV E protein expressed by the JE-4B clone was demonstrated by epitope mapping by WFA using a panel of JEV E-specific murine monoclonal antibodies (Mab) (Kimura-Kuroda et al., J. Virol. 45: 124-132 (1983); Kimura-Kuroda et al., J. Gen. Virol. 67: 2663-2672 (1986); Zhang et al., J. Med. Virol. 29: 133-138 (1989); and Roehrig et al., Virol. 128: 118-126 (1983)). JEV HIAF and normal mouse serum were used as positive and negative antibody controls, respectively.
  • Four JEV-specific, six flavivirus-subgroup specific, and two flavivirus-group reactive Mabs reacted similarly with the 4B clone or JEV-infected COS-1 cells (Table 2).
  • JE-4B COS-1 cells were grown and maintained in medium containing 200 ⁇ g/mL of neomycin. The cultured medium was routinely harvested and stored at 4° C., and replenished twice weekly, and the cells were split 1:5 every 7-10 days. Culture medium was clarified by centrifugation at 10,000 rpm for 30 min in a Sorvall F16/250 rotor at 4° C., and centrifuged further for 4 hr at 39,000 rpm in a Sorvall TH641 rotor at 4° C.
  • the subviral particles were purified from both pelleted and PEG-precipitated preparations by rate zonal centrifugation in a 5-25% continuous sucrose gradient in TN at 38,000 rpm at 4° C. for 90 min.
  • 1-mL fractions were collected from the top of the gradient, tested by antigen capture ELISA (see below), and the positive fractions loaded onto a 25-50% sucrose gradient in TN. This was centrifuged overnight in an equilibrium density centrifugation at 35,000 rpm at 4° C. 0.9-mL fractions from the equilibrium gradients were collected from the bottom. They were tested by antigen-capture ELISA and assessed for hemagglutination (HA) activity at pH 6.6.
  • HA hemagglutination
  • E protein 4 shows a comparison of the M and E proteins produced by JEV infected C6/36 and JE-4B COS-1 cells. Some nonspecific reactivity to E protein was observed in the normal mouse ascitic fluid and JM01 anti-peptide serum. Proteins identical in size to M and E were secreted in the subviral particles and could be detected by E-specific Mab 4G2 and prM-specific JM01 antiserum, respectively.
  • Hemagglutination (HA) activity was determined in the pH range from 6.1 to 7.0 by the method of Clarke and Casals ( Amer. J. Trop. Med. Hyg. 7: 561-573 (1958)).
  • the subviral particle secreted by JE-4B cells and the virion particle produced by JEV infected COS-1 cells had a similar HA profile with the optimum pH determined to be 6.6.
  • mice Groups of five 3-week-old female, ICR outbred mice were injected intramuscularly in the left and right quadriceps with 100 ⁇ g of pCDJE2-7 plasmid in 100 ⁇ L of dH 2 O or were given doses of JE-VAX (manufactured by the Research Foundation for Microbial Disease of Osaka University and distributed by Connaught Laboratories, Swiftwater, Pa.) subcutaneously that are one-fifth the dose given to humans.
  • the plasmid pcDNA3/CAT Invitrogen, which encodes and expresses an unrelated protein, was used as the negative vaccination control.
  • JEV antibody titers were determined by enzyme-linked immunosorbent assay (ELISA) against purified JEV or by plaque reduction neutralization tests (PRNT) (Roehrig et al., Virol. 171: 49-60 (1989); and Hunt and Calisher, Amer. J. Trop. Med. Hyg. 28: 740-749 (1979)).
  • ELISA enzyme-linked immunosorbent assay
  • PRNT plaque reduction neutralization tests
  • the pCDJE2-7 nucleic acid vaccine and JE-VAX provided 100% seroconversion within three weeks after the first vaccination in all three groups of mice (Table 3).
  • the JEV ELISA and PRNT antibody titers reached the highest level at week 6 and week 9, respectively, after immunization. Mice receiving 1 dose of DNA vaccine had similar antibody responses as those receiving 2 doses. Comparable ELISA antibody titers were maintained in DNA-vaccinated groups up to 60 weeks, after which the experiment was terminated. However, only one of four mice in the JE-VAX group was JEV antibody positive at 60 weeks post-inoculation. The pcDNA3/CAT control group did not have any measurable JEV antibody. These results demonstrate that a single dose of JEV-specific nucleic acid vaccine is more effective in maintaining JEV antibody in mice than the commercial, FDA-approved JE-VAX vaccine.
  • JEV protein was expressed by COS-1 cells transformed by either pCDJE2-7, pCBJE1-14, or pCIBJES14. JEV antibody induction by these nucleic acid constructs was compared to JE-VAX commercial vaccine at two different ages at vaccination. Three-day (mixed sex) or 3-week-old (female) ICR outbred mice, 10 per group, were vaccinated intramuscularly with 50 or 100 ⁇ g of plasmid DNA, or subcutaneously with doses of JE-VAX that are one-tenth or one-fifth the dose given to humans. Serum specimens were collected at 3 and 7 weeks after immunization and tested at a 1:1600 dilution by ELISA using purified JEV as an antigen. Results are shown in Table 4.
  • Plasmid pCBJE1-14 provided the highest extent of seroconversion, i.e., antibody titer greater than 1:1600, achieving 80-100% at both ages of vaccination.
  • Administration of pCDJE2-7 or pCIBJES14 provided moderate seroconversion by 7 weeks when 3-day old mice were vaccinated (60% for each), but weaker seroconversion (40% and 10%, respectively) when measured 3 weeks after vaccination.
  • these plasmids were administered at the age of 3 weeks, however, seroconversions of 90% or 100% were attained at both 3 weeks and 7 weeks after vaccination.
  • the commercial vaccine, JE-VAX conferred no seroconversion when administered at 3 days of age, and 100% when given at 3 weeks of age.
  • the nucleic acid TU's for JEV prM and E provided an extent of seroconversion better than a very high dose of the commercial vaccine, and unexpectedly high seroconversion in both young and more mature animals.
  • mice at the age of 3 weeks were vaccinated with either one dose or two doses spaced two days apart of pCDJE2-7 plasmid DNA, at 100 ⁇ g/100 ⁇ L, or with two doses of JE-VAX that were one-fifth the dose given to humans.
  • the negative control group received two doses of 100 ⁇ g/100 ⁇ L of pcDNA-3/CAT plasmid.
  • Passive protection by maternal antibody was evaluated in pups resulting from matings of experimental females with non-immunized male mice that occurred nine weeks following the first vaccination or 6 weeks following the second vaccination.
  • Pups were challenged between 3-15 days after birth by intraperitoneal administration of 5,000 pfu/100 ⁇ L of mouse-adapted SA14 virus and observed daily for 3 weeks (Table 6).
  • the survival rates correlated with the maternal neutralizing antibody titers. 100% of pups nursed by mothers with a PRNT of 1:80 survived viral infection, whereas none of the pups from the control mother survived (Table 6). Partial protection of 45% and 75% was observed in older pups that were nursed by mothers with a PRNT titer of 1:20 and 1:40, respectively.
  • the survival rates also correlated with the length of time that pups were nursed by the immune mother. As just indicated, 13-15 day old pups had high survival rates.
  • mice were inoculated intramuscularly with 1 or 2, 100 ⁇ g doses of plasmid DNA, or subcutaneously with two, 1 ⁇ 5 human doses of JE-VAX vaccine. Sera were collected 9 weeks post-vaccination for PRNT testing prior to mating with non-immune male.
  • Genomic RNA was extracted from 150 ⁇ L of Vero cell culture medium infected with NY 99-6480 strain, an strain isolated from the outbreak in New York 1999, using the QIAampTM Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in 80 ⁇ l of nuclease-free water, and used as a template for the amplification of WNV prM and E gene coding sequences. Primer sequences were obtained from the work of Lanciotti et al. ( Science 286: 2333-2337 (1999)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR).
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • Restriction sites BsmBI and KasI were engineered at the 5′ terminus of the cDNA by using amplimer WN466 (nucleotide sequence, SEQ ID NO: 12).
  • An in-frame translation termination codon, followed by a NotI restriction site was introduced at the 3′ terminus of the cDNA by using amplimer cWN2444 (SEQ ID NO: 13).
  • the RT-PCR product was purified by a QIAquickTM PCR Purification Kit (Qiagen).
  • the double-stranded amplicon produced by use of the two amplimers above (SEQ ID NO: 12 and SEQ ID NO: 13) was digested with KasI and NotI enzymes to generate a 998 bp (nt-1470 to 2468) fragment of DNA was inserted into the KasI and NotI sites of a pCBJESS vector to form an intermediate plasmid, pCBINT.
  • the pCBJESS was derived from the pCBamp plasmid, that contained the cytomegalovirus early gene promoter and translational control element and an engineered JE signal sequence element (Chang et al., J. Virol. 74: 4244-4252 (2000)).
  • the JE signal sequence element comprises the JE signal sequence (SEQ ID NO: 14).
  • the cDNA amplicon was subsequently digested with BsmBI and Kas I enzymes and the remaining 1003 bp fragment (nt-466 to 1470) was inserted in to the KasI site of pCBINT to form pCBWN (nucleic acid sequence, SEQ ID NO: 15; amino acid sequence, SEQ ID NO: 16).
  • pCBWN nucleic acid sequence, SEQ ID NO: 15; amino acid sequence, SEQ ID NO: 16.
  • Automated DNA sequencing using an ABI prism 377 Sequencer (Applied Biosystems/Perkin Elmer, Foster City, Calif.) was used to confirm that the recombinant plasmid had a correct prM and E sequence as defined by Lanciotti et al. ( Science 286: 2333-2337 (1999)).
  • Plasmid DNA for use in the in vitro transformation of mammalian cells or mouse immunization experiments was purified by anion exchange chromatography as described in Example 1.
  • WNV specific gene products encoded by the pCBWN plasmid were expressed in COS-1 cells.
  • Cells were electroporated and transformed with pCBWN plasmid according to Chang et al. ( J. Virol. 74: 4244-4252 (2000)). Electroporated cells were seeded onto 75 cm 2 culture flasks or a 12-well tissue culture dish containing one sterile coverslip/well. All flasks and 12-well plates were kept at 37° C., 5% CO 2 incubator. Forty hours following electroporation, coverslips containing adherent cells were removed from the wells, washed briefly with PBS, fixed with acetone for 2 minutes at room temperature, and allowed to air dry.
  • Protein expression was detected using indirect immunofluorescence antibody assay (IFA), as described in Example 2.
  • IFA indirect immunofluorescence antibody assay
  • Flavivirus E-protein specific monoclonal antibody (Mab) 4G2, WNV mouse hyperimmune ascitic fluid (RAF) and normal mouse serum (NMS) at 1:200 dilution in PBS were used as the primary antibody to detect protein expression (Henchal et al., Am. J. Trop. Med. Hyg. 31: 830-836 (1982)).
  • Tissue culture medium was harvested 40 and 80 hours following electroporation.
  • Antigen-capture (Ag-capture) ELISA was used to detect secreted WN virus antigen in the culture medium of transiently transformed COS-1 cells.
  • the Mab 4G2 and horseradish peroxidase-conjugated Mab 6B6C-1 were used to capture the WN virus antigens and detect captured antigen, respectively (Chang et al., J. Virol. 74: 4244-4452 (2000); Henchal et al., Am. J. Trop. Med. Hyg. 31: 830-836 (1983); Roehrig et al., Virology 128: 118-126 (1983)).
  • WN virus antigen in the medium was concentrated by precipitation with 10% polyethylene glycol (PEG)-8000.
  • the precipitant was resuspended in TNE buffer (50 mM Tris, 100 mM NaCl, 10 mM EDTA, pH 7.5), clarified by centrifugation, and stored at 4° C.
  • the precipitant was resuspended in a lyophilization buffer (0.1 M TRIZMA and 0.4% bovine serum albumin in borate saline buffer, pH 9.0), lyophilized and stored at 4° C. Lyophilized preparations were used as antigen for the evaluation in MAC- and indirect IgG ELISAs.
  • WN virus-specific protein was detected by IFA on the transiently transformed COS-1 cells. E, prM and M proteins expressed in these cells were secreted into the culture medium. WN virus antigen concentrated by PEG precipitation was extracted with 7.0% ethanol to remove residual PEG (Aizawa et al., Appl. Enviro. Micro. 39: 54-57 (1980)). Ethanol extracted antigens and gradient-purified WN virions were analyzed on a NuPAGE, 4-12% gradient Bis-Tris Gel in a Excel Plus Electrophoresis Apparatus (Invitrogen Corp., Carlsbad, Calif.) and followed by electroblotting onto nitrocellulose membranes using a Excel Plus Blot Unit (Invitrogen Corp.).
  • WN virus-specific proteins produced by the transiently transformed COS-1 cells were detected by WN virus specific mouse HIAF or flavivirus E protein reactive Mab 4G2 in a Western blot analysis, using NMS as a negative serum control.
  • the proteins displayed similar reactivity and identical molecular weights to the corresponding gradient purified virion E, prM and M protein derived from WN virus infected suckling mouse brain (SMB).
  • NRA as an antigen for diagnostic ELISA
  • one vial of lyophilized NRA representing antigen harvested from 40 ml of tissue culture fluid, was reconstituted in 1.0 ml of distilled water and compared with the reconstituted WN virus infected suckling mouse brain (SMB) antigen provided as lyophilized as ⁇ -propiolactone-inactivated sucrose-acetone extracts (Clarke et al., Am. J. Trop. Med. Hyg. 7: 561-573 (1958)).
  • SMB suckling mouse brain
  • All recombinant proteins, prM, M and E had a similar reactivity to that of the gradient-purified virion E, prM and M proteins.
  • the antigen could be detected in the medium one day following transformation; and the maximum ELISA titer (1:32-1:64) in the culture fluid without further concentration was observed between day two and day four.
  • NRA was concentrated by PEG precipitation, resuspended in a lyophilization buffer, and lyophilized for preservation.
  • one vial of lyophilized NRA was reconstituted with 1.0 ml distilled water and titrated in the MAC- or indirect IgG ELISA using WN virus positive and negative reference human sera (Johnson et al., J. Clin. Microbiol. 38: 1827-1831 (2000); Martin et al., J. Clin. Microbiol. 38: 1823-1826 (2000)).
  • Dilutions 1:320 and 1:160 of the NRA were found to be the optimal concentrations for use in MAC- and IgG ELISA, respectively. These dilutions resulted in a P/N OD 450 ratio of 4.19 and 4.54, respectively, for MAC- and IgG test.
  • the WN virus SMB antigens produced by NY-6480 and Eg101 strains were used at 1:320 and 1:640 dilution for MAC-ELISA, and 1:120 and 1:320 for IgG ELISA, respectively.
  • the negative control antigens, PEG precipitates of the culture medium of normal COS-1 cells and normal SMB antigen, were used at the same dilutions as for the respective NRA and SMB antigen.
  • Human serum specimens, diluted at 1:400, were tested concurrently in triplicate with virus-specific and negative control antigens. For the positive test result to be valid, the OD 450 for the test serum reacted with viral antigen (P) had to be at least two-fold greater than the corresponding optical density value of the same serum reacted with negative control antigen (N).
  • the cerebrospinal fluid had IgM P/N reading of 13.71 and 2.04 against Eg-101- and SLE-SMB antigens, respectively.
  • Day-31 and day-44 specimens were negative ( ⁇ 1:400) by using NY-SMB antigen but positive by using NRA and Eg101-SMB.
  • Compatible IgG titers were observed with all three antigens used in the test.
  • mice Groups of ten, three-wk-old female ICR mice were used in the study. Mice were injected intramuscularly (i.m.) with a single dose of pCBWN or a green fluorescent protein expressing plasmid (pEGFP) DNA (Clonetech, San Francisco, Calif.). The pCBWN plasmid DNA was purified from XL-1 blue cells with EndoFree Plasmid Giga Kits (Qiagen) and resuspended in PBS, pH 7.5, at a concentration of 1.0 ⁇ g/ ⁇ l. Mice that received 100 ⁇ g of pEGFP were used as unvaccinated controls.
  • pCBWN green fluorescent protein expressing plasmid
  • mice were injected with the pCBWN plasmid at a dose of 100, 10, 1.0, or 0.1 ⁇ g in a volume of 100 ⁇ l.
  • Groups that received 10, 1.0, or 0.1 ⁇ g of pCBWN were vaccinated by the electrotransfer mediated in vivo gene delivery protocol using the EMC-830 square wave electroporator (Genetronics Inc. San Diego, Calif.).
  • the electrotransfer protocol was based on the method of Mir et al., ( Proc. Natl. Acad. Sci. USA 96: 4262-4267. (1999)).
  • transcutaneous electric pulses were applied by two stainless steel plate electrodes, placed 4.5-5.5 mm apart, at each side of the leg.
  • mice were bled every 3 wks following injection.
  • the WN virus specific antibody response was evaluated by Ag-capture ELISA and plaque reduction neutralization test (PRNT). Individual sera were tested by IgG-ELISA, and pooled sera from 10 mice of each group were assayed by PRNT. All the mice vaccinated with pCBWN had IgG ELISA titers ranging from 1:640 to 1:1280 three wks after vaccination. The pooled sera collected at three and six wks had a Nt antibody titer of 1:80. None of the serum specimens from pEGFP control mice displayed any ELISA or Nt titer to WN virus.
  • mice were challenged with NY-6480 virus either by intraperitoneal injection or by exposure to the bite of virus-infected Culex mosquitoes.
  • Half of the mouse groups were challenged intraperitoneally (ip) at 6 wks post vaccination with 1,000 LD 50 (1,025 PFU/100 ⁇ l) of NY99-6480 virus.
  • the remaining mice were each exposed to the bites of three Culex tritaeniorhynchus mosquitoes that has been infected with NY99-6480 virus 7 days prior to the challenge experiment.
  • Mosquitoes were allowed to feed on mice until they were fully engorged. Mice were observed twice daily for three wks after challenge.
  • mice immunized with WN virus DNA remained healthy after virus challenge while all control mice developed symptoms of CNS infection 4-6 days following virus challenge and died on an average of 6.9 and 7.4 days after intraperitoneal or infective mosquito challenge, respectively.
  • mice were immunized with 10.0 to 0.1 ⁇ g of pCBWN per animal by use of electrotransfer. All groups that received pCBWN were completely protected from virus challenge. At 6 wks after immunization all groups of electrotransfer mice had Nt titer less than four-fold different than animals receiving 100 ⁇ g of pCBWN by conventional i.m. injection without electrotransfer. Both these results evidencing effective immunization suggest that the electrotransfer protocol enhances the immunogenicity and protective efficacy of the DNA vaccine of the invention (when carried out as described in (Mir et al., Proc. Natl. Acad. Sci. USA. 96: 4262-4267. (1999))).
  • WN virus and SLE virus antibody-negative by ELISA and PRNT were shown to be WN virus and SLE virus antibody-negative by ELISA and PRNT.
  • Four horses were injected i.m. with a single dose (1,000 ⁇ g/1,000 ⁇ l in PBS, pH 7.5) of pCBWN plasmid. Serum specimens were collected every other day for 38 days prior to virus challenge, and the WN virus specific antibody response was evaluated by MAC- or IgG ELISA and PRNT.
  • Body temperature was recorded, and serum specimens collected twice daily from days 0 (day of infection) to 10, then once daily through day 14. Pulse and respiration were recorded daily after challenge. The collected serum samples were tested by plaque titration for detection of viremia, and by MAC- or IgG ELISA and PRNT for antibody response.
  • the only horse from the entire study to display clinical signs of disease was horse #11, which became febrile and showed neurologic signs beginning 8 days after infection. This horse progressed to severe clinical disease within 24 hours and was euthanized on day 9.
  • Virus titers ranged from 10 1.0 PFU/ml of serum (in horse #10), the lowest level detectable in our assay, to 10 2.4 /ml (in horse #9).
  • Horse #14 did not develop a detectible viremia during the test period. However, this horse was infected by the virus, as evidenced by Nt antibody detected after day 12.
  • Nt antibody response was not observed in vaccinated horses as evidenced by the gradual increase in Nt titer during the experiment.
  • Pre-existing Nt antibody in the vaccinated horse prior to mosquito challenge could suppress initial virus infection and replication. Without virus replication, the challenge virus antigen provided by infected mosquitoes may not contain a sufficient antigen mass to stimulate anamnestic immune response in the vaccinated horse. All vaccinated horses were euthanized at 14 days after virus challenge. Gross pathological and histopathological lesions indicative of WN viral infection were not observed.
  • Genomic RNA was extracted from 150 ⁇ L of YFV strain TRI-788379 or SLE strain 78V-6507 virus seeds using Q1AampTM Viral RNA Kit (Qiagen, Santa Clarita, Calif.). The viral RNA was used as a template for amplification of YFV or SLEV prM and E gene coding regions.
  • Primers YFDV389 (nucleotide sequence, SEQ ID NO:4; amino acid sequence, SEQ ID NO:5), cYFDV2452 (SEQ ID NO:6), SLEDV410 (nucleotide sequence, SEQ ID NO:7; amino acid sequence, SEQ ID NO:8) and cSLEDV2449 (SEQ ID NO:9) were used to generate the corresponding recombinant nucleic acids as described above for the preparation of the JEV and WNV recombinant plasmids.
  • RT-PCR amplified cDNA digested with KpnI and NotI enzymes, was inserted into the KpnI-NotI site of a eukaryotic expression plasmid vector, pcDNA3 (Invitrogen). Both strands of the cDNA were sequenced and verified for identity to sequences from YFV strain TRI-788379 or SLEV strain 78V-6507.
  • Recombinant plasmids pCDYF2 and pCDSLE4-3 which contained the nucleotide sequences of the prM and E coding regions for YFV or SLEV, respectively, were purified using an EndoFreeTM Plasmid Maxi Kit (Qiagen), and used for in vitro transformation or mouse immunization.
  • YFV or SLEV specific antigens were expressed in COS-1 cells transformed by pCDYF2 or pCDSLE4-3, respectively.
  • the level of expressed proteins was similar to a YFV- or SLEV-infected COS-1 cell control.
  • COS-1 cell lines transformed by vectors bearing genes for the viral antigens were obtained which constitutively express YFV or SLEV antigenic proteins.
  • Epitope mapping by IFA using a panel of YFV or SLEV E-specific Mabs indicated that the authentic E protein was expressed by the pCDYF2- or pCDSLE4-3-transformed COS-1 cells.
  • a preliminary study indicated that 100% of three week-old female, ICR mice seroconverted after intramuscular inoculation with a single dose of 100 ⁇ g/100 ⁇ L of pCDSLE4-3 plasmid in deionized water.
  • Genomic RNA was extracted from 150 ⁇ L of Vero cell culture medium infected with MSI-7 strain of St. Louis encephalitis virus using the QIAampTM Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in 80 ⁇ l of nuclease-free water, and used as a template for the amplification of St. Louis encephalitis virus prM and E gene coding sequences. Primer sequences were obtained from the work of Trent et al. ( Virology 156: 293-304 (1987)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR).
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • Restriction site AfeI was engineered at the 5′ terminus of the cDNA by using amplimer SLE463 (SEQ ID NO:30). An in-frame translation termination codon, followed by a NotI restriction site was introduced at the 3′ terminus of the cDNA by using amplimer cSLE2447 (SEQ ID NO:31). The RT-PCR product was purified by a QIAquickTM PCR Purification Kit (Qiagen).
  • the double-stranded amplicon produced by use of the two amplimers above (SEQ ID NO:30 and SEQ ID NO:31), was digested with AfeI and NotI enzymes to generate a 2004 fragment of DNA (463 to 2466 nt), and inserted into the AfeI and NotI sites of a pCBJESS-M vector to form pCBSLE (nucleotide sequence, SEQ ID NO:21; amino acid sequence, SEQ ID NO:22).
  • the pCBJESS-M was derived from the pCBamp plasmid, that contained the cytomegalovirus early gene promoter and translational control element and an engineered, modified JE signal sequence element (SEQ ID NO:27).
  • the JE signal sequence element comprises the modified JE signal sequence at ⁇ 4 (Cys to Gly) and ⁇ 2 (Gly to Ser) position in the original pCBJESS plasmid.
  • Genomic RNA was extracted from 150 ⁇ L of Vero cell culture medium infected with 17D-213 strain of yellow fever virus using the QIAampTM Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in 80 ⁇ l of nuclease-free water, and used as a template for the amplification of yellow fever virus prM and E gene coding sequences. Primer sequences were obtained from the work of dos Santos et al. ( Virus Research 35: 35-41 (1995)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR).
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • Restriction site AfeI was engineered at the 5′ terminus of the cDNA by using amplimer YF482 (SEQ ID NO:28). An in-frame translation termination codon, followed by a NotI restriction site was introduced at the 3′ terminus of the cDNA by using amplimer cYF2433 (SEQ ID NO:29). The RT-PCR product was purified by a QIAquickTM PCR Purification Kit (Qiagen).
  • the double-stranded amplicon produced by use of the two amplimers above (SEQ ID NO:28 and SEQ ID NO:29), was digested with AfeI and NotI enzymes to generate a 1971 fragment of DNA (482 to 2452 nt), and inserted into the AfeI and NotI sites of a pCBJESS-M vector to form pCBYF (nucleotide sequence, SEQ ID NO:23; amino acid sequence, SEQ ID NO:24).
  • the pCBJESS-M was derived from the pCBamp plasmid, that contained the cytomegalovirus early gene promoter and translational control element and an engineered JE signal sequence element (SEQ ID NO:27).
  • the JE signal sequence element comprises the modified JE signal sequence at ⁇ 4 (Cys to Gly) and ⁇ 2 (Gly to Ser) position of JESS in the pCBJESS plasmid.
  • Genomic RNA was extracted from 150 ⁇ L of Vero cell culture medium infected with LB strain of Powassan virus using the QIAampTM Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in 80 ⁇ l of nuclease-free water, and used as a template for the amplification of Powassan virus prM and E gene coding sequences. Primer sequences were obtained from the work of Mandl et al. ( Virology 194: 173-184 (1993)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR).
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • Restriction site AfeI was engineered at the 5′ terminus of the cDNA by using amplimer POW454 (SEQ ID NO:25). An in-frame translation termination codon, followed by a NotI restriction site was introduced at the 3′ terminus of the cDNA by using amplimer cPOW2417 (SEQ ID NO:26). The RT-PCR product was purified by a QIAquickTM PCR Purification Kit (Qiagen).
  • the double-stranded amplicon produced by use of the two amplimers above (SEQ ID NO:25 and SEQ ID NO:26), was digested with AfeI and NotI enzymes to generate a 1983 bp fragment of DNA (454 to 2436 nt), and inserted into the AfeI and NotI sites of a pCBJESS-M vector to form pCBPOW (nucleotide sequence, SEQ ID NO: 19; amino acid sequence, SEQ ID NO:20).
  • the pCBJESS-M was derived from the pCBamp plasmid, that contained the cytomegalovirus early gene promoter and translational control element and an engineered JE signal sequence element (SEQ ID NO:27).
  • the JE signal sequence element comprises the modified JE signal sequence at ⁇ 4 (Cys to Gly) and ⁇ 2 (Gly to Ser) position of JESS in the pCBJESS plasmid.
  • vectors including nucleic acid TU's for dengue serotype 2 antigens are to be followed to prepare vectors including nucleic acid TU's for dengue serotype 2 antigens.
  • the amplimers used for construction of the vectors may be chosen to engineer the normal dengue virus signal sequence or they may be chosen so as to engineer a signal sequence from another flavivirus, such as a modified Japanese encephalitis virus signal sequence.
  • a plasmid containing the dengue serotype 2 gene region from prM to E is to be constructed.
  • the dengue serotype 2 prM and E genes (Deubel et al., Virology 155:365-377 (1986); Gruenberg et al., J. Gen. Virol. 69: 1301-1398 (1988); Hahn et al., Virology 162:167-180 (1988)) are to be ligated into a plasmid such as pcDNA3, and then excised and cloned into vectors such as pCBamp, pCEP4, pREP4, or pRc/RSV (supplied by Invitrogen, Carlsbad, Calif.) to enable expression.
  • a dengue serotype 2 virus-specific sequence encoded in a cDNA sequence may be amplified using a procedure such as the polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • a DNA sequence may be amplified by a RT-PCR procedure.
  • a DNA fragment including an initiation codon at the 5′ end, and a termination codon at the 3′ end is to be cloned into an expression vector at an appropriate restriction nuclease-specific site, in such a way that the cytomegalovirus (CMV) immediate early (1E) promoter, an initiation codon, and a terminator, are operably linked to the dengue serotype 2 virus sequence.
  • CMV cytomegalovirus
  • the dengue serotype 2 nucleic TU vaccine encoding the gene region from prM to E prepared in Example 16 is to be suspended in a suitable pharmaceutical carrier, such as water for injection or buffered physiological saline, and injected intramuscularly into groups of weanling mice. Control groups receive a comparable plasmid preparation lacking the dengue serotype 2 specific genes.
  • the generation of dengue serotype 2-specific antibodies, and/or of dengue serotype 2-specific immune system cytotoxic cells is to be assessed at fixed intervals thereafter, for example at weekly intervals.
  • mice are to be challenged with dengue serotype 2 virus. Levels of viremia are to be assessed at appropriate intervals thereafter, such as every second day. Passive protection by maternal antibody is to be assessed as indicated in Example 8.
  • Signal peptides can determine the translocation and orientation of inserted protein, hence, the topology of prM and E proteins.
  • the most common feature of signal peptides of eukaryotes consists of an 8 to 12 stretch of hydrophobic amino acids called the h-region (von Heijne, “Signal sequences. The limits of variation” J. Mol. Biol. 184: 99-105 (1985)).
  • the region between the initiator Met and the h-region, which is known as the n-region usually has one to five amino acids, and normally carries positively charged amino acids.
  • the c-region which consists of three to seven polar but mostly uncharged amino acid residues.
  • Signal peptide differences in various plasmid constructs can account, at least in part, for the difference in protein translocation, cleavage site presentation and correct topology, thus, prM and E secretion and VLP formation.
  • the modulation or optimization of these attributes can be improved by selection or use of signal sequences with properties that impart the desired characteristics. This can be accomplished by use of machine-learning computer programs using, for example, a hidden Markov model (HMM) trained on eukaryotes (see Henrik Nielsen et al., “Prediction of signal peptides and signal anchors by a hidden Markov model,” In Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology (ISMB 6), AAAI Press, Menlo Park, Calif., pp.
  • HMM hidden Markov model
  • the signal peptide sequences in these constructs are different in the length of n-region which may or may not contain charged amino acids (Table 7).
  • the n-region containing positively charged amino acids forms a short loop in the cytoplasmic side that causes the h-region (transmembrane helix) to be inserted in a tail orientation, exposing the signalase cleavage site.
  • secreted VLPs containing prM/M and E proteins could be purified from culture medium of the pCDJE2-7 transformed cell line, JE4B, or pCBJE1-14 transiently transformed COS-1 cells.
  • the gradient-purified VLPs and virions have identical immunological and biochemical properties.
  • prM and E proteins expressed by pCDJE2-7 and pCBJE1-14 can be expressed as type II transmembrane proteins in the orientation similar to that of virion prM and E (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)).
  • the prM protein of pcDNA3JEME could be expressed as a type II membrane protein with its transmembrane h-region inserted in a head orientation because of the absence of positively charged amino acids in its n-region (Konishi et al., “Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes,” J. Virol. 72: 4925-4930 (1998)).
  • Efficient protein synthesis in combination with the expressed protein having the correct topology, particularly of the expressed prM and E, can enhance VLP formation and secretion, and thus promote the immunogenicity of the DNA vaccine (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)).
  • WN virus expression plasmid (Table 2) (Davis et al., “West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays,” J. Virol. 75: 4040-4047 (2001)).
  • the pCBWN plasmid consists of a short version of JE virus signal peptide followed by WN virus prM-E gene sequence. Vaccine potential of this construct was amply demonstrated, as a single i.m. injection of pCBWN DNA not only induced a protective immunity but also prevented WN virus infection in mice and horses.
  • virus-encoded signal sequence from the same virus as the antigen-coding regions is not necessarily the optimal signal peptide available.
  • non-modified signal sequence is not necessarily optimal.
  • the signal peptide encoded in the pCBJE1-14 plasmid can be improved, as measured by the signal sequence probability by shortening n-region, by altering c-region sequence, or by the combination of both modifications ( FIG. 6 ).
  • a shortened version of JE virus signal peptide has been used for the expression of WN virus prM and E genes as described herein and in papers incorporated herein by reference for the teaching (Davis et al., “West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays,” J. Virol. 75: 4040-4047 (2001)).
  • Multivalent and/or combination vaccines designed to immunize against multiple flaviviruses can also be produced.
  • monovalent vaccine components are prepared that include elements related to pathogens of interest, such as YF, different serotypes of DEN, JE, WN, SLE and TBE (RSSE and CEE) viruses or any other combination of flaviviruses.
  • Design and production of DNA constructs as described in the other examples and in the specification are carried out as described.
  • Combinations of appropriate vaccines can be made to provide multivalent or combination vaccines protective against multiple pathogens. Preliminary data from our group has demonstrated that i.m.
  • mice Each monovalent component, even if constructed using identical transcriptional and translational regulators, should preferably be tested in an analogous model system to ensure its vaccine potential.
  • a combination vaccine cocktail can then be formulated. These vaccine cocktails can be tailored specifically for particular geographic regions. For example, a vaccine cocktail for tropical and subtropical Asia should include four serotypes of DEN, WN and JE virus vaccines. Similarly useful vaccine cocktails for Africa and Latin America should include four serotypes of DEN, WN and YF virus vaccines and four serotypes of DEN, Rocio and YF virus vaccines, respectively.
  • MAb Monoclonal antibody reactivity indicated that all three plasmids expressed E protein epitopes that reacted with a panel of domain 1, 2 and 3 antibodies.
  • pCB8D2-2J-2-9-1 construct SEQ ID NO:46
  • M matured prM
  • E into the media of the plasmid-transformed COS-1 cells.
  • Replacement of 20% of the sequence encoding the E protein of DEN-2 E with sequence encoding the corresponding JE E protein sequence had no effect on MAbs reactivity.
  • mice received two intramuscular immunization of selected plasmids at 0 and 3-wks, and the immune response was evaluated by determining specific neutralizing and ELISA antibody.
  • the plasmid expressing secreted prM and E which can form subviral-particles (SVPs), was superior to other constructs in stimulating an antibody response.
  • SVPs subviral-particles
  • Dengue fever fever is an acute infection that occurs in subtropical and tropical areas. It is one of the most important flaviviral diseases of humans.
  • DEN serotypes DEN-1, DEN-2, DEN-3 and DEN-4
  • DF dengue fever
  • DHF/DSS dengue shock syndrome
  • Safe vaccines must minimize the potential risk of serious infection by virulent viruses.
  • virulent viruses can arise by gene reversion or recombination of some types of vaccines derived from attenuated vaccine viruses. Such occurrences did arise in the poliovirus eradication campaign (Guillot et al., “Natural Genetic Exchanges between Vaccine and Wild Poliovirus Strains in Humans,” J. Virol. 74: 8434-8443 (2000); Liu et al., “Molecular Evolution of a Type 1 Wild-Vaccine Poliovirus Recombinant during Widespread Circulation in China,” J. Virol. 74: 11153-11161 (2000)).
  • genomic sequencing of an American strain of yellow fever virus, TRINID79A demonstrates that there is extensive similarity between this strain and the attenuated yellow fever vaccine virus, FNV (Chang et al., “Nucleotide sequence variation of the envelope protein gene identifies two distinct genotypes of yellow fever virus,” J. Virol. 69: 5773-5780 (1995); Pisano et al., “Complete nucleotide sequence and phylogeny of an American strain of yellow fever virus, TRINID79A,” Arch. Virol. 144: 1837-1843 (1999)). While not conclusive in and of itself, the similarity strongly suggests that TRINID 79A is derived from the FNV vaccine virus.
  • DNA-based vaccines are novel and promising immunization approach for the development of flavivirus vaccines (as described herein, in Chang et al., “Flavivirus DNA vaccines: current status and potential,” Ann. NY Acad. Sci. 951: 272-285 (2001), and in references cited therein).
  • DEN-2 vaccines were produced and the immune response in mice after i.m. immunization of DEN-2 constructs were correlated with the efficiency of prM/M and E secretion.
  • One construct that led to the secretion of significant amounts of prM/M and E antigens was shown to be capable of stimulating high titers of neutralizing antibodies in plasmid-vaccinated mice.
  • COS-1 cells ATCC, Manassas, Va.; 1650-CRL
  • DMEM Dulbecco's modified Eagle minimal essential medium
  • FBS heat-inactivated fetal bovine serum
  • Vero and C6/36 cells were grown under the same conditions used for COS-1 cells.
  • DEN-2 virus strain-16681, was used for cDNA cloning, IgG ELISA and the plaque reduction neutralization test (PRNT).
  • Virus was propagated in the C6/36 cell culture.
  • Virus used for immunological or biochemical studies was purified by precipitation with 7% polyethylene glycol (PEG-8000; Fisher Scientific, Fair Lawn, N.J.) followed by ultracentrifugation on 30% glycerol-45% potassium-tartrate gradients (Obijeski et al., “Segmented genome and nucleocapsid of La Crosse virus,” J. Virol. 20:664-675 (1976)).
  • Genomic RNA was extracted from 150 ⁇ l of C6/36 cell culture medium infected with DEN-2 16681 strain using the QIAampTM Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was resuspended in 80 ⁇ l of diethyl pyrocarbonate-treated water (DEPC, Sigma, ST. Louis, Mo.) and then used as a template in reverse transcriptase-PCR(RT-PCR) amplification of DEN-2 virus prM and E genes.
  • DEPC diethyl pyrocarbonate-treated water
  • Primer sequences (Table 9) were designed based on published sequences (Gadkari et al., “Critical evaluation of Kyasanur Forest disease virus neutralizing antibodies found in bats (a preliminary report),” Indian J. Med. Res. 64: 64-67 (1976); Kinney et al., “Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53 ,” Virology 230: 300-308 (1997)). The recognition and cleavage site for restriction enzyme KasI was incorporated at the 5′ terminus of the cDNA amplicon.
  • DEN-2 virus cDNA amplicon was digested with KasI and NotI enzymes, and was then inserted into the KasI and NotI sites of a pCBJESS vector to form the 100% DEN-2 E plasmid, pCBD2-14-6 (SEQ ID NO:42).
  • PCR amplified DNA fragments for the 90% DEN-2-10% JE E protein gene were digested with BxtXI restriction endonuclease, ligated using T4 DNA ligase, digested with KasI and NotI enzyme, and inserted into the KasI and NotI sites of the pCBJESS vector to obtain the plasmid, pCB9D2-1J-4-3 (SEQ ID NO:44).
  • PCR amplified DNA fragments for the 80% DEN-2-20% JE E gene were digested with BsmBI, ligated with T4 DNA ligase, digested with KasI and NotI enzyme, and inserted into the KasI and NotI sites of the pCBJESS vector to obtain the plasmid, pCB8D2-2J-2-9-1 (SEQ ID NO:46).
  • Schematic representations of the three plasmid constructs are shown in FIG. 7 .
  • the 90% DEN-2-10% JE E and the 80% DEN-2-20% JE E protein junction regions, respectively, are shown in Table 9.
  • DEN-2 recombinant antigen in COS-1 cells by electroporation.
  • COS-1 cells were electroporated separately with each DEN-2 plasmid or green fluorescent protein expression plasmid control (pEGFP, Clonetech, San Francisco, Calif.) using the protocol described elsewhere in the examples and in Chang et al., (“A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)).
  • Electroporated cells were seeded onto 75 cm 2 culture flasks, and kept at 37° C. and 5% CO 2 . Six hours following electroporation the growth media were replaced with a maintenance media containing 2% fetal bovine serum. Tissue culture medium and cells were harvested separately 48 hours following electroporation for antigen characterization.
  • Recombinant antigen in the medium was concentrated by precipitation with 10% polyethylene glycol (PEG)-8000.
  • the precipitant was resuspended in TNE buffer (50 mM Tris, 100 mM NaCl, 10 mM EDTA, pH 7.5) to 1/100% of the original volume, clarified by centrifugation, and stored at 4° C.
  • Recombinant antigen concentrated by PEG precipitation and resuspended in TNE buffer was extracted with 4.0% ethanol to remove residual PEG (Hunt et al., “A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen,” J. Virol. Methods.
  • Ethanol-extracted antigens, hydrophobic membrane proteins from the transformed cells and gradient-purified DEN-2 virions were analyzed on a NuPAGE, 4-12% Bis-Tris gradient gel in an Excel Plus Electrophoresis ApparatusTM (Invitrogen Corp., Carlsbad, Calif.), followed by electroblotting onto nitrocellulose membranes using a Excel Plus Blot Unit (Invitrogen Corp.).
  • DEN-2 virus-specific protein was detected by western blot using DEN-2 virus specific MAbs 1A6A-8 (E specific) and 1A2A-1 (capsid specific), as well as rabbit antiserum specific for DEN-2 prM and mouse serum specific for a peptide composed of amino acid 1-34 of the DEN-2 M protein, and normal mouse ascitic fluid was used as negative control (Murray et al., “Processing of the dengue virus type 2 proteins prM and C-prM,” J. Gen. Virol. 74 (Pt 2): 175-182 (1993); Roehrig et al., “Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica,” Virology 246: 317-328 (1998)).
  • mice were i.m. injected with pCBD2-14-6, pCB9D2-1J-4-3, pCB8D2-2J-2-9-1 or pEGFP on week-0 and week-3 at a dose of 100 ⁇ g in a volume of 100 ⁇ l per mouse.
  • the plasmid DNA was purified from XL-1 blue cells with EndoFree Plasmid Giga KitsTM (Qiagen) and resuspended in PBS, pH 7.5, at a concentration of 1.0 ⁇ g/ ⁇ l.
  • Mice that received 100 ⁇ g of pEGFP were used as plasmid-vaccinated controls. Mice were bled every 3 wks following injection, and the DEN-2 virus specific antibody response was evaluated by use of indirect ELISA and PRNT.
  • DEN-2 virion Pre- and post-vaccination serum specimens were tested for antibody binding ability to purified DEN-2 virion by ELISA, for neutralizing (Nt) antibody by PRNT, and for antibodies that recognize purified DEN-2 virus proteins by Western blotting.
  • PRNT was performed with Vero cells, as previously described (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)), using DEN-2 (strain-16681) and JE (strain-Nakayama) virus.
  • Endpoints were determined at a 90% plaque-reduction level (Hunt et al., “A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen,” J. Virol. Methods. 97: 133-149 (2001)).
  • DEN-2 virus recombinant antigen i. Transient expression of DEN-2 virus recombinant antigen. Expression of the prM and E genes of DEN-2 virus or a chimeric E gene from a combination of DEN-2 and JE virus sequences (80% DEN-20% JE or 90% DEN-10% JE) was accomplished by separate transformations of each of the three recombinant DEN-2 DNA plasmids into COS-1 cells.
  • the basic plasmid design was based on results from previous studies with JE virus and WN virus recombinant plasmids in which plasmid-transformed cells expressed, and secreted authentic viral proteins into the cell culture fluid (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000); Davis et al., “West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays,” J. Virol. 75: 4040-4047 (2001)).
  • Transient expression of DEN-2 recombinant proteins was initially assessed by Ag-capture ELISA of cell culture supernatants and by IFA of acetone-fixed, transformed COS-1 cells (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)). The point of optimum antigen expression was determined to be 48 hours following electroporation.
  • DEN-2 protein expressed by transiently-transformed COS-1 cells was evaluated by IFA using a panel of murine MAbs with known reactivity to DEN-2 virus (Table 10; Henchal et al., “Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies,” Am. J. Trop. Med. Hyg. 34: 162-169 (1985); Roehrig et al., “Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica,” Virology 246: 317-328 (1998)).
  • the MAb panel included antibodies reactive with each of the three antigenic domains of the E protein of flaviviruses as well as prM and C proteins.
  • the MAb panel included antibodies reactive with each of the three antigenic domains of the E protein of flaviviruses as well as prM and C proteins.
  • Mahl et al. “Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model,” J. Virol. 63: 564-571 (1989); Rey et al., “The envelope glycoprotein from tick-borne encephalitis virus at 2 ⁇ resolution,” Nature 375: 291-298 (1995)).
  • the MAbs specific for flavivirus antigenic Domains 2 and 3 showed nearly identical qualitative reactivity with DEN-2 virus and each of the three plasmid-expressed proteins.
  • iii Comparison of secreted protein and membrane-bound protein produced by each of the three DEN-2 recombinant plasmids. Similar amounts of cell culture fluid were harvested from COS-1 cells 48 hours post-transformation for each recombinant DEN-2 plasmid. Secreted recombinant antigen found in the culture fluid was concentrated 100-fold by PEG precipitation, followed by ethanol extraction to remove PEG which interfered with subsequent analysis by polyacrylamide gel electrophoresis. The relative amount of secreted antigen expressed by each plasmid was determined by Ag-capture ELISA analysis of both PEG-precipitated and ethanol-extracted cell culture fluid preparations (Table 11).
  • any assessment of the expression of these proteins by the three recombinant DEN-2 plasmids should include an evaluation of cell membrane preparations from plasmid-transformed cells.
  • the Mem-PER Mammalian Membrane Protein Extraction Reagent kit (Pierce) was used to isolate the integral membrane proteins from equivalent numbers of cells transformed by each of the recombinant plasmids. Hydrophobic proteins were separated from hydrophilic proteins by phase partitioning.
  • mice vaccinated with three different DEN-2 recombinant DNA plasmids Three-week old ICR mice were immunized by i.m. injection with 100 ⁇ g of pCB8D2-2J-2-9-1 (SEQ ID NO:46), pCB9D2-1J-4-3 (SEQ ID NO:44), pCBD2-14-6 (SEQ ID NO:42), or pEGFP on weeks 0 and 3. Mice were bled 3, 6, and 9 weeks after the primary immunization.
  • mice were tested by indirect ELISA, using screening dilutions of 1:100 and 1:400 at 3 and 6 weeks post-vaccination and endpoint titrations at 9 weeks post-vaccination.
  • Nine-week sera were also tested by PRNT with both DEN-2 and JE viruses.
  • the ELISA results showed that after one immunization (3-week sera), all mice given pCB8D2-2J-2-9-1 had seroconverted, whereas only 50% of pCB9D2-1J-4-3 and 20% of pCBD2-14-6-vaccinated mice reacted with DEN-2 virus (Table 12).
  • mice vaccinated with either pCB8D2-2J-2-9-1 or pCBD2-1J-4-3 demonstrated anti-DEN-2 ELISA reactivity; however, the geometric mean titers differed significantly (titers of 1:20,000 versus 1:708, respectively). Only 40% of pCBD2-14-6-immunized mice had anti-DEN-2 ELISA titers greater than 1:100.
  • a western blot of pooled 9-week sera from pCB8D2-2J-2-9-1-immunized mice on purified DEN-2 virus showed that the immunodominant response was to the E glycoprotein. Slight reactivity reactivity to prM and M were also detected.
  • mice immunized with the control plasmid pEGFP exhibited no reactivity to either DEN-2 or JE viruses.
  • DEN-2 plasmid pCBD2-14-6 (SEQ ID NO:42), consisting of the authentic DEN-2 prM and E gene region.
  • these COS-1 cells transformed by the plasmid encoding an authentic DEN-2 prM and E region failed to secrete detectable DEN-2 antigen into the culture fluid (as measured by antigen-capture ELISA).
  • DEN-2 virus DNA vaccine Previous attempts for the development of DEN-2 virus DNA vaccine has resulted in varying degrees of success (Kochel et al., “Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice,” Vaccine 15: 547-552 (1997); Konishi et al., “A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice,” Vaccine 18: 1133-1139 (2000)). To improve the level of effectiveness, differing strategies have been adopted.
  • flavivirus DNA immunization could be benefited by manipulation of an expression plasmid to enhance transcription and translation and targeting prM and E proteins for secretion that promote correct polyprotein processing and assembly (Chang et al., “Flavivirus DNA vaccines: current status and potential,” Ann. NY Acad. Sci. 951: 272-285 (2001)). Future improvements could be focused on enhancing DNA uptake by antigen presenting cells or by muscle cells (Rodriguez et al., “Enhancing DNA immunization,” Virology 268: 233-238 (2000)).
  • Sera were collected 9 weeks post-vaccination for PRNT testing prior to mating with non-immune male. 1 No Survivors/total for each litter. 2 Number of JEV ELISA-antibody-positive animals (titer ⁇ 1:400)/No. of survivors; sera were collected for testing 12 weeks after challenge.
  • DNA vaccines were inoculated by intramuscluar (im), intradermal (id), or gene gun (gg) method.
  • mice immunized with different doses of the combined WN and JE virus DNA vaccines pCBWN + pCBJE1-14 pCB Dose per plasmid ( ⁇ g) 100 + 100 40 + 40 20 + 20 10 + 10 Control 100 Percentage of mice with Nt: WN virus/JE virus: 100/100 100/70 70/0 60/0 0/0 Range of PRNT 90 titer: WN virus: 1:320-1:80 1:80-1:20 1:80- ⁇ 1:10 1:20- ⁇ 1:10 ⁇ 1:10 JE virus: 1:40-1:10 1:10- ⁇ 1:10 ⁇ 1:10 ⁇ 1:10 ⁇ 1:10 Groups of ten, three-week-old female ICR out-bred mice were i.m.
  • DEN-2 JE 90-10 Junction 100% DEN-2 prM-E: D2KasI-438 a 5′ TGTGCA TTCCATTTAACCACACGTAACG (SEQ ID NO: 48) CD2NotI-2402 5′ TCGA TCAACTAATTAGGCCTGCACCATGACTC (SEQ ID NO: 49) 90% DEN-2E & 10% JE E: T7 5′ CTTATCGAAATTAATACGACTCACTATAGG (SEQ ID NO: 50) CD2BstXI-2244 5′ ATAGATTGCT AA C ACT TGG (SEQ ID NO: 51) JE-2281 5′ ACTCCATAGGAAAAGCCGTTCACC (SEQ ID NO: 52) CSP6 5′ GCGAGCTCTAGCATTTAGGTGACACTATAG (SEQ ID NO: 53) DEN-2 JE 90-10 Junction: Le
  • mice were immunized intramuscularly with 100 ⁇ g plasmid DNA on weeks 0 and 3.
  • c ELISA screens used sera diluted 1:100 and 1:400.
  • d ND not done.
  • Sera were collected 9 weeks post-vaccination (weeks 0 and 3). Number of mice with titer of ⁇ 1:100/total number of mice is shown, including the endpoint ELISA titer of the pooled serum sample. c Number of mice with plaque-reduction neutralization titers (PRNT, 90% reduction) ⁇ 1:10/ total number of mice. Sera were collected 9 weeks post-vaccination. d Of the 7 mice with neutralizing antibody, 3 mice had PRNT titers of >1:1000, 3 had titers of ⁇ 1:100 ⁇ 1:1000, and one had a titer of 1:40.

Abstract

The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus or of a chimeric immunogenic flavivirus antigen comprising sequence from more than one flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This is a divisional of U.S. application Ser. No. 10/500,796, filed Jul. 6, 2004, and issued as U.S. Pat. No. 7,662,394; which is the §371 U.S. national stage of PCT/US02/10764, filed Apr. 4, 2002; which is a continuation-in-part of, and claims the benefit of U.S. application Ser. No. 09/826,115, filed Apr. 4, 2001, and issued as U.S. Pat. No. 7,227,011. U.S. application Ser. No. 09/826,115 is a continuation-in-part of, and claims the benefit of U.S. application Ser. No. 09/701,536, filed Jun. 18, 2001, and issued as U.S. Pat. No. 7,417,136. U.S. application Ser. No. 09/701,536 is the §371 U.S. national stage of PCT/US99/12298, filed Jun. 3, 1999; which claims the benefit of U.S. provisional application No. 60/087,908, filed June 4, 1998. Each of these applications is hereby incorporated by reference herein in its entirety.
FIELD OF THE INVENTION
This invention relates to novel vaccines, diagnostics and methods of using both in the treatment and prevention of the diseases caused by flaviviruses. In particular, the vaccines are recombinant nucleic acids which contain genes for structural proteins of flaviviruses, such as Japanese encephalitis virus (JEV), West Nile virus (WNV) or related flaviviruses. These vaccines serve as a transcriptional unit for the biosynthesis of the virus protein antigens when administered in vivo. The diagnostics are compositions containing antigens produced from the recombinant nucleic acids that can be used to detect flavivirus infection.
BACKGROUND OF THE INVENTION
Flaviviruses are members of the genus Flavivirus, which is classified within the family Flaviviridae. The flaviviruses are largely pathogenic to humans and other mammals. Flaviviruses that inflict disease upon humans and animals include Alfuy, Apoi, Aroa, Bagaza, Banzi, Batu Cave, Bouboui, Bukalasa bat, Bussuquara, Cacipacore, Carey Island, Cowbone Ridge, Dakar bat, Dengue (serotypes 1, 2, 3 and 4), Edge Hill, Entebbe bat, Gadgets Gully, Iguape, Ilheus, Israel turkey meningoencephalitis, Japanese encephalitis, Jugra, Jutiapa, Kadam, Karshi, Kedougou, Kokobera, Koutango, Kunjin, Kyasanur Forest disease, Langat, Meaban, Modoc, Montana myotis leukoencephalitis, Murray Valley encephalitis, Naranjal, Negishi, Ntaya, Omsk hemorrhagic fever, Phnom Penh bat, Potiskum, Powassan, Rio Bravo, Rocio, Royal Farm, Russian spring summer encephalitis, Saboya, Sal Vieja, San Perlita, Saumarez Reef, Sepik, Sokuluk, Spondweni, St. Louis encephalitis, Stratford, Tick-borne encephalitis—central European subtype, Tick-borne encephalititis—far eastern subtype, Tembusu, THCAr, Tyuleniy, Uganda S, Usutu, West Nile, Yaounde, Yellow fever, Yokose, Ziki, Cell fusing agent and other related flaviviruses, as listed in Kuno et al. (J. Virol. 72: 73-83 (1998)).
The flaviviruses contain the following three structural proteins: prM/M, the premembrane and membrane protein; E, the envelope protein; and C, the capsid protein. (Monath, in Virology (Fields, ed.), Raven Press, New York, 1990, pp. 763-814; Heinz and Roehrig, in Immunochemistry of Viruses II: The Basis for Serodiagnosis and Vaccines (van Regenmortel and Neurath, eds.), Elsevier, Amsterdam, 1990, pp. 289-305). M has a molecular weight (MW) of about 7-8 kilodaltons (kDa) and E has a MW of about 55-60 kDa. M is synthesized as a larger precursor termed prM. The pr portion of prM is removed when prM is processed to form M protein in mature virions. M and E are located in the membrane of the flavivirus particle, and so have long been considered to constitute important immunogenic components of the viruses.
The flaviviruses are RNA viruses comprising single stranded RNA having a length, among the various species, of about 10 kilobases (kb). The C protein, with a MW of 12-14 kDa, complexes with the RNA to form a nucleocapsid complex. Several nonstructural proteins are also encoded by the RNA genome which are termed NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5. The genome is translated within the host cell as a polyprotein, then processed co- or post-translationally into the individual gene products by viral- or host-specific proteases (FIG. 1).
The nucleotide sequences of the genomes of several flaviviruses are known, as summarized in U.S. Pat. No. 5,494,671. That for JEV is provided by Sumiyoshi et al. (Virology 161: 497-510 (1987)) and Hashimoto et al. (Virus Genes 1: 305-317 (1988)). The nucleotide sequences of the virulent strain SA-14 of JEV and the attenuated strain SA-14-14-2, used as a vaccine in the People's Republic of China, are compared in the work of Nitayaphan et al. (Virology 177: 541-552 (1990)).
Nucleotide sequences encoding the structural proteins of other flavivirus species are also known. In many cases, the sequences for the complete genomes have been reported. The sequences available include dengue serotype 1 virus, dengue serotype 2 virus (Deubel et al., Virology 155: 365-377 (1986); Gruenberg et al., J. Gen. Virol. 69: 1391-1398 (1988); Hahn et al. Virology 162: 167-180 (1988)), dengue serotype 3 virus (Osatomi et al., Virus Genes 2: 99-108 (1988)), dengue serotype 4 virus (Mackow et al., Virology 159: 217-228 (1987), Zhao et al., Virology 155: 77-88 (1986)), West Nile virus (Lanciotti et al., Science 286: 2331-2333 (1999)), Powassan virus (Mandl et al., Virology 194: 173-184 (1993)) and yellow fever virus (YFV) (Rice et al., Science 229: 726-733 (1985)).
Many flaviviruses, including St. Louis encephalitis virus (SLEV), WNV and JEV, are transmitted to humans and other host animals by mosquitoes. They therefore occur over widespread areas and their transmission is not easily interrupted or prevented.
West Nile fever is a mosquito-borne flaviviral infection that is transmitted to vertebrates primarily by various species of Culex mosquitoes. Like other members of the Japanese encephalitis (JE) antigenic complex of flaviviruses, including JE, SLE and Murray Valley encephalitis (MVE) viruses, WNV is maintained in a natural cycle between arthropod vectors and birds. The virus was first isolated from a febrile human in the West Nile district of Uganda in 1937 (Smithburn et al., Am. J. Trop. Med. Hyg. 20: 471-492 (1940)). It was soon recognized as one of the most widely distributed flaviviruses, with its geographic range including Africa, the Middle East, Western Asia, Europe and Australia (Hubalek et al., Emerg. Infect. Dis. 5: 643-50 (1999)). Clinically, West Nile fever in humans is a self-limited acute febrile illness accompanied by headache, myalgia, polyarthropathy, rash and lymphadenopathy (Monath and Tsai, in Clinical Virology, (Richman, Whitley and Hayden eds.), Churchill-Livingtone, New York, 1997, pp. 1133-1186). Acute hepatitis or pancreatis has been reported on occasion and cases of WNV infection in elderly patients are sometimes complicated by encephalitis or meningitis (Asnis et al., Clin. Infect. Dis. 30: 413-418 (2000)). Thus, infection by WNV is a serious health concern in many regions of the world.
The geographical spread of the disease, particularly the introduction of WNV into the U.S. in 1999, has greatly increased awareness of the human and animal health concerns of this disease. Between late August and early September 1999, New York City and surrounding areas experienced an outbreak of viral encephalitis, with 62 confirmed cases, resulting in seven deaths. Concurrent with this outbreak, local health officials observed increased mortality among birds (especially crows) and horses. The outbreak was subsequently shown to be caused by WNV, based on monoclonal antibody (Mab) mapping and detection of genomic sequences in human, avian and mosquito specimens (Anderson et al., Science 286: 2331-2333 (1999); Jia et al., Lancet 354: 1971-1972 (1999); Lanciotti et al., Science 286: 2333-2337 (1999)). Virus activity detected during the ensuing winter months indicated that the virus had established itself in North America (Morb. Mortal. Wkly. Rep. 49: 178-179 (2000); Asnis et al., Clin. Infect. Dis. 30: 413-418 (2000); Garmendia et al., J. Clin. Micro. 38: 3110-3111 (2000)). Surveillance data reported from the northeastern and mid-Atlantic states during the year 2000 confirmed an intensified epizootic/epidemic transmission and a geographic expansion of the virus with documentation of numerous cases of infection in birds, mosquitoes and horses, as well as cases in humans (Morb. Mortal. Wkly. Rep. 49: 820-822 (2000)).
Currently, no human or veterinary vaccine is available to prevent WNV infection and mosquito control is the only practical strategy to combat the spread of the disease.
Japanese encephalitis virus (JEV) infects adults and children and there is a high mortality rate among infants, children and the elderly in areas of tropical and subtropical Asia (Tsai et al., in Vaccines (Plotkin, ed.) W.B. Saunders, Philadelphia, Pa., 1999, pp. 672-710). Among survivors, there are serious neurological consequences, related to the symptoms of encephalitis, that persist after infection. In more developed countries of this region, such as Japan, the Republic of China (Taiwan) and Korea, JEV has been largely controlled by use of a vaccine of inactivated JEV. Nevertheless, it is still prevalent in other countries of the region.
Vaccines available for use against JEV infection include live virus inactivated by such methods as formalin treatment, as well as attenuated virus (Tsai et al., in Vaccines (Plotkin, ed.) W.B. Saunders, Philadelphia, Pa., 1994, pp. 671-713). Whole virus vaccines, although effective, do have certain problems and/or disadvantages. The viruses are cultivated in mouse brain or in cell culture using mammalian cells as the host. Such culture methods are cumbersome and expensive. Furthermore, there is the attendant risk of incorporating antigens from the host cells, i.e., the brain or other host, into the final vaccine product, potentially leading to unintended and undesired allergic responses in the vaccine recipients. There is also the risk of inadvertent infection among workers involved in vaccine production. Finally, there is the risk that the virus may not be fully or completely inactivated or attenuated and thus, the vaccine may actually cause disease.
Dengue fever and dengue hemorrhagic fever (DF/DHF) are caused by dengue virus, which is also a mosquito-borne flavivirus. There are four antigenically related, but distinct, dengue virus serotypes, (DEN-1, DEN-2, DEN-3 and DEN-4), all of which can cause DF/DHF. Symptoms of DF, the mild form of dengue-related disease, include fever, rash, severe headache and joint pain. Mortality among those subjects suffering from DF is low; however, among those subjects suffering from DHF, mortality can be as high as 5%. From available evidence, more than 3 million cases of DHF and 58,000 deaths have been attributed to DHF over the past 40 years, making DHF a major emerging disease (Halstead, in Dengue and Dengue Hemorrhagic Fever (Gubler and Kuno, eds.) CAB International, New York, N.Y., (1997) pp 23-44). Nevertheless, despite decades of effort, safe and effective vaccines to protect against dengue virus infection are not yet available.
Yellow fever is prevalent in tropical regions of South America and sub-Saharan Africa and is transmitted by mosquitos. Infection leads to fever, chills, severe headache and other pains, anorexia, nausea and vomiting, with the emergence of jaundice. A live virus vaccine, 17D, grown in infected chicken embryos, is considered safe and effective. Nevertheless, there remains a need for a vaccine that is stable under adverse conditions, such as are commonly encountered in the tropical regions of Africa and the Americas where the vaccine is most needed.
A recombinant flavivirus which is a chimera between two flaviviruses is disclosed in PCT publication WO 93/06214. The chimera is a construct fusing non-structural proteins from one “type,” or serotype, of dengue virus or a flavivirus, with structural proteins from a different “type,” or serotype, of dengue virus or other flavivirus.
Several recombinant subunit and viral vaccines have been devised in recent years. U.S. Pat. No. 4,810,492 describes the production of the E glycoprotein of JEV for use as the antigen in a vaccine. The corresponding DNA is cloned into an expression system in order to express the antigen protein in a suitable host cell such as E. coli, yeast, or a higher organism cell culture. U.S. Pat. No. 5,229,293 discloses recombinant baculovirus harboring the gene for JEV E protein. The virus is used to infect insect cells in culture such that the E protein is produced and recovered for use as a vaccine.
U.S. Pat. No. 5,021,347 discloses a recombinant vaccinia virus genome into which the gene for JEV E protein has been incorporated. The live recombinant vaccinia virus is used as the vaccine to immunize against JEV. Recombinant vaccinia viruses and baculoviruses in which the viruses incorporate a gene for a C-terminal truncation of the E protein of dengue serotype 2, dengue serotype 4 and JEV are disclosed in U.S. Pat. No. 5,494,671. U.S. Pat. No. 5,514,375 discloses various recombinant vaccinia viruses which express portions of the JEV open reading frame extending from prM to NS2B. These pox viruses induced formation of extracellular particles that contain the processed M protein and the E protein. Two recombinant viruses encoding these JEV proteins produced high titers of neutralizing and hemagglutinin-inhibiting antibodies, and protective immunity, in mice. The extent of these effects was greater after two immunization treatments than after only one. Recombinant vaccinia virus containing genes for the prM/M and E proteins of JEV conferred protective immunity when administered to mice (Konishi et al., Virology 180: 401-410 (1991)). HeLa cells infected with recombinant vaccinia virus bearing genes for prM and E from JEV were shown to produce subviral particles (Konishi et al., Virology 188: 714-720 (1992)). Dmitriev et al. reported immunization of mice with a recombinant vaccinia virus encoding structural and certain nonstructural proteins from tick-borne encephalitis virus (J. Biotechnology 44: 97-103 (1996)).
Recombinant virus vectors have also been prepared to serve as virus vaccines for dengue fever. Zhao et al. (J. Virol. 61: 4019-4022 (1987)) prepared recombinant vaccinia virus bearing structural proteins and NS1 from dengue serotype 4 and achieved expression after infecting mammalian cells with the recombinant virus. Similar expression was obtained using recombinant baculovirus to infect target insect cells (Zhang et al., J. Virol. 62: 3027-3031 (1988)). Bray et al. (J. Virol. 63: 2853-2856 (1989)) also reported a recombinant vaccinia dengue vaccine based on the E protein gene that confers protective immunity to mice against dengue encephalitis when challenged. Falgout et al. (J. Virol 63: 1852-1860 (1989)) and Falgout et al. (J. Virol. 64: 4356-4363 (1990)) reported similar results. Zhang et al. (J. Virol 62: 3027-3031 (1988)) showed that recombinant baculovirus encoding dengue E and NS1 proteins likewise protected mice against dengue encephalitis when challenged. Other combinations in which structural and nonstructural genes were incorporated into recombinant virus vaccines failed to produce significant immunity (Bray et al., J. Virol. 63: 2853-2856 (1989)). Also, monkeys failed to develop fully protective immunity to dengue virus challenge when immunized with recombinant baculovirus expressing the E protein (Lai et al. (1990) pp. 119-124 in F. Brown, R. M. Chancock, H. S. Ginsberg and R. Lerner (eds.) Vaccines 90: Modern approaches to new vaccines including prevention of AIDS, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).
Immunization using recombinant DNA preparations has been reported for SLEV and dengue-2 virus, using weanling mice as the model (Phillpotts et al., Arch. Virol. 141: 743-749 (1996); Kochel et al., Vaccine 15: 547-552 (1997)). Plasmid DNA encoding the prM and E genes of SLEV provided partial protection against SLEV challenge with a single or double dose of DNA immunization. In these experiments, control mice exhibited about 25% survival and no protective antibody was detected in the DNA-immunized mice (Phillpotts et al., Arch. Virol. 141: 743-749 (1996)). In mice that received three intradermal injections of recombinant dengue-2 plasmid DNA containing prM, 100% developed anti-dengue-2 neutralizing antibodies and 92% of those receiving the corresponding E gene likewise developed neutralizing antibodies (Kochel et al., Vaccine 15: 547-552 (1997)). Challenge experiments using a two-dose schedule, however, failed to protect mice against lethal dengue-2 virus challenge.
The vaccines developed to date for immunizing against infection by JEV, SLEV, dengue virus and other flaviviruses have a number of disadvantages and problems attending their use. Inactivated vaccine is costly and inconvenient to prepare. In addition, any such vaccine entails the risk of allergic reaction originating from proteins of the host cell used in preparing the virus. Furthermore, such vaccines present considerable risk to the workers employed in their production. Candidate attenuated JEV vaccines are undergoing clinical trials, but as of 1996 have not found wide acceptance outside of the People's Republic of China (Hennessy et al., Lancet 347: 1583-1586 (1996)).
Recombinant vaccines based on the use of only certain proteins of flaviviruses, such as JEV, produced by biosynthetic expression in cell culture with subsequent purification or treatment of antigens, do not induce high antibody titers. Also, like the whole virus preparations, these vaccines carry the risk of adverse allergic reaction to antigens from the host or to the vector. Vaccine development against dengue virus and WNV is less advanced and such virus-based or recombinant protein-based vaccines face problems similar to those alluded to above.
There is therefore a need for vaccines or improved vaccines directed against flaviviruses such as yellow fever virus, dengue virus, JEV, SLEV and WNV which are inexpensive to prepare, present little risk to workers involved in their manufacture, carry minimal risk of adverse immunological reactions due to impurities or adventitious immunogenic components and are highly effective in eliciting neutralizing antibodies and protective immunity. There is furthermore a need for a vaccine against JEV, WNV and related flaviviruses that minimizes the number of immunizing doses required.
Many of the shortcomings of the current art as described in detail for the production of vaccines also apply to the production of antigens and antibodies to be used for the production of immunodiagnostics. Particularly, the concurrent risks and costs involved in the production of antigens from viruses and the failure of most currently available recombinantly expressed antigens to elicit effective immune responses are paralleled in the field of immunodiagnostics by the same risks, high costs and a corresponding lack of sensitivity. Thus, because of the high costs, risk of accidental infection with live virus and the lower than desired levels of sensitivity of the previously available tests, there exists a need for rapid, simple and highly sensitive diagnostic tests for detecting flavivirus infection and/or contamination.
The present invention meets these needs by providing highly immunogenic recombinant antigens for use in diagnostic assays for the detection of antibodies to selected flaviviruses. The present invention further provides for the use of recombinant antigens derived from flaviviruses, flavivirus genes or mimetics thereof in immunodiagnostic assays for the detection of antibodies to flavivirus proteins.
SUMMARY OF THE INVENTION
The present invention provides a nucleic acid molecule which contains a transcriptional unit (TU) for an immunogenic flavivirus antigen. The TU directs a host cell, after being incorporated within the cell, to synthesize the antigen. In an important aspect of the invention, the flavivirus can be yellow fever virus (YFV), dengue serotype 1 virus (DEN-1), dengue serotype 2 virus (DEN-2), dengue serotype 3 virus (DEN-3), dengue serotype 4 virus (DEN-4), St. Louis encephalitis virus (SLEV), Japanese encephalitis virus (JEV), West Nile virus (WNV), Powassan virus or any other flavivirus. In important embodiments of the present invention, the antigen can be the flavivirus prM/M protein, the E protein, or both. In important embodiments of the present invention, the antigen can be a chimeric flavivirus protein. In particular, when the TU includes both the prM/M and E proteins, the host cell secretes subviral particles containing the prM/M and E antigens. In a further important aspect of the invention, the nucleic acid is a DNA molecule. In additional significant embodiments, the nucleic acid TU includes a control sequence disposed appropriately such that it operably controls the expression of the prM/M and E antigens and this control sequence can be the cytomegalovirus immediate early promoter. In an additional embodiment, the nucleotide sequence of the TU is engineered to optimize eukaryotic translation by minimizing large hairpin structures in the 5′-end untranslated region of an mRNA produced by the TU and/or the inclusion of a Kozak consensus sequence at the translational start site of an mRNA produced by the TU. In an additional embodiment, the transcriptional unit also includes a poly-A terminator.
The present invention further provides a host cell comprising a nucleic acid molecule which includes a transcriptional unit for an immunogenic flavivirus antigen that directs the host cell to synthesize the immunogenic antigen. The flavivirus may be YFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flavivirus. In important embodiments, the antigen may be the prM/M protein, the E protein, or both the prM/M and the E proteins. In the latter case, the cell secretes subviral particles containing the prM/M and E antigens.
Additionally, the invention provides a composition for vaccinating a subject against a flavivirus containing a nucleic acid molecule that includes a transcriptional unit for an immunogenic flaviviral antigen. The transcriptional unit directs a cell within the body of the subject, after being incorporated therein, to synthesize the immunogenic antigen. The composition further includes a pharmaceutically acceptable carrier. In significant embodiments, the flavivirus may be YFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flavivirus. Furthermore, the antigen may be the prM/M protein, the E protein, or both the prM/M and the E proteins. In the latter instance, the cell secretes subviral particles comprising the flavivirus prM/M and E antigens. These subviral particles are also referred to as noninfectious recombinant antigen (NRA). In important embodiments, the nucleic acid molecule is a DNA molecule. In further significant embodiments, the transcriptional unit additionally contains a control sequence disposed appropriately such that it operably controls the synthesis of the prM/M and E antigens when the nucleic acid is introduced into the cell of the subject. This control sequence can be the cytomegalovirus immediate early promoter. In a still further embodiment, the transcriptional unit can also include a poly-A terminator.
The compositions provided by the present invention for vaccinating a subject against a flavivirus can include a nucleic acid molecule, or molecules, that include transcriptional units for more than one immunogenic flaviviral antigen. The more than one immunogenic flaviviral antigen can be from different flavivirus species, strains or isolates in any combination. In significant embodiments, the flaviviruses included can be two or more, three or more, four or more, five or more, or seven or more flaviviruses. Examples of such flaviviruses include, but are not limited to YFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flaviviruses. Combination vaccines can be formulated to confer immunity to flavivirus disease common to particular geographical regions. In a particular embodiment directed toward tropical and subtropical Asia, DEN-1, DEN-2, DEN-3, DEN-4, WN, and JE viruses can be selected. In a particular embodiment directed to Africa, DEN-1, DEN-2, DEN-3, DEN-4, WN and YF can be selected. In a particular embodiment directed to Latin America, DEN-1, DEN-2, DEN-3, DEN-4, Rocio and YF viruses can be selected.
The invention provides still further a method of immunizing a subject against infection by a flavivirus. The method involves administering to the subject an effective amount of a vaccinating composition that contains a nucleic acid molecule which includes a transcriptional unit for an immunogenic flavivirus antigen. The transcriptional unit directs a cell within the body of the subject, after being taken up by the cell, to synthesize the immunogenic antigen. The composition additionally includes a pharmaceutically acceptable carrier. In significant embodiments of the method, the flavivirus may be YFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flavivirus. In yet other important aspects of the method, the antigen may be the prM/M protein, the E protein, or both the prM/M and the E proteins. When the antigen is both the prM/M and the E proteins, the cell within the body of the subject, after incorporating the nucleic acid within it, secretes subviral particles comprising the flaviviral prM/M and E antigens. Additionally, in significant embodiments of the method, the vaccinating composition is administered to the subject in a single dose, via a parenteral route. In yet a further aspect of the method, the nucleic acid is a DNA molecule. In yet additional embodiments of the method, the transcriptional unit further includes a control sequence disposed appropriately such that it operably controls the synthesis of the prM/M and E antigens and in a significant aspect of this embodiment, the control sequence is the cytomegalovirus immediate early promoter. Furthermore, the transcriptional unit may include a poly-A terminator.
These aspects and embodiments of the invention are the basis for its distinct attributes and advantages. Being a nucleic acid construct involving only portions of the flavivirus genome rather than the sequence encompassing the complete genome, the nucleic acid TU-containing vaccine is completely nonviable. It therefore poses no danger of infection by the flavivirus to those involved in its manufacture or to subjects receiving the vaccine. The nucleic acid vaccine is easy to prepare and easy to administer and is stable in storage prior to use. Unexpectedly it has been found that the nucleic acid vaccine of the invention is essentially 100% successful in conferring protective immunity in mammals after administering only a single dose. A further unexpected result is that the nucleic acid TU is able to engender immunity to a flavivirus in a female mammal which can be transmitted to its progeny through the milk. Without wishing to be limited by theory, the inventor believes that a possible mechanism for the success of the nucleic acid in conferring protective immunity is that a host cell harboring the nucleic acid, such as the cell of a subject to whom the vaccine is administered, produces subviral particles containing the flaviviral prM/M and E antigens. These particles mimic the immunogenic attributes of native flavivirus virions.
The present invention also provides noninfectious antigenic polypeptides, antigenic polypeptide fragments and NRA comprising the prM/M and/or E proteins of flaviviruses, wherein the transmembrane signal sequence is derived from a first flavivirus and the M and/or E proteins are derived from a second flavivirus. Further, the prM/M protein can comprise amino acid sequences from both the first and the second flaviviruses. Further, the E protein can comprise amino acid sequences from both the first and second flaviviruses. “Chimeric” as used herein means any protein or nucleic acid comprising sequence from more than one flavivirus. As used herein, “non-virulent” means the antigen or vaccine of this invention is incapable of causing disease. More particularly, the recombinant protein antigens are free of contaminating genomic material from flaviviruses that is necessary for flavivirus infection, replication and pathogenesis.
The polypeptides of the present invention can comprise the amino acid sequences defined herein, or that are known in the art, of the prM, M and/or E proteins of selected flaviviruses. The nucleic acids of this invention can comprise nucleotide sequence that encodes the prM, M and/or E proteins of selected flaviviruses.
The antigens of the present invention can be unconjugated, or they can be conjugated to a carrier molecule that facilitates placement of the antigen on a solid phase. A carrier molecule is one to which antigens can be conjugated and which will not react with antibodies in human serum. An example of such a carrier is bovine serum albumin (BSA).
The antigens of the present invention can also be recombinant proteins obtained by expressing nucleic acids encoding the antigen in an expression system capable of producing the antigen.
The amino acid sequences of the present antigens can contain an immunoreactive portion of the prM, M and/or E antigen. These antigens may further be attached to sequences designed to provide for some additional property, such as to remove/add amino acids capable of disulfide bonding to increase the reactivity of an epitope by providing a more rigid secondary structure, to increase its bio-longevity or to alter its cytotoxicity or to prevent infection. In any case, the antigen must possess immunoreactivity and/or immunogenicity.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic representation of flaviviral polyprotein processing. The central horizontal region provides a schematic representation of the viral genome. The lines denote the 5′ and 3′ non-translated regions and the boxed regions represent the open reading frame for structural (left and top) and non-structural (right and bottom) proteins. Cleavage by host cell signalase occurs simultaneously with translation at the E protein C-terminus, separating structural and non-structural regions. A subtilase-like cellular enzyme, furin, may be responsible for prM cleavage. Potential transmembrane domains of viral polyprotein are indicated by shaded areas.
FIG. 2 is a map of the JEV genome (top) and the DNA sequence of oligonucleotides used in a reverse transcriptase-polymerase chain reaction (RT-PCR) (center) to construct the transcription unit for the expression of prM-E protein coding regions (bottom). Potential transmembrane domains of viral polyprotein are indicated by shaded areas.
FIG. 3 shows a schematic representation of the plasmid vectors, pcDNA3, pCBamp, and pCIBamp, and the relationship between them. These plasmids include the CMV (cytomegalovirus) promoter/enhancer element, BGHp(A) (bovine growth hormone polyadenylation signal and transcription termination sequence), ampicillin resistance gene and ColE1 origin of replication for selection and maintenance in E. coli. The f1 origin of replication for single-stranded rescue in E. coli cells, SV40 origin of replication (SV40 ORI), neomycin resistance coding region and SV40p(A) sequences were deleted from pcDNA3 to generate pCBamp. An intron sequence was inserted in the NcoI-KpnI site of pCBamp to generate plasmid pCIBamp.
FIG. 4 shows SDS-PAGE-immunoblot analyses of the sucrose gradient purified subviral particles from JE-4B COS-1 culture fluid (4B, right lane of each pair). The density gradient purified JE virion from JEV infected C6/36 cell culture was used as a positive control (JEV, left lane of each pair). JE RAF (hyperimmune ascitic fluid); 4G2, anti-E monoclonal antibody; JM01, anti-M monoclonal antibody; NMAF (normal mouse ascitic fluid).
FIG. 5 shows a profile of the E antigen in a rate zonal sucrose gradient analysis prepared from the PEG precipitate of JE-4B cell culture medium with or without Triton X-100 treatment.
FIG. 6 shows signal peptide probability of the pCBJE1-14 (pCBJE) predicted by the SignalP-HMM program (panel A; amino acids 1-39 of SEQ ID NO: 18). The signal peptide probability is improved by altering the c-region sequence at −4 and −2 positions (C-4G and G-2S) (panel B, JE-LSS-M; SEQ ID NO: 62), by shortening the n-region (panel C, JE-SS-ORI; SEQ ID NO: 63), or by a combination of both modifications (panel D, JE-SS-M; SEQ ID NO: 64).
FIG. 7 shows schematic representations of plasmid vectors pCBD2-14-16 (100% DEN-2 E), pCBD2-1J-4-3 (90% DEN-2 E: 10% JEV E), and pCB8D2-2H-2-9-1 (80% DEN-2 E: 20% JEV E). These plasmids include the human cytomegalovirus (CMV) early gene promoter; JE virus signal sequence; DEN-2 virus prM and E gene region (amino terminal 100%, 90%, or 80%, respectively); JE virus E gene region (none, 10% or 20%, respectively); and bovine growth hormone poly A signal (BGH).
FIG. 8 shows a comparison of secreted and membrane-bound recombinant protein by western blot. (A) Analysis of secreted recombinant antigen following PEG-precipitation and ethanol extraction of culture fluid for DEN-2 plasmids pCB8D2-2J-2-9-1, pCB9D2-1J-4-3, pCBD2-14-16, and control plasmid pEGFP. Lane 1(V), purified DEN-2 virus stained by Gold Blot (Owl Separation Systems, Portsmouth, N.H.). Reactivity of secreted, recombinant antigen from each plasmid with a, anti-envelope (E) specific Mab 1A6A-8; b, a mixture of MAB 1A6A-8, anti-capsid (C) specific Mab 1A2A-1, anti-serum specific for DEN-2 virus premembrane (prM) protein; and c, normal mouse ascites. (B) Analysis of recombinant plasmid-transformed cell hydrophobic membrane proteins. Lane 1 (V), purified DEN-2 virus stained by Gold Blot; lane 2 (V), reactivity of purified DEN-2 virus with a mixture of Mab 1A6A-8, Mab 1A2A-1, anti-serum specific for DEN-2 virus M protein, and anti-serum for DEN-2 virus prM protein. Reactivity of isolated hydrophobic membrane proteins from each plasmid-transformed cell line with a, Mab 1A6A-8; b, a mixture of Mab 1A6A-8, Mab 1A2A-1, anti-serum specific for DEN-2 virus M protein, and anti-serum for DEN-2 virus prM protein; and c, normal mouse ascites.
 DETAILED DESCRIPTION OF THE INVENTION
The invention encompasses nucleic acid transcriptional units which encode flaviviral antigenic proteins, such as the prM/M and E protein antigens. The nucleic acids function to express the prM/M and E protein antigens when the nucleic acid is taken up by an appropriate cell, especially when the cell is the cell of a subject. The invention also encompasses a vaccine whose active agent is the nucleic acid transcriptional unit (TU). The invention further encompasses cells containing a TU. The invention in addition encompasses a method of immunizing a subject against flaviviral infection by administering to the subject an effective amount of a vaccine containing the nucleic acid TU molecules.
The invention provides an isolated nucleic acid comprising a transcriptional unit encoding a signal sequence of a structural protein of a first flavivirus and an immunogenic flavivirus antigen of a second flavivirus, wherein the transcriptional unit directs the synthesis of the antigen. The invention further encompasses the use of the nucleic acid transcriptional unit (TU) to generate flaviviral antigens and the flaviviral antigens produced by the nucleic acid TU. The flaviviral antigens encompassed by the present invention include chimeric flavivirus antigens incorporating amino acid sequence from a first flavivirus and at least one further flavivirus. The invention still further encompasses the use of the flaviviral antigens encoded by the TU of the invention to produce flavivirus-specific antibodies and to detect the presence of flavivirus-specific antibodies.
In one embodiment, the isolated nucleic acid of this invention can comprise a transcriptional unit encoding a Japanese encephalitis virus signal sequence.
In another embodiment, the transcriptional unit of this invention can encode an immunogenic flavivirus antigen which can be from one or more of the following flaviviruses: yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, Japanese encephalitis virus, Powassan virus and West Nile virus.
In another embodiment, the transcriptional unit of this invention can encode an immunogenic chimeric flavivirus antigen which can include sequence from more than one of the following flaviviruses: yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, Japanese encephalitis virus, Powassan virus and West Nile virus.
In a particular embodiment, the nucleic acid of this invention can encode a signal sequence of Japanese encephalitis virus and an M protein and an E protein of West Nile virus, SLEV, YFV and/or Powassan virus. The nucleic acid can also encode an immunogenic antigen which can be an M protein of a flavivirus, an E protein of a flavivirus, both an M protein and an E protein of a flavivirus, a portion of an M protein of a flavivirus, a portion of an E protein of a flavivirus and/or both a portion of an M protein of a flavivirus and a portion of an E protein of a flavivirus. In a preferred embodiment, the isolated nucleic acid encodes both the M protein and the E protein of the flavivirus. Further, the nucleic acid of the invention can be DNA and can comprise nucleotide sequence SEQ ID NO:15, SEQ ID NO: 19, SEQ ID NO:21, SEQ ID NO:23 or SEQ ID NO: 42.
In another particular embodiment, the nucleic acid of this invention can encode a signal sequence of Japanese encephalitis virus, an M protein of a second virus and a chimeric E protein formed by from substitution of a portion of the nucleic acid encoding the second virus' E protein with nucleic acid encoding the corresponding portion of the JEV E protein. Alternatively, the portion of sequence corresponding to the deleted portion of the second virus' E protein can be substituted by other sequence selected from a third virus or it can be a non-viral sequence. The second protein can be West Nile virus, SLEV, YFV, Powassan and/or a serotype of Dengue virus. Chimeric E proteins can include those where the carboxy terminal portion can be from one flavivirus and the remainder of the chimeric E protein is from another flavivirus. The carboxy terminal portion can be, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, or 75% of the chimeric E protein. The nucleic acid of the invention can be DNA and can comprise the protein-encoding sequence from nucleotide sequence SEQ ID NO:44 or SEQ ID NO:46. The nucleic acid of the invention can comprise nucleotide sequence SEQ ID NO:44 or SEQ ID NO:46.
The transcriptional unit of this invention can also comprise a control sequence disposed appropriately so that it operably controls the synthesis of the antigen. The control sequence can be, for example, the cytomegalovirus immediate early promoter. The nucleic acid of this invention can also comprise a Kozak consensus sequence located at a translational start site for a polypeptide comprising the antigen encoded by the transcriptional unit. The transcriptional unit of this invention can also comprise a poly-A terminator.
The present invention further provides a cell comprising the nucleic acid of this invention.
Also provided is a composition comprising a pharmaceutically acceptable carrier and nucleic acid or cell or antigen of this invention. The present invention additionally provides a method of immunizing a subject against infection by a flavivirus, comprising administering to the subject an effective amount of a composition of this invention. In a particular embodiment, the composition used to immunize a subject directs the synthesis of both the M protein and the E protein of a flavivirus and a cell within the body of the subject, after incorporating the nucleic acid within it, secretes subviral particles comprising the M protein and the E protein. Alternatively, the composition can comprise an M protein and/or E protein of a flavivirus or subviral particles comprising the M protein and E protein. In the methods of this invention, the immunizing composition can be administered to the subject in a single dose and can be administered via a parenteral route.
This invention further provides the antigens produced from the isolated nucleic acids of this invention. As an example, the antigen from the second flavivirus encoded by the nucleotide sequence of TU can be the M protein which can be, for example, from West Nile virus. The antigen can also be protein from dengue virus, St. Louis encephalitis virus, Japanese encephalitis virus, Powassan virus and/or yellow fever virus. In a further embodiment, the antigen comprises a prM/M protein comprising the transmembrane signal sequence from a first flavivirus and further amino acid sequence comprising the remainder of the prM/M protein from a second flavivirus, which can be from SLEV, JEV, YFV, WNV and/or Powassan virus. The transmembrane signal sequence from a first flavivirus can be an improved or modified signal sequence wherein the signal sequence imparts desired characteristics such as a high signal sequence probability. Accomplishing these goals by design or selection can be with the use of machine-learning computer programs including, but not limited to, those using a hidden Markov model.
The antigen encoded by the nucleotide sequence of the TU can be West Nile virus antigen, dengue virus antigen, St. Louis encephalitis virus antigen, Japanese encephalitis virus antigen, Powassan virus antigen and/or yellow fever virus antigen.
The antigen encoded by the nucleotide sequence of the TU can also be the E protein, which can be the E protein from West Nile virus, dengue virus, St. Louis encephalitis virus, Japanese encephalitis virus, Powassan virus and/or yellow fever virus. The antigen encoded can also be a chimeric E protein comprising amino acid sequence selected from more than one flavivirus.
Additionally, the antigen encoded by the nucleotide sequence of the TU can be the M protein and the E protein, which can be from West Nile virus, dengue virus, St. Louis encephalitis virus, Japanese encephalitis virus, Powassan virus and/or yellow fever virus.
As used herein, “M protein” or “pr/M protein” or “prM/M protein” means a flavivirus M protein or flavivirus prM protein. Examples include, but are not limited to, prM proteins comprising amino acid sequence from one or more flavivirus prM proteins, M proteins comprising no additional amino acid sequence and proteins comprising additional amino acid sequences which are processed in vitro or in vivo to generate the mature M protein.
As used herein, “nucleic acid transcriptional unit” or “nucleic acid transcriptional unit molecule” means a nucleic acid encoding one or more specified proteins. The TU has biological activity such that, after having been introduced into a suitable cell, the nucleic acid induces the synthesis of one or more specified gene products encoded by the nucleic acid. The gene product(s) is (are) other biological macromolecules, such as proteins, not chemically related to the TU. The nucleic acid TU induces the cell to employ its cellular components to produce the specific gene product or products encoded by the nucleic acid of the TU. Although any nucleic acid may serve as a TU, in a preferred embodiment, the TU is the DNA of a plasmid or similar vector, wherein the plasmid or vector comprises coding sequences of marker genes or other sequence constructions that facilitate use of the TU for experimentation and biosynthesis.
As used herein, a “control sequence” is a regulatory nucleotide sequence incorporated within a TU which interacts with appropriate cellular components of the cell and leads to enhanced or activated biosynthesis of the gene products encoded by the TU. Thus a suitable control sequence is one with which the components of the cell have the capability to interact, resulting in synthesis of the gene product. When operably disposed in a nucleic acid with respect to a specified coding sequence, a control sequence effectively controls expression of the specified nucleic acid to produce the gene product.
As used herein, a “promoter” is a nucleotide sequence in a TU which serves as a control sequence.
As used herein, a “Kozak sequence” or “Kozak consensus sequence” is a nucleotide sequence at the translational start site which optimizes translation of eukaryotic mRNAs (Kozak, Mol. Cell. Biology 9: 5134-5142 (1989)).
As used herein, a “terminator” is an extended nucleotide sequence which acts to induce polyadenylation at the 3′ end of a mature mRNA. A terminator sequence is found after, or downstream from, a particular coding sequence.
As used herein, a “cell” is a prokaryotic or eukaryotic cell comprising a TU coding for one or more gene products, or into which such a TU has been introduced. Thus, a cell harbors a foreign or heterologous substance, the TU, which is not naturally or endogenously found in the cell as a component. A suitable cell is one which has the capability for the biosynthesis of the gene products as a consequence of the introduction of the TU. In particular, a suitable cell is one which responds to a control sequence and to a terminator sequence, if any, that may be included within the TU. In important embodiments of the present invention, the cell is a mammalian cell. In particularly important embodiments of this invention, the cell is a naturally occurring cell in the body of a human or nonhuman subject to whom (which) the TU has been administered as a component of a vaccine. Alternatively, in analytical, or diagnostic applications, including preparation of antigen for use as a vaccine or in immunodiagnostic assays, or for demonstrative purposes, the cell may be a human or nonhuman cell cultured in vitro.
As used herein, a “vaccine” or a “composition for vaccinating a subject” specific for a particular pathogen means a preparation, which, when administered to a subject, leads to an immunogenic response in a subject. As used herein, an “immunogenic” response is one that confers upon the subject protective immunity against the pathogen. Without wishing to be bound by theory, it is believed that an immunogenic response may arise from the generation of neutralizing antibodies (i.e., a humoral immune response) or from cytotoxic cells of the immune system (i.e., a cellular immune response) or both. As used herein, an “immunogenic antigen” is an antigen which induces an immunogenic response when it is introduced into a subject, or when it is synthesized within the cells of a host or a subject. As used herein, an “effective amount” of a vaccine or vaccinating composition is an amount which, when administered to a subject, is sufficient to confer protective immunity upon the subject. Historically, a vaccine has been understood to contain as an active principle one or more specific molecular components or structures which comprise the pathogen, especially its surface. Such structures may include surface components such as proteins, complex carbohydrates, and/or complex lipids which commonly are found in pathogenic organisms.
As used herein, however, it is to be stressed that the terms “vaccine” or “composition for vaccinating a subject” extend the conventional meaning summarized in the preceding paragraph. As used herein, these terms also relate to the TU of the instant invention or to compositions containing the TU. The TU induces the biosynthesis of one or more specified gene products encoded by the TU within the cells of the subject, wherein the gene products are specified antigens of a pathogen. The biosynthetic antigens then serve as an immunogen. As already noted, the TU, and hence the vaccine, may be any nucleic acid that encodes the specified immunogenic antigens. In a preferred embodiment of this invention, the TU of the vaccine is DNA. The TU can include a plasmid or vector incorporating additional genes or particular sequences for the convenience of the skilled worker in the fields of molecular biology, cell biology and viral immunology (See Molecular Cloning: A Laboratory Manual, 2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989; and Current Protocols in Molecular Biology, Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly), which are incorporated herein by reference).
The TU molecules of the instant invention comprise nucleic acids, or derivatives of nucleic acids, having nucleotide sequences that encode specific gene products related to antigens of flaviviruses such as, but not limited to, WNV, JEV, dengue virus, yellow fever virus and SLEV. Although any nucleic acid may serve as a TU, in an important embodiment, the TU is DNA. Alternatively, the nucleic acids may be RNA molecules. They may also be any one of several derivatives of DNA or RNA having a backbone of phosphodiester bonds that have been chemically modified to increase the stability of the TU as a pharmaceutical agent. Modifications so envisioned include, but are not limited to, phosphorothioate derivatives or phosphonate derivatives. These and other examples of derivatives are well known to persons skilled in the field of nucleic acid chemistry.
The genome of JEV has been characterized and sequenced (FIGS. 1 and 2). The M structural protein is expressed as a portion of the polyprotein which includes a pre-M sequence (pr). This pr sequence, immediately amino terminal to the M protein sequence, prevents conformational problems in the processing of the polyprotein. In particular, the presence of the pr sequence is important in preventing misfolding of the E protein. Thus, the presence of prM allows for assembly of JEV particles. Once the virion or particle is formed, the pr sequence can be cleaved from the prM protein to yield mature virus particles containing M proteins, although cleavage of the prM protein to yield M protein is not necessary to produce infectious particles. The prM sequences from many different, related flaviviruses are cleaved to but a low extent, but the flaviviruses themselves are nonetheless, infectious. Examples of such related flaviviruses with similar genomic structures and functions include, but are not limited to WNV, YFV, dengue virus and SLEV.
In one embodiment, the TU encoding flaviviral M and E proteins in the instant invention is DNA. In accord with the discussion in the preceding paragraph, this DNA comprises a nucleotide sequence which encodes the M protein, comprising the pre-M sequence, and a nucleotide sequence encoding the E protein. In this way, the intended gene products are enabled to form subviral particles within the cell. The pre-M sequence can then be cleaved in a fashion analogous to that which occurs with respect to replete virions.
In order to function effectively in vivo as a vaccine, it is advantageous to include within the TU a control sequence that has the effect of enhancing or promoting the transcription of the nucleotide sequences encoding the antigens. Use of such promoters is well known to those of skill in the fields of molecular biology, cell biology and viral immunology (See Molecular Cloning: A Laboratory Manual, 2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989; and Current Protocols in Molecular Biology, Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly)). When the TU is used as a vaccine in a mammalian host, the promoter to be employed is preferably one which operates effectively in mammalian cells. Such a promoter is disposed with respect to the coding sequences from which transcription is to be promoted, at a position at which it may operably promote such transcription. In a significant embodiment of the instant invention, this promoter is the cytomegalovirus early promoter. In addition, in a further preferred embodiment of the invention, the coding sequences are followed, in the TU nucleic acid, by a terminator sequence (Sambrook et al.). Particular embodiments of the invention relate to both prokaryotic and eukaryotic cells. Many promoter sequences are known that are useful in either prokaryotic or eukaryotic cells. (See Sambrook et al.)
The nucleic acids of the invention may further include DNA sequences known to those of skill in the art to act as immunostimulatory elements. Examples of such elements include, but are not limited to, certain CpG motifs in bacterial DNA (Sato et al., Science 273: 352-354 (1996); Klinman et al., Vaccine 17: 19-25 (1998)).
Preparation of the Tu of the Invention is Readily Accomplished by Methods Well known to workers of skill in the field of molecular biology. Procedures involved are set forth, for example, in Molecular Cloning: A Laboratory Manual, 2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989 and Current Protocols in Molecular Biology, Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly). The flaviviral RNA molecule may be isolated from a sample of live virus by methods widely known among virologists familiar with flaviviruses, for example, and with other groups of viruses as well. Methods used with JEV are summarized in Kuno et al. (J. Virol. 72: 73-83 (1998)). The RNA is used as a template for the synthesis of cDNA using reverse transcriptase. From the cDNA, a fragment containing the pre-M through E coding region (FIG. 2) is obtained by digestion with restriction nucleases known to cleave the cDNA appropriately to provide such fragments. Examples of restriction digestion of JEV are provided in Nitayaphan et al. (1990) and Konishi et al. (1991). Incorporation of promoters, such as the cytomegalovirus promoter, sequences to promote efficient translation, such as the Kozak sequence, and of the polyadenylation signal, is likewise well known to skilled practitioners in molecular biology and recombinant DNA engineering (Kozak, Mol. Cell. Biology 9: 5134-5142 (1989); Azevedo et al., Braz. J. Med. Biol. Res. 32: 147-153 (1999)). When a nucleic acid comprising a TU containing the desired coding sequences and control sequences is prepared, it may be obtained in larger quantities by methods that amplify nucleic acids. Such methods are widely known to workers skilled in molecular biology and recombinant DNA engineering. Examples of these methods include incorporation of the nucleic acid into a plasmid for replication by culturing in a cell such as a prokaryotic cell and harvesting the plasmid after completing the culture, as well as amplification of the nucleic acid by methods such as PCR and other amplification protocols, as are well known in the art. These examples are not intended to limit the ways in which the nucleic acid containing the TU may be obtained.
The TU-containing nucleic acid molecules of the instant invention may be introduced into appropriate cells in many ways well known to skilled workers in the fields of molecular biology and viral immunology. By way of example, these include, but are not limited to, incorporation into a plasmid or similar nucleic acid vector which is taken up by the cells, or encapsulation within vesicular lipid structures such as liposomes, especially liposomes comprising cationic lipids, or adsorption to particles that are incorporated into the cell by endocytosis.
In general, a cell of this invention is a prokaryotic or eukaryotic cell comprising a TU, or into which a TU has been introduced. The TU of the present invention induces the intracellular biosynthesis of the encoded prM/M and E antigens. A suitable cell is one which has the capability for the biosynthesis of the gene products as a consequence of the introduction of the nucleic acid. In particular embodiments of the invention, a suitable cell is one which responds to a control sequence and to a terminator sequence, if any, which may be included within the TU. In order to respond in this fashion, such a cell contains within it components which interact with a control sequence and with a terminator and act to carry out the respective promoting and terminating functions. When the cell is cultured in vitro, it may be a prokaryote, a single-cell eukaryote or a multicellular eukaryote cell. In particular embodiments of the present invention, the cell is a mammalian cell. In these cases, the synthesized prM/M and E protein gene products are available for use in analytical, or diagnostic applications, including preparation of antigen for use as a vaccine or in immunodiagnostic assays, or for demonstrative purposes.
In some circumstances, such as when the cell is a cultured mammalian cell, the prM/M and E antigens are secreted in the form of subviral particles. These are aggregates of prM/M and E proteins resembling live virus in surface ultrastructural morphology and immunogenic properties. Since the TU of the invention does not include the remainder of the flaviviral genome, however, there is no capsid incorporated, and most importantly, no infectious viral RNA.
In another important embodiment of this invention, the cell is a natural cellular component of the subject to whom the TU has been administered as a vaccine. The TU, when administered to the subject, is taken up by the cells of the subject. The subject's cells have the capability of responding to any promoter sequences, and terminator, if present. In any case, the TU induces the subject's cells to synthesize flaviviral prM/M and E gene products. Without wishing to be constrained by theoretical considerations, it is believed that the subject's cells produce subviral particles in vivo consisting of the prM/M and E antigens, just as has been found to occur with cultured mammalian cells in vitro. Such subviral particles, it is believed, then serve as the in vivo immunogen, stimulating the immune system of the subject to generate immunological responses which confer protective immunity on the subject. Again without wishing to be limited by theory, the resulting protective immunity may arise via either humoral or cellular immunity, i.e., via either an MHC class II- or class I-restricted mechanism, respectively, or by both mechanisms.
According to the invention, subjects are immunized against infection by flaviviruses, such as JEV, YFV, dengue virus, SLEV, WNV or other flaviviruses by administering to them an effective amount of a TU comprising nucleic acid which encodes the prM and/or E antigens. The nucleic acid, after being incorporated into the cells of the subject, leads to the synthesis of the flaviviral prM/M and/or E antigens.
In order to administer the TU to the subject, it is incorporated into a composition which comprises a pharmaceutically acceptable carrier. The term “pharmaceutically acceptable” means a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an subject along with the immunogenic material (i.e., recombinant flavivirus protein antigens or portions thereof) without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the vaccine in which it is contained. Examples of pharmaceutically acceptable carriers, or components thereof, include water, physiological saline and common physiological buffers (for further examples, see Amon, R. (Ed.) Synthetic Vaccines I: pp. 83-92, CRC Press, Inc., Boca Raton, Fla., 1987).
It is understood by those skilled in the art that the critical value in describing a vaccination dose is the total amount of immunogen needed to elicit a protective response in a host which is subject to infectious disease caused by virulent or wild-type flavivirus infection. The number and volume of doses used can be varied and are determined by the practitioner based on such parameters as, age, weight, gender, species, type of vaccine to be administered, mode of administration, overall condition of the subject, et cetera, as well as other important factors recognized by those of skill in the art.
The TU may be administered to a subject orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, intranasally, topically or the like. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation. The exact amount of the TU required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the immunogenicity of the vaccine used, the strain or species of flavivirus against which the subject is being immunized, the mode of administration and the like. Thus, it is not possible to specify an exact amount for every embodiment of the present invention. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein and what is available in the art.
Parenteral administration of the vaccine of the present invention, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Pat. No. 3,610,795, which is incorporated by reference herein.
For solid compositions, conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences (Martin, E. W. (ed.), latest edition, Mack Publishing Co., Easton, Pa.).
In one embodiment, the TU of this invention can be administered to the subject by the use of electrotransfer mediated in vivo gene delivery, wherein immediately following administration of the TU to the subject, transcutaneous electric pulses are applied to the subject, providing greater efficiency and reproducibility of in vivo nucleic acid transfer to tissue in the subject (Mir et al., Proc. Nat. Acad. Sci USA 96: 4262-4267 (1999)).
In the methods of the present invention which describe the immunization of a subject by administering a vaccine of this invention to a subject, the efficacy of the immunization can be monitored according the clinical protocols well known in the art for monitoring the immune status of a subject.
An effective amount of a vaccinating composition is readily determined by those of skill in the art to be an amount which, when administered to a subject, confers protective immunity upon the subject. In order to undertake such a determination, the skilled artisan can assess the ability to induce flaviviral prM/M- and E-specific antibodies and/or flaviviral prM/M- and E-specific cytotoxic T lymphocytes present in the blood of a subject to whom the vaccine has been administered. One can also determine the level of protective immunity conferred upon an experimental subject by challenge with live flavivirus corresponding to the antigenic composition used to immunize the experimental subject. Such challenge experiments are well known to those of skill in the art.
In general, in order to immunize a subject against infection by WNV, JEV, YFV, dengue virus, SLEV, or other flaviviruses according to the present invention, and recognizing that the TUs employed in such methods may have differing overall sizes, doses ranging from about 0.1 μg/kg body weight to about 50 μg/kg body weight can be used.
It has unexpectedly been found that a TU of the present invention which is a DNA confers protective immunity at a level of effectiveness approximating 100% after administration of only a single effective dose of the TU by i.m. injection or by electrotransfer. This is in contrast to many immunization methods carried out using conventional vaccines (as described above), which require one or more booster vaccinations and which may not confer protective immunity to an effectiveness near 100%.
It has further been found unexpectedly that protective immunity may be transmitted from a vaccinated female subject to the offspring of the subject. A significant proportion of neonatal mice was shown to be protected against viral challenge after the mothers were vaccinated using the TU DNA of the invention. Without wishing to be limited by theory, it is known that passive immunity may be conferred on neonatal mammals due to the presence in maternal milk of neutralizing antibodies specific for various pathogens. It is possible that the protective immunity against JEV found within the neonates was transmitted to them in this way.
In another embodiment of the invention, the TU encodes a signal sequence of a structural protein of a first flavivirus and an immunogenic flavivirus antigen of a second flavivirus. Thus, in one embodiment, for example, the signal sequence of structural protein of a first flavivirus is replaced by a signal sequence of structural protein of a second flavivirus, which results in proper folding of the nascent polypeptide, proper processing in a host, and/or proper folding of the processed protein.
In another embodiment of the invention, the TU may encode an immunogenic flavivirus antigen wherein the antigen comprises sequence from one or more than one flavivirus. The signal sequence can be an improved signal peptide. Improvement of signal sequences, or selection of more optimal signal sequences, can be accomplished by application of the principles and techniques taught in Example 18 and references cited therein, each of which are incorporated herein by reference for the express teachings in each related to the selection, identification and design of signal sequences with desired properties and functions. Generally, these desired properties and functions will include a high signal sequence probability.
In another embodiment of the invention, more than one TU or a TU encoding an immunogenic flavivirus antigen from more than one flavivirus are included in a single composition. Thus, in one embodiment, for example, a TU can encode a nascent polypeptide or polypeptides that are processed into proteins from more than one flavivirus. Preferably, the processed proteins form subviral particles that elicit an immunological response against the proteins. The subviral particles can be formed from processed proteins derived from the sequence of the same flavivirus, a combination of flaviviruses, or chimeric flavivirus proteins. Combination vaccines, comprising more than one TU or a TU encoding an immunogenic flavivirus antigen from more than one flavivirus can be tailored for use in particular geographical regions by inclusion of proteins from flaviviruses endemic to the region or otherwise likely to be encountered. For example, a vaccine for tropical and subtropical Asia can include TU(s) that encode proteins from the four serotypes of DEN, WN and JE virus vaccines. Similarly useful vaccines for Africa and Latin America could include TU(s) that encode proteins from the four serotypes of DEN, WN and YF viruses and the four serotypes of DEN, Rocio and YF viruses, respectively.
In another embodiment, the TU encodes a signal sequence of a structural protein of a first flavivirus and an immunogenic chimeric flavivirus antigen that includes amino acid sequence from more than one flavivirus. The signal sequence can be a Japanese encephalitis virus signal sequence. The chimeric flavivirus antigen can include sequence from a Japanese encephalitis virus antigen. In certain embodiments, the chimeric antigen is an E protein. The carboxy terminal portion of the E protein can be E protein sequence from the Japanese encephalitis virus. The carboxy terminal portion can be, for example, 5, 10, 15, 20, 25, 30, 40, 50 or 75% of the chimeric E protein. In a preferred embodiment, the TU encodes a signal sequence of a structural protein of Japanese encephalitis virus, a prM protein of a Dengue virus and a chimeric E protein containing sequence from both the Japanese encephalitis virus and the Dengue virus. The chimeric protein can be an E protein wherein the carboxy terminal portion comprises Japanese encephalitis virus sequence. Examples of TUs include nucleic acid sequences shown in SEQ ID NO:44 and SEQ ID NO:46 that can direct the synthesis of flavivirus antigens such as those shown in SEQ ID NO:45 and SEQ ID NO:47.
The present invention further provides immunogenic compositions comprising the polypeptides of this invention in a pharmaceutical acceptable carrier for use as a protein vaccine. Antigens produced from the transcriptional units of the present invention can be used to elicit effective immune responses in a subject. Antigens for this purpose can comprise flavivirus prM protein, flavivirus M protein, flavivirus E protein or any combination thereof, including immunogenic fragments of the proteins. A particularly preferred embodiment is the use of the NRA described herein. A further preferred embodiment is a chimeric protein comprising the signal sequence of one flavivirus and the structural protein(s) of one or more different flaviviruses. In a particularly preferred embodiment, the signal sequence of the antigen is the Japanese encephalitis virus signal sequence. In other preferred embodiments, the signal sequence is a an improved signal peptide. Improvement of signal sequences, or selection of more optimal signal sequences, can be accomplished by application of the principles and techniques taught in Example 18 and references cited therein each of which are incorporated herein by reference for the express teachings in each related to the selection, identification and design of signal sequences with desired properties and function. Generally, these desired properties and function will include a high signal sequence probability.
In other embodiments, the protein vaccine of this invention further comprises a suitable adjuvant. As used herein, an “adjuvant” is a potentiator or enhancer of the immune response. The term “suitable” is meant to include any substance which can be used in combination with the vaccine immunogen (i.e., flavivirus prM protein, flavivirus M protein, flavivirus E protein, or any combination thereof) to augment the immune response, without producing adverse reactions in the vaccinated subject. Effective amounts of a specific adjuvant may be readily determined so as to optimize the potentiation effect of the adjuvant on the immune response of a vaccinated subject. In a preferred embodiment, adjuvanting of the vaccines of this invention is a 2-stage process, utilizing first a 2% aluminum hydroxide solution and then a mineral oil. In specific embodiments, suitable adjuvants can be chosen from the following group: mineral, vegetable or fish oil with water emulsions, incomplete Freund's adjuvant, E. coli J5, dextran sulfate, iron oxide, sodium alginate, Bacto-Adjuvant, certain synthetic polymers such as Carbopol (BF Goodrich Company, Cleveland, Ohio), poly-amino acids and co-polymers of amino acids, saponin, carrageenan, REGRESSIN (Vetrepharm, Athens, Ga.), AVRIDINE (N,N-dioctadecyl-N′,N′-bis(2-hydroxyethyl)-propanediamine), long chain polydispersed β (1,4) linked mannan polymers interspersed with O-acetylated groups (e.g. ACEMANNAN), deproteinized highly purified cell wall extracts derived from non-pathogenic strain of Mycobacterium species (e.g. EQUIMUNE, Vetrepharm Research Inc., Athens Ga.), Mannite monooleate, paraffin oil and muramyl dipeptide.
In another aspect, this invention provides a method for immunizing subjects with immunogenic amounts of the protein vaccine of the invention to elicit an effective immune response in the subject. Immunization can be carried out orally, parenterally, intranasally, intratracheally, intramuscularly, intramammarily, subcutaneously, intravenously and/or intradermally. The vaccine containing the flavivirus prM protein, flavivirus M protein and/or the flavivirus E protein can be administered by injection, by inhalation, by ingestion, or by infusion. A single dose can be given and/or repeated doses of the vaccine preparations, i.e. “boosters,” can be administered at periodic time intervals to enhance the initial immune response or after a long period of time since the last dose. The time interval between vaccinations can vary, depending on the age and condition of the subject.
The term “immunogenic amount” means an amount of an immunogen, or a portion thereof, which is sufficient to induce an immune response in a vaccinated subject and which protects the subject against disease caused by wild-type or virulent flavivirus infections upon exposure thereto or which has a therapeutic or commercially beneficial effect that lessens the effect of flavivirus infection on the vaccinated subject.
The invention further provides an antibody produced in response to immunization by the antigen of this invention. The antibodies of the present invention can include polyclonal and monoclonal antibodies which can be intact immunoglobulin molecules, chimeric immunoglobulin molecules, “humanized antibodies,” or Fab or F(ab′)2 fragments. Such antibodies and antibody fragments can be produced by techniques well known in the art which include those described in Harlow and Lane (Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989) and Kohler et al. (Nature 256:495-97, 1975) and U.S. Pat. Nos. 5,545,806, 5,569,825 and 5,625,126, incorporated herein by reference. The antibodies can be of any isotype IgG, IgA, IgD, IgE and IgM.
The present invention can also include single chain antibodies (ScFv), comprising linked VH and VL domains and which retain the conformation and specific binding activity of the native idiotype of the antibody. Such single chain antibodies are well known in the art and can be produced by standard methods. (see, e.g., Alvarez et al., Hum. Gene Ther. 8: 229-242 (1997)).
Antibodies can be produced against the antigens of this invention which are synthesized from nucleic acid sequences encoding immunogenic amino acid sequences of the prM, M and/or E antigens of one or more flaviviruses and the signal sequence of a different flavivirus (e.g., JEV). Immunogenic peptides synthesized from the use of these chimeric constructs can easily be identified by use of methods well known in the art for identifying immunogenic regions in an amino acid sequence and used to produce the antibodies of this invention.
Conditions whereby an antigen/antibody complex can form, as well as assays for the detection of the formation of an antigen/antibody complex and quantitation of the detected protein, are standard in the art. Such assays can include, but are not limited to, Western blotting, immunoprecipitation, immunofluorescence, immunocytochemistry, immunohistochemistry, fluorescence activated cell sorting (FACS), fluorescence in situ hybridization (FISH), immunomagnetic assays, ELISA, ELISPOT (Coligan et al., eds. 1995. Current Protocols in Immunology. Wiley, New York.), agglutination assays, flocculation assays, cell panning, etc., as are well known to the artisan.
As used herein, the term “bind” means the well characterized binding of antibody to antigen as well as other nonrandom association with an antigen. “Specifically bind” as used herein describes an antibody or other ligand that does not cross react substantially with any antigen other than the one specified, which in this case, is an antigen of this invention.
The antibody or ligand of this invention can be bound to a substrate (e.g., beads, tubes, slides, plates, nitrocellulose sheets, etc.) or conjugated with a detectable moiety or both bound and conjugated. The detectable moieties contemplated for the present invention can include, but are not limited to, an immunofluorescent moiety (e.g., fluorescein, rhodamine), a radioactive moiety (e.g., 32P, 125I, 35S), an enzyme moiety (e.g., horseradish peroxidase, alkaline phosphatase), a colloidal gold moiety and a biotin moiety. Such conjugation techniques are standard in the art (for example, Harlow and Lane, Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989); Yang et al., Nature 382: 319-324 (1996)).
The present invention further provides a method of detecting flavivirus antibody in a sample, comprising contacting the sample with the flavivirus antigen of the present invention, under conditions whereby an antigen/antibody complex can form; and detecting formation of the complex, thereby detecting flavivirus antibody in the sample.
The present invention further provides a method of detecting flavivirus antigen in a sample, comprising contacting the sample with an antibody of this invention under conditions whereby an antigen/antibody complex can form; and detecting formation of the complex, thereby detecting flavivirus antigen in the sample.
The method of detecting flavivirus antigen in a sample can be performed, for example, by contacting a fluid or tissue sample from a subject with an antibody of this invention and detecting binding of the antibody to the antigen. It is contemplated that the antigen will be on an intact flavivirus virion, will be a flavivirus-encoded protein displayed on the surface of a flavivirus-infected cell expressing the antigen, or will be a fragment of the antigen. A fluid sample of this method can comprise any biological fluid which could contain the antigen or a cell containing the antigen, such as cerebrospinal fluid, blood, bile, plasma, serum, saliva and urine. Other possible examples of body fluids include sputum, mucus and the like.
The method of detecting flavivirus antibody in a sample can be performed, for example, by contacting a fluid or tissue sample from a subject with an antigen of this invention and detecting the binding of the antigen to the antibody. A fluid sample of this method can comprise any biological fluid which could contain the antibody, such as cerebrospinal fluid, blood, bile, plasma, serum, saliva and urine. Other possible examples of body fluids include sputum, mucus and the like.
Enzyme immunoassays such as immunofluorescence assays (IFA), enzyme linked immunosorbent assays (ELISA) and immunoblotting can be readily adapted to accomplish the detection of flavivirus antibodies according to the methods of this invention. An ELISA method effective for the detection of the antibodies can, for example, be as follows: (1) bind the antigen to a substrate; (2) contact the bound antigen with a fluid or tissue sample containing the antibody; (3) contact the above with a secondary antibody bound to a detectable moiety which is reactive with the bound antibody (e.g., horseradish peroxidase enzyme or alkaline phosphatase enzyme); (4) contact the above with the substrate for the enzyme; (5) contact the above with a color reagent; and (6) observe/measure color change or development.
Another immunologic technique that can be useful in the detection of flavivirus antibodies uses monoclonal antibodies (MAbs) for detection of antibodies specifically reactive with flavivirus antigens in a competitive inhibition assay. Briefly, sample is contacted with an antigen of this invention which is bound to a substrate (e.g., an ELISA 96-well plate). Excess sample is thoroughly washed away. A labeled (e.g., enzyme-linked, fluorescent, radioactive, etc.) monoclonal antibody is then contacted with any previously formed antigen-antibody complexes and the amount of monoclonal antibody binding is measured. The amount of inhibition of monoclonal antibody binding is measured relative to a control (no antibody), allowing for detection and measurement of antibody in the sample. The degree of monoclonal antibody inhibition can be a very specific assay for detecting a particular flavivirus variety or strain, when based on monoclonal antibody binding specificity for a particular variety or strain of flavivirus. MAbs can also be used for direct detection of flavivirus antigens in cells by, for example, immunofluorescence assay (IFA) according to standard methods.
As a further example, a micro-agglutination test can be used to detect the presence of flavivirus antibodies in a sample. Briefly, latex beads, red blood cells or other agglutinable particles are coated with the antigen of this invention and mixed with a sample, such that antibodies in the sample that are specifically reactive with the antigen crosslink with the antigen, causing agglutination. The agglutinated antigen-antibody complexes form a precipitate, visible with the naked eye or measurable by spectrophotometer. In a modification of the above test, antibodies of this invention can be bound to the agglutinable particles and antigen in the sample thereby detected.
The present invention further provides a method of diagnosing a flavivirus infection in a subject, comprising contacting a sample from the subject with the antigen of this invention under conditions whereby an antigen/antibody complex can form; and detecting antigen/antibody complex formation, thereby diagnosing a flavivirus infection in a subject.
The present invention further provides a method of diagnosing a flavivirus infection in a subject, comprising contacting a sample from the subject with the antibody of this invention under conditions whereby an antigen/antibody complex can form; and detecting antigen/antibody complex formation, thereby diagnosing a flavivirus infection in a subject.
In the diagnostic methods taught herein, the antigen of this invention can be bound to a substrate and contacted with a fluid sample such as blood, serum, urine or saliva. This sample can be taken directly from the patient or in a partially purified form. In this manner, antibodies specific for the antigen (the primary antibody) will specifically react with the bound antigen. Thereafter, a secondary antibody bound to, or labeled with, a detectable moiety can be added to enhance the detection of the primary antibody. Generally, the secondary antibody or other ligand, which is reactive, either specifically with a different epitope of the antigen or nonspecifically with the ligand or reacted antibody, will be selected for its ability to react with multiple sites on the primary antibody. Thus, for example, several molecules of the secondary antibody can react with each primary antibody, making the primary antibody more detectable.
The detectable moiety allows for visual detection of a precipitate or a color change, visual detection by microscopy, or automated detection by spectrometry, radiometric measurement or the like. Examples of detectable moieties include fluorescein and rhodamine (for fluorescence microscopy), horseradish peroxidase (for either light or electron microscopy and biochemical detection), biotin-streptavidin (for light or electron microscopy) and alkaline phosphatase (for biochemical detection by color change).
Particular embodiments of the present invention are set forth in the examples which follow. These examples are not intended to limit the scope of the invention as disclosed in this specification.
EXAMPLES
General methods utilizing molecular biology and recombinant DNA techniques related to preparing and expressing the nucleic acid TU molecules of the invention are set forth in, for example, Current Protocols in Molecular Biology, Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly), and Molecular Cloning: A Laboratory Manual 2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989.
Example 1 Preparation of Recombinant Plasmids Containing the Transcriptional Unit Encoding JEV prM and E Antigens
Genomic RNA was extracted from 150 μL of JEV strain SA 14 virus seed grown from mouse brain using a QIAamp™ Viral RNA Kit (Qiagen, Santa Clarita, Calif.). RNA, adsorbed on a silica membrane, was eluted in 80 μL of nuclease-free water, and used as a template for the amplification of JEV prM and E gene coding sequences. Primer sequences were obtained from the work of Nitayaphan et al. (Virology 177: 541-552 (1990)). A single cDNA fragment containing the genomic nucleotide region 389-2478 was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR). Restriction sites KpnI and XbaI, the consensus Kozak ribosomal binding sequence, and the translation initiation site were engineered at the 5′ terminus of the cDNA by amplimer 14DV389 (nucleotide sequence, SEQ ID NO: 1; amino acid sequence, SEQ ID NO:2). An in-frame translation termination codon, followed by a NotI restriction site, was introduced at the 3′ terminus of the cDNA by amplimer c14DV2453 (SEQ ID NO:3) (FIG. 2). One-tube RT-PCR was performed using a Titan RT-PCR Kit (Boehringer Mannheim, Indianapolis, Ind.). 10 μL of viral RNA was mixed with 1 μL each of 14DV389 (50 μM) and c14DV2453 (50 μM) and 18 μL of nuclease-free water and the mixture was heated at 85° C. for 5 min and then cooled to 4° C. 75 μL of reaction mix [20 μL 5× buffer, 2 μL of dNTP mixture (10 mM each), 5 μL of dithiothreitol (0.1 mM), 0.5 μL of RNasin™ (40 U/μL, Boehringer Mannheim), 2 μL of polymerase mixture, and 45.5 μL of nuclease-free water] was added and RT-PCR performed as follows: 1 cycle (50° C. for 30 min, 94° C. for 3 min, 50° C. for 30 s, 68° C. for 2.5 min), 9 cycles (94° C. for 30 s, 50° C. for 30 s, 68° C. for 2.5 min), 20 cycles (94° C. for 30 s, 50° C. for 30 s, 68° C. for 2.5 min in the first cycle, with an increment of 5 s per cycle thereafter), and a final extension at 68° C. for 15 min. The RT-PCR product was purified by a QIAquick™ PCR Purification Kit (Qiagen) and eluted with 50 μL of 1 mM Tris-HCl, pH 7.5.
All vector constructions and analyses were carried out by using standard techniques (Sambrook et al., 1989). RT-PCR amplified cDNA, digested with KpnI and NotI nucleases, was inserted into the KpnI-NotI site of eukaryotic expression plasmid vector (pcDNA3, Invitrogen, Carlsbad, Calif.). Electroporation-competent Escherichia coli XL1-Blue cells (Stratagene, La Jolla, Calif.) were transformed by electroporation (Gene Pulser™, Bio-Rad, Hercules, Calif.) and plated onto LB agar plates containing 100 μg/mL carbenicillin (Sigma Chemical Co., St. Louis, Mo.). Clones were picked and inoculated into 3 mL LB broth containing 100 μg/mL carbenicillin. Plasmid DNA was extracted from a 14 h culture using a QIAprep™ Spin Miniprep Kit (Qiagen). Automated DNA sequencing was performed as recommended (Applied Biosystems/Perkin Elmer, Foster City, Calif.). Both strands of the cDNA were sequenced and shown to be identical to the sequence for the original SA14 strain (Nitayaphan et al., 1990).
The fragment of plasmid pcDNA3 (Invitrogen, Carlsbad, Calif.) from nucleotide (nt) 1289 to nt 3455, containing f1 ori, SV40 ori, the neomycin resistance gene, and SV40 poly(A) elements was deleted by PvuII digestion and then ligated to generate the pCBamp plasmid. The vector pCIBamp, containing a chimeric intron insertion at the NcoI/KpnI site of the pCBamp was constructed by excising the intron sequence from pCI (Promega, Madison, Wis.) by digestion with NcoI and KpnI. The resulting 566-bp fragment was cloned into pCBamp by digesting with NcoI-KpnI to replace its 289-bp fragment. FIG. 3 presents the relationships between the plasmids pCDA3, pCBamp, and pCIBamp.
Plasmids containing the transcriptional unit encoding JEV prM and E proteins were prepared from these plasmids. The cDNA fragment containing the JEV prM and E coding regions in the recombinant plasmid pCDJE2-7 (nucleotide sequence, SEQ ID NO: 10; amino acid sequence, SEQ ID NO: 11), derived from the pcDNA3 vector, was excised by digestion with NotI and KpnI or XbaI and cloned into the KpnI-NotI site of pCBamp, pCIBamp, pCEP4 (Invitrogen, Carlsbad, Calif.), or pREP4 (Invitrogen, Carlsbad, Calif.), or into the SpeI-NotI site of pRc/RSV (Invitrogen, Carlsbad, Calif.) expression vector to create pCBJE1-14 (nucleotide sequence, SEQ ID NO: 17; amino acid sequence, SEQ ID NO:18), pCIBJES14, pCEJE, pREFE, and pRCJE, respectively. Both strands of the cDNA from clones of each plasmid were sequenced and recombinant clones with the correct nucleotide sequence were identified. Plasmid DNA for use in the in vitro transformation of mammalian cells or mouse immunization experiments was purified by anion exchange chromatography using an EndoFree™ Plasmid Maxi Kit (Qiagen).
Example 2 Evaluation of JEV prM and E Proteins Expressed by Various Recombinant Plasmids Using an Indirect Immunofluorescent Antibody Assay
The expression of JEV specific gene products by the various recombinant expression plasmids was evaluated in transiently transfected cell lines of COS-1, COS-7 and SV-T2 (ATCC, Rockville Md.; 1650-CRL, 1651-CRL, and 163.1-CCL, respectively) by indirect immunofluorescent antibody assay (IFA). The SV-T2 cell line was excluded from further testing since a preliminary result showed only 1-2% of transformed SV-T2 cells were JEV antigen positive. For transformation, cells were grown to 75% confluence in 150 cm2 culture flasks, trypsinized, and resuspended at 4° C. in phosphate buffered saline (PBS) to a final cell count 5×106 per mL. 10 μg of plasmid DNA was electroporated into 300 μL of cell suspension using a BioRad Gene Pulse™ (Bio-Rad) set at 150 V, 960 μF and 100Ω resistance. Five minutes after electroporation, cells were diluted with 25 mL fresh medium and seeded into a 75 cm2 flask. 48 h after transformation the medium was removed from the cells, and the cells were trypsinized and resuspended in 5 mL PBS with 3% normal goat serum. 10 μL aliquots were spotted onto slides, air dried and fixed with acetone at −20° C. for 20 min. IFA was performed with acetone-fixed plasmid-transformed cells using fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin G (Sigma Chemical Co.) and JEV HIAF.
To determine the influence of various promoter and poly(A) elements on the JEV prM and E protein expression, COS-1 and COS-7 cell lines were transiently transformed by an equal amount of pCDJE2-7 (SEQ ID NO: 10), pCEJE, pREJE, or pRCJE plasmid DNA. JEV antigens were expressed in both cell lines transformed by all four recombinant plasmids, thus confirming that the CMV or RSV (rous sarcoma virus) promoter and BGH or SV40 poly(A) elements were functionally active. However, the percentage of transformed cells and the level of JEV antigens expressed, as determined by the number of IFA positive cells and IFA intensity, respectively, differed greatly among the various plasmids (Table 1). A significantly high percentage of COS-1 cells transformed by pCDJE2-7 (SEQ ID NO: 10), pCBJE1-14 (SEQ ID NO: 17) and pCIBJES14 expressed the JEV antigens, and the level of the expressed proteins was compatible with JEV-infected cells. Cells transfected with pCEJE, pREJE, or pRCJE vectors, on the other hand, had a low percentage of antigen-expressing cells, as well as a low intensity of fluorescence, indicating weak expression of the antigens.
In order to ascertain whether the enhanced expression of JEV proteins by pCDJE2-7 (SEQ ID NO: 10) was influenced by the SV40-encoded eukaryotic origin of replication, the plasmid pCBJE1-14 (SEQ ID NO: 17) was constructed so that a 2166-bp fragment, containing f1 ori, SV40 ori, the neomycin resistance gene and SV40 poly(a) elements from pCDJE2-7, was deleted. A chimeric intron was then inserted into pCBJE1-14 to generate pCIBJES14. The pCIBJES14 plasmid was used to determine if the expression of JEV proteins could be enhanced by the intron sequence. Following transformation, cells harboring both pCBJE1-14 and pCIBJES14 vectors expressed a level of JEV antigens similar to that observed with pCDJE2-7 (Table 1). This result indicates that expression of JEV prM and E antigens by recombinant vectors is influenced only by the transcriptional regulatory elements. Neither the eukaryotic origin of replication nor the intron sequence enhanced JEV antigen expression in the cells used. Vectors containing the CMV promoter and BGH poly(A) (FIG. 3) were selected for further analysis.
Example 3 Selection of an In Vitro Transformed Stable Cell Line Constitutively Expressing JEV Specific Gene Products
COS-1 cells were transformed with 10 μg of pCDJE2-7 DNA by electroporation as described in the previous example. After a 24 hr incubation in non-selective culture medium, cells were treated with neomycin (0.5 mg/mL, Sigma Chemical Co.). Neomycin-resistant colonies, which became visible after 2-3 weeks, were cloned by limited dilution in neomycin-containing medium. Expression of vector-encoded JEV gene products was initially screened by IFA using JEV HIAF. One JEV-IFA positive clone (JE-4B) and one negative clone (JE-SA) were selected for further analysis and maintained in medium containing 200 μg/nL neomycin.
Authenticity of the JEV E protein expressed by the JE-4B clone was demonstrated by epitope mapping by WFA using a panel of JEV E-specific murine monoclonal antibodies (Mab) (Kimura-Kuroda et al., J. Virol. 45: 124-132 (1983); Kimura-Kuroda et al., J. Gen. Virol. 67: 2663-2672 (1986); Zhang et al., J. Med. Virol. 29: 133-138 (1989); and Roehrig et al., Virol. 128: 118-126 (1983)). JEV HIAF and normal mouse serum were used as positive and negative antibody controls, respectively. Four JEV-specific, six flavivirus-subgroup specific, and two flavivirus-group reactive Mabs reacted similarly with the 4B clone or JEV-infected COS-1 cells (Table 2).
Example 4 Antigenic Properties and Immunological Detection of Subviral Particles Secreted by the JE-4B COS-1 Cell Line
a. Preparation of subviral particles. JE-4B COS-1 cells were grown and maintained in medium containing 200 μg/mL of neomycin. The cultured medium was routinely harvested and stored at 4° C., and replenished twice weekly, and the cells were split 1:5 every 7-10 days. Culture medium was clarified by centrifugation at 10,000 rpm for 30 min in a Sorvall F16/250 rotor at 4° C., and centrifuged further for 4 hr at 39,000 rpm in a Sorvall TH641 rotor at 4° C. through a 5% sucrose cushion (w/w, prepared with 10 mM Tris HCl, pH 7.5, 100 mM NaCl (TN buffer)). The pellet containing subviral particles was resuspended in TN buffer and stored at 4° C. Alternatively, 7% or 10% PEG-8000 (w/v) was added to the clarified culture medium. The mixture was stirred at 4° C. for at least 2 hr, and the precipitated particles were collected by centrifugation at 10,000 rpm for 30 min. The precipitate was resuspended in TN buffer and stored at 4° C. The subviral particles were purified from both pelleted and PEG-precipitated preparations by rate zonal centrifugation in a 5-25% continuous sucrose gradient in TN at 38,000 rpm at 4° C. for 90 min. 1-mL fractions were collected from the top of the gradient, tested by antigen capture ELISA (see below), and the positive fractions loaded onto a 25-50% sucrose gradient in TN. This was centrifuged overnight in an equilibrium density centrifugation at 35,000 rpm at 4° C. 0.9-mL fractions from the equilibrium gradients were collected from the bottom. They were tested by antigen-capture ELISA and assessed for hemagglutination (HA) activity at pH 6.6. An aliquot of 100 μL of each fraction was weighed precisely to determine its density. The ELISA-positive fractions were pooled and pelleted at 39,000 rpm at 4° C. for 3-4 hr and the pellet resuspended in TN buffer. Antigen-capture ELISA and HA titers were determined on the pelleted samples. JEV-infected COS-1 cell supernatant was also subjected to similar purification protocols as detailed above and used as a positive control for the gradient analysis. JE virions were also purified from infected C6/36 cells 5-6 days postinfection by sedimentation in a glycerol/tartrate equilibrium gradient.
b. Western blots of subviral particles. Gradient-purified samples of the subviral particles were mixed with electrophoresis sample buffer and run on 10 or 12.5% sodium dodecyl sulfate-containing polyacrylamide gels (SDS-PAGE) as described by Laemmli (Nature 277: 680-685 (1970)). Proteins were transferred to a nitrocellulose membrane and immunochemically detected with polyclonal JEV HIAF, flavivirus cross-reactive anti-E Mab 4G2 (Henchal et al., Amer. J. Trop. Med. Hyg. 31: 830-836 (1982)), or mouse anti-prM peptide hyperimmune serum (JM10). FIG. 4 shows a comparison of the M and E proteins produced by JEV infected C6/36 and JE-4B COS-1 cells. Some nonspecific reactivity to E protein was observed in the normal mouse ascitic fluid and JM01 anti-peptide serum. Proteins identical in size to M and E were secreted in the subviral particles and could be detected by E-specific Mab 4G2 and prM-specific JM01 antiserum, respectively.
c. Density gradient detection of JEV subviral particles in culture medium. For ELISA, antigen-capture antibody (4G2) was diluted in 0.1 M sodium carbonate buffer, pH 9.6, and used to coat 96-well microtiter plates (Immulon II, Dynatech. Chantilly, Va.) by overnight incubation at 4° C. After blocking with 3% normal goat serum in PBS, two-fold serially-diluted samples were added to the 4G2-coated plate and incubated 1.5 hours at 37° C. Captured antigen was detected by horseradish peroxidase-conjugated 6B6C-1 Mag, and incubated for 1 hour at 37° C. The enzyme activity on the solid phase was then detected with TMB (3,3′,5,5′-tetramethylbenzidine)-ELISA (Life Technologies, Grand Island, N.Y.).
Approximately 500 mL of cell culture medium from 15×150 cm2 flasks of JE-4B cells was collected four days after cells were seeded. PEG-precipitated subviral particles were resuspended in 2 mL of TN buffer, pH 7.5; a 0.7 mL aliquot of this resuspended pellet was loaded onto a 5-25% sucrose gradient. Triton X-100, which disrupts subviral particles, was added to another 0.7 mL aliquot to a final concentration of 0.1% and this was loaded onto a 5-25% sucrose gradient prepared in TN buffer containing 0.1% Triton X-100. A definite opaque band was observed approximately 2.5 cm from the top of the gradient containing Triton X-100, but not in the gradient without detergent. Fractions (1 mL) were collected from top to bottom for each gradient (FIG. 5). Each collected fraction was analyzed by antigen capture ELISA. Antigen was detected in fractions 4-6, indicating relatively rapid sedimentation characteristic of subviral particles. Treatment of the PEG precipitate from JE-4B culture medium with Triton X-100 shifted the position of ELISA-reactive material to the top of the gradient. Thus treatment with Triton X-100 produces only slow-sedimenting molecules. A similar finding was reported by Konishi et al. (Virol. 188: 714-720 (1992)). These results show that rapidly sedimenting subviral particles containing prM/M and E could be disrupted by detergent treatment.
Hemagglutination (HA) activity was determined in the pH range from 6.1 to 7.0 by the method of Clarke and Casals (Amer. J. Trop. Med. Hyg. 7: 561-573 (1958)). The subviral particle secreted by JE-4B cells and the virion particle produced by JEV infected COS-1 cells had a similar HA profile with the optimum pH determined to be 6.6.
Example 5 Comparison of the Immune Response in Mice Vaccinated with pCDJE2-7 Nucleic Acid Vaccine of the Invention and Commercial JEV Vaccine
Groups of five 3-week-old female, ICR outbred mice were injected intramuscularly in the left and right quadriceps with 100 μg of pCDJE2-7 plasmid in 100 μL of dH2O or were given doses of JE-VAX (manufactured by the Research Foundation for Microbial Disease of Osaka University and distributed by Connaught Laboratories, Swiftwater, Pa.) subcutaneously that are one-fifth the dose given to humans. The plasmid pcDNA3/CAT (Invitrogen), which encodes and expresses an unrelated protein, was used as the negative vaccination control. Except for one group of pCDJE2-7-vaccinated mice, all animals were boosted 3 weeks later with an additional dose of plasmid or JE-VAX. Mice were bled from the retroorbital sinus at 3, 6, 9, 23, 40 and 60 weeks after inoculation. JEV antibody titers were determined by enzyme-linked immunosorbent assay (ELISA) against purified JEV or by plaque reduction neutralization tests (PRNT) (Roehrig et al., Virol. 171: 49-60 (1989); and Hunt and Calisher, Amer. J. Trop. Med. Hyg. 28: 740-749 (1979)).
The pCDJE2-7 nucleic acid vaccine and JE-VAX provided 100% seroconversion within three weeks after the first vaccination in all three groups of mice (Table 3). The JEV ELISA and PRNT antibody titers reached the highest level at week 6 and week 9, respectively, after immunization. Mice receiving 1 dose of DNA vaccine had similar antibody responses as those receiving 2 doses. Comparable ELISA antibody titers were maintained in DNA-vaccinated groups up to 60 weeks, after which the experiment was terminated. However, only one of four mice in the JE-VAX group was JEV antibody positive at 60 weeks post-inoculation. The pcDNA3/CAT control group did not have any measurable JEV antibody. These results demonstrate that a single dose of JEV-specific nucleic acid vaccine is more effective in maintaining JEV antibody in mice than the commercial, FDA-approved JE-VAX vaccine.
Example 6 Comparison of Various Nucleic Acid Vaccine Constructs of the Invention and Commercial JEV Vaccine for Effectiveness of Vaccination at Different Ages
A similar level of JEV protein was expressed by COS-1 cells transformed by either pCDJE2-7, pCBJE1-14, or pCIBJES14. JEV antibody induction by these nucleic acid constructs was compared to JE-VAX commercial vaccine at two different ages at vaccination. Three-day (mixed sex) or 3-week-old (female) ICR outbred mice, 10 per group, were vaccinated intramuscularly with 50 or 100 μg of plasmid DNA, or subcutaneously with doses of JE-VAX that are one-tenth or one-fifth the dose given to humans. Serum specimens were collected at 3 and 7 weeks after immunization and tested at a 1:1600 dilution by ELISA using purified JEV as an antigen. Results are shown in Table 4.
Plasmid pCBJE1-14 provided the highest extent of seroconversion, i.e., antibody titer greater than 1:1600, achieving 80-100% at both ages of vaccination. Administration of pCDJE2-7 or pCIBJES14 provided moderate seroconversion by 7 weeks when 3-day old mice were vaccinated (60% for each), but weaker seroconversion (40% and 10%, respectively) when measured 3 weeks after vaccination. When these plasmids were administered at the age of 3 weeks, however, seroconversions of 90% or 100% were attained at both 3 weeks and 7 weeks after vaccination. In contrast, the commercial vaccine, JE-VAX, conferred no seroconversion when administered at 3 days of age, and 100% when given at 3 weeks of age. Thus the nucleic acid TU's for JEV prM and E provided an extent of seroconversion better than a very high dose of the commercial vaccine, and unexpectedly high seroconversion in both young and more mature animals.
Example 7 Protective Immunity Conferred by the Nucleic Acid Vaccine of the Invention
Three-day old vaccinated groups from Example 6 were challenged 7 weeks after vaccination by intraperitoneal injection of 50,000 pfu/100 μL of the mouse-adapted JEV strain SA14 and observed for 3 weeks. 100% protection was achieved in groups that received various nucleic acid TU-containing vaccine constructs for up to 21 days (Table 5). In contrast, 60% of the JE-VAX-vaccinated mice, as well as 70% of the pcDNA3/CAT-vaccinated negative controls, did not survive virus challenge by 21 days. These results indicate that the nucleic acid TU's of the invention confer unexpectedly effective protection on vaccinated mice. This suggests the possibility of employing the nucleic acid vaccine of the invention as an early childhood vaccine for humans. In contrast, JE-VAX, the inactivated human vaccine currently used, does not appear to be effective in young animals.
Example 8 Passive Protection of Neonatal Mice Correlated with the Maternal Antibody Titer
Female ICR mice at the age of 3 weeks were vaccinated with either one dose or two doses spaced two days apart of pCDJE2-7 plasmid DNA, at 100 μg/100 μL, or with two doses of JE-VAX that were one-fifth the dose given to humans. The negative control group received two doses of 100 μg/100 μL of pcDNA-3/CAT plasmid. Passive protection by maternal antibody was evaluated in pups resulting from matings of experimental females with non-immunized male mice that occurred nine weeks following the first vaccination or 6 weeks following the second vaccination. Pups were challenged between 3-15 days after birth by intraperitoneal administration of 5,000 pfu/100 μL of mouse-adapted SA14 virus and observed daily for 3 weeks (Table 6). The survival rates correlated with the maternal neutralizing antibody titers. 100% of pups nursed by mothers with a PRNT of 1:80 survived viral infection, whereas none of the pups from the control mother survived (Table 6). Partial protection of 45% and 75% was observed in older pups that were nursed by mothers with a PRNT titer of 1:20 and 1:40, respectively. The survival rates also correlated with the length of time that pups were nursed by the immune mother. As just indicated, 13-15 day old pups had high survival rates. None of the 3-4 day old pups, however, survived virus challenge when the mother had a PRNT titer of 1:20 or 1:40. Thus maternal antibody provides partial to complete protective immunity to the offspring. In addition, JEV antibody was detected by ELISA in the sera of 97% ( 29/30) of the post-challenge pups.
Mice were inoculated intramuscularly with 1 or 2, 100 μg doses of plasmid DNA, or subcutaneously with two, ⅕ human doses of JE-VAX vaccine. Sera were collected 9 weeks post-vaccination for PRNT testing prior to mating with non-immune male.
Example 9 Preparation of Recombinant Plasmids Containing the Transcriptional Unit Encoding WNV prM and E Antigens
Genomic RNA was extracted from 150 μL of Vero cell culture medium infected with NY 99-6480 strain, an strain isolated from the outbreak in New York 1999, using the QIAamp™ Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in 80 μl of nuclease-free water, and used as a template for the amplification of WNV prM and E gene coding sequences. Primer sequences were obtained from the work of Lanciotti et al. (Science 286: 2333-2337 (1999)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR). Restriction sites BsmBI and KasI were engineered at the 5′ terminus of the cDNA by using amplimer WN466 (nucleotide sequence, SEQ ID NO: 12). An in-frame translation termination codon, followed by a NotI restriction site was introduced at the 3′ terminus of the cDNA by using amplimer cWN2444 (SEQ ID NO: 13). The RT-PCR product was purified by a QIAquick™ PCR Purification Kit (Qiagen).
The double-stranded amplicon produced by use of the two amplimers above (SEQ ID NO: 12 and SEQ ID NO: 13) was digested with KasI and NotI enzymes to generate a 998 bp (nt-1470 to 2468) fragment of DNA was inserted into the KasI and NotI sites of a pCBJESS vector to form an intermediate plasmid, pCBINT. The pCBJESS was derived from the pCBamp plasmid, that contained the cytomegalovirus early gene promoter and translational control element and an engineered JE signal sequence element (Chang et al., J. Virol. 74: 4244-4252 (2000)). The JE signal sequence element comprises the JE signal sequence (SEQ ID NO: 14).
The cDNA amplicon was subsequently digested with BsmBI and Kas I enzymes and the remaining 1003 bp fragment (nt-466 to 1470) was inserted in to the KasI site of pCBINT to form pCBWN (nucleic acid sequence, SEQ ID NO: 15; amino acid sequence, SEQ ID NO: 16). Automated DNA sequencing using an ABI prism 377 Sequencer (Applied Biosystems/Perkin Elmer, Foster City, Calif.) was used to confirm that the recombinant plasmid had a correct prM and E sequence as defined by Lanciotti et al. (Science 286: 2333-2337 (1999)).
Plasmid DNA for use in the in vitro transformation of mammalian cells or mouse immunization experiments was purified by anion exchange chromatography as described in Example 1.
Example 10 Immunochemical Characterization and Evaluation of WNV prM and E Proteins Expressed by pCBWN
WNV specific gene products encoded by the pCBWN plasmid were expressed in COS-1 cells. Cells were electroporated and transformed with pCBWN plasmid according to Chang et al. (J. Virol. 74: 4244-4252 (2000)). Electroporated cells were seeded onto 75 cm2 culture flasks or a 12-well tissue culture dish containing one sterile coverslip/well. All flasks and 12-well plates were kept at 37° C., 5% CO2 incubator. Forty hours following electroporation, coverslips containing adherent cells were removed from the wells, washed briefly with PBS, fixed with acetone for 2 minutes at room temperature, and allowed to air dry.
Protein expression was detected using indirect immunofluorescence antibody assay (IFA), as described in Example 2. Flavivirus E-protein specific monoclonal antibody (Mab) 4G2, WNV mouse hyperimmune ascitic fluid (RAF) and normal mouse serum (NMS) at 1:200 dilution in PBS were used as the primary antibody to detect protein expression (Henchal et al., Am. J. Trop. Med. Hyg. 31: 830-836 (1982)).
Tissue culture medium was harvested 40 and 80 hours following electroporation. Antigen-capture (Ag-capture) ELISA was used to detect secreted WN virus antigen in the culture medium of transiently transformed COS-1 cells. The Mab 4G2 and horseradish peroxidase-conjugated Mab 6B6C-1 were used to capture the WN virus antigens and detect captured antigen, respectively (Chang et al., J. Virol. 74: 4244-4452 (2000); Henchal et al., Am. J. Trop. Med. Hyg. 31: 830-836 (1983); Roehrig et al., Virology 128: 118-126 (1983)).
WN virus antigen in the medium was concentrated by precipitation with 10% polyethylene glycol (PEG)-8000. The precipitant was resuspended in TNE buffer (50 mM Tris, 100 mM NaCl, 10 mM EDTA, pH 7.5), clarified by centrifugation, and stored at 4° C. Alternatively, the precipitant was resuspended in a lyophilization buffer (0.1 M TRIZMA and 0.4% bovine serum albumin in borate saline buffer, pH 9.0), lyophilized and stored at 4° C. Lyophilized preparations were used as antigen for the evaluation in MAC- and indirect IgG ELISAs.
WN virus-specific protein was detected by IFA on the transiently transformed COS-1 cells. E, prM and M proteins expressed in these cells were secreted into the culture medium. WN virus antigen concentrated by PEG precipitation was extracted with 7.0% ethanol to remove residual PEG (Aizawa et al., Appl. Enviro. Micro. 39: 54-57 (1980)). Ethanol extracted antigens and gradient-purified WN virions were analyzed on a NuPAGE, 4-12% gradient Bis-Tris Gel in a Excel Plus Electrophoresis Apparatus (Invitrogen Corp., Carlsbad, Calif.) and followed by electroblotting onto nitrocellulose membranes using a Excel Plus Blot Unit (Invitrogen Corp.). WN virus-specific proteins produced by the transiently transformed COS-1 cells were detected by WN virus specific mouse HIAF or flavivirus E protein reactive Mab 4G2 in a Western blot analysis, using NMS as a negative serum control. The proteins displayed similar reactivity and identical molecular weights to the corresponding gradient purified virion E, prM and M protein derived from WN virus infected suckling mouse brain (SMB).
In analysis of the NRA as an antigen for diagnostic ELISA, one vial of lyophilized NRA, representing antigen harvested from 40 ml of tissue culture fluid, was reconstituted in 1.0 ml of distilled water and compared with the reconstituted WN virus infected suckling mouse brain (SMB) antigen provided as lyophilized as β-propiolactone-inactivated sucrose-acetone extracts (Clarke et al., Am. J. Trop. Med. Hyg. 7: 561-573 (1958)). All recombinant proteins, prM, M and E, had a similar reactivity to that of the gradient-purified virion E, prM and M proteins.
Coded human specimens were tested concurrently with antigens in the same test at the developmental stage. The MAC- and IgG ELISA protocols employed were identical to the published methods (Johnson et al., J. Clin. Microbiol. 38: 1827-1831 (2000); Martin et al., J. Clin. Microbiol. 38: 1823-1826. (2000)). Human serum specimens were obtained from the serum bank in our facility, which consists of specimens sent to the DVBID for WN virus confirmation testing during the 1999 outbreak In these tests, a screening MAC- and IgG ELISA were performed on a 1:400 specimen dilution. Specimens yielding positive/negative (P/N) OD ratios between 2 and 3 were considered suspect positives. Suspect serum specimens were subject to confirmation as positives by both ELISA end-point titration and plaque-reduction neutralization test (PRNT). All specimens yielding P/N OD ratios greater than 3.0 were considered positives without further confirmatory testing.
An Ag-capture ELISA employing flavivirus-group reactive, anti-E Mab, 4G2 and 6B6C-1, was used to detect NRA secreted into culture fluid of pCBWN transformed COS-1 cells. The antigen could be detected in the medium one day following transformation; and the maximum ELISA titer (1:32-1:64) in the culture fluid without further concentration was observed between day two and day four. NRA was concentrated by PEG precipitation, resuspended in a lyophilization buffer, and lyophilized for preservation. For diagnostic test development, one vial of lyophilized NRA was reconstituted with 1.0 ml distilled water and titrated in the MAC- or indirect IgG ELISA using WN virus positive and negative reference human sera (Johnson et al., J. Clin. Microbiol. 38: 1827-1831 (2000); Martin et al., J. Clin. Microbiol. 38: 1823-1826 (2000)). Dilutions 1:320 and 1:160 of the NRA were found to be the optimal concentrations for use in MAC- and IgG ELISA, respectively. These dilutions resulted in a P/N OD450 ratio of 4.19 and 4.54, respectively, for MAC- and IgG test. The WN virus SMB antigens produced by NY-6480 and Eg101 strains were used at 1:320 and 1:640 dilution for MAC-ELISA, and 1:120 and 1:320 for IgG ELISA, respectively. The negative control antigens, PEG precipitates of the culture medium of normal COS-1 cells and normal SMB antigen, were used at the same dilutions as for the respective NRA and SMB antigen. Human serum specimens, diluted at 1:400, were tested concurrently in triplicate with virus-specific and negative control antigens. For the positive test result to be valid, the OD450 for the test serum reacted with viral antigen (P) had to be at least two-fold greater than the corresponding optical density value of the same serum reacted with negative control antigen (N).
The reactivity of NRA and NY-06480, Eg101 and SLE virus SMBs were compared by the MAC- and IgG ELISAs using 21 coded human serum specimens. Of the 21 specimens, 19 had similar results on all three antigens (8 negatives and 11 suspect positives or positives). Eighteen specimens were also tested separately using SLE SMB antigen. Only three of 13 Eg-101-SMB positive specimens were positive in the SLE MAC-ELISA (Table 1). None of WN antigen negative specimens was positive by SLE MAC-ELISA. This result confirmed a previous observation that anti-WN virus IgM did not cross-react significantly with other flaviviruses (Tardei et al., J. Clin. Microbiol. 38: 2232-2239 (1940)) and was specific to diagnose acute WN virus infection regardless of whether NRA or SMB antigen was used in the test. All of the specimens were also tested concurrently by indirect IgG ELISA. Ten of 21 specimens were positive using any of the three antigens.
The two discrepant serum specimens (7 and 9) both from the same patient, collected on day-4 and 44 after onset of disease, respectively, were IgM-negative with NRA and SMB NY antigen and IgM-positive using Eg-101 SMB antigen in the initial test. To investigate these two discordant specimens further, six sequentially collected specimens from this patient were retested by end-point MAC- and IgG ELISAs. A greater than 32-fold serial increase shown in the MAC-ELISA titer between day-3 and day-15 could be demonstrated with all antigens used. Cerebrospinal fluid collected on day-9 after onset of disease also confirmed that this patient indeed was infected by WN shortly prior to taking the sample. The cerebrospinal fluid had IgM P/N reading of 13.71 and 2.04 against Eg-101- and SLE-SMB antigens, respectively. Day-31 and day-44 specimens were negative (<1:400) by using NY-SMB antigen but positive by using NRA and Eg101-SMB. Compatible IgG titers were observed with all three antigens used in the test.
Example 11 Evaluation of the Immune Response in Animals Vaccinated with pCBWN
Groups of ten, three-wk-old female ICR mice were used in the study. Mice were injected intramuscularly (i.m.) with a single dose of pCBWN or a green fluorescent protein expressing plasmid (pEGFP) DNA (Clonetech, San Francisco, Calif.). The pCBWN plasmid DNA was purified from XL-1 blue cells with EndoFree Plasmid Giga Kits (Qiagen) and resuspended in PBS, pH 7.5, at a concentration of 1.0 μg/μl. Mice that received 100 μg of pEGFP were used as unvaccinated controls. Mice were injected with the pCBWN plasmid at a dose of 100, 10, 1.0, or 0.1 μg in a volume of 100 μl. Groups that received 10, 1.0, or 0.1 μg of pCBWN were vaccinated by the electrotransfer mediated in vivo gene delivery protocol using the EMC-830 square wave electroporator (Genetronics Inc. San Diego, Calif.). The electrotransfer protocol was based on the method of Mir et al., (Proc. Natl. Acad. Sci. USA 96: 4262-4267. (1999)). Immediately following DNA injection, transcutaneous electric pulses were applied by two stainless steel plate electrodes, placed 4.5-5.5 mm apart, at each side of the leg. Electrical contact with the leg skin was ensured by completely wetting the leg with PBS. Two sets of four pulses of 40 volts/mm of 25 msec duration with a 200 msec interval between pulses were applied. The polarity of the electrode was reversed between the set of pulses to enhance electrotransfer efficiency.
Mice were bled every 3 wks following injection. The WN virus specific antibody response was evaluated by Ag-capture ELISA and plaque reduction neutralization test (PRNT). Individual sera were tested by IgG-ELISA, and pooled sera from 10 mice of each group were assayed by PRNT. All the mice vaccinated with pCBWN had IgG ELISA titers ranging from 1:640 to 1:1280 three wks after vaccination. The pooled sera collected at three and six wks had a Nt antibody titer of 1:80. None of the serum specimens from pEGFP control mice displayed any ELISA or Nt titer to WN virus.
To determine if the single i.m. vaccination of pCBWN could protect mice from WN virus infection, mice were challenged with NY-6480 virus either by intraperitoneal injection or by exposure to the bite of virus-infected Culex mosquitoes. Half of the mouse groups were challenged intraperitoneally (ip) at 6 wks post vaccination with 1,000 LD50 (1,025 PFU/100 μl) of NY99-6480 virus. The remaining mice were each exposed to the bites of three Culex tritaeniorhynchus mosquitoes that has been infected with NY99-6480 virus 7 days prior to the challenge experiment. Mosquitoes were allowed to feed on mice until they were fully engorged. Mice were observed twice daily for three wks after challenge.
It was evident that the presence of Nt antibodies correlated with protective immunity, since all mice immunized with WN virus DNA remained healthy after virus challenge while all control mice developed symptoms of CNS infection 4-6 days following virus challenge and died on an average of 6.9 and 7.4 days after intraperitoneal or infective mosquito challenge, respectively. In the vaccinated group, the pooled sera collected three wks after virus challenge (9-wk post immunization) had Nt antibody titers of 1:640 or 1:320. Pooled vaccinated mouse sera reacted only with E protein in the Western blot analysis.
Groups of ten mice were immunized with 10.0 to 0.1 μg of pCBWN per animal by use of electrotransfer. All groups that received pCBWN were completely protected from virus challenge. At 6 wks after immunization all groups of electrotransfer mice had Nt titer less than four-fold different than animals receiving 100 μg of pCBWN by conventional i.m. injection without electrotransfer. Both these results evidencing effective immunization suggest that the electrotransfer protocol enhances the immunogenicity and protective efficacy of the DNA vaccine of the invention (when carried out as described in (Mir et al., Proc. Natl. Acad. Sci. USA. 96: 4262-4267. (1999))).
Mixed-bred mares and geldings of various ages used in this study were shown to be WN virus and SLE virus antibody-negative by ELISA and PRNT. Four horses were injected i.m. with a single dose (1,000 μg/1,000 μl in PBS, pH 7.5) of pCBWN plasmid. Serum specimens were collected every other day for 38 days prior to virus challenge, and the WN virus specific antibody response was evaluated by MAC- or IgG ELISA and PRNT.
Two days prior to virus challenge, 12 horses (4 vaccinated and 8 control) were relocated into a bio-safety level (BSL)-3 containment building at the Colorado State University. The eight unvaccinated control horses were the subset of a study that was designed to investigate WN virus induced pathogenesis in horses and the potential of horses to serve as amplifying hosts. Horses were each challenged by the bite of 14 or 15 Aedes albopictus mosquitoes that had been infected by NY99-6425 or BC787 virus 12 days prior to horse challenge. Mosquitoes were allowed to feed on horses for a period of 10 min. Horses were examined for signs of disease twice daily. Body temperature was recorded, and serum specimens collected twice daily from days 0 (day of infection) to 10, then once daily through day 14. Pulse and respiration were recorded daily after challenge. The collected serum samples were tested by plaque titration for detection of viremia, and by MAC- or IgG ELISA and PRNT for antibody response.
No systemic or local reaction was observed in any vaccinated horse. Individual horse sera were tested by PRNT. Vaccinated horses developed Nt antibody greater than or equal to 1:5 between days 14 and 31. End point titers for vaccinated horses, #5, #6, #7, and #8, on day-37 (two days prior to mosquito challenge) were 1:40, 1:5, 1:20, and 1:20, respectively. Horses vaccinated with the pCBWN plasmid remained healthy after virus challenge. None of them developed a detectible viremia or fever from days 1 to 14. All unvaccinated control horses became infected with WN virus after exposure to infected mosquito bites. Seven of the eight unvaccinated horses developed viremia that appeared during the first 6 days after virus challenge. Viremic horses developed Nt antibody between day-7 and day-9 after virus challenge. The only horse from the entire study to display clinical signs of disease was horse #11, which became febrile and showed neurologic signs beginning 8 days after infection. This horse progressed to severe clinical disease within 24 hours and was euthanized on day 9. Four representing horses, #9, 10, 14 and 15, presenting viremia for 0, 2, 4, or 6 days, were selected and used as examples in this example. Virus titers ranged from 101.0 PFU/ml of serum (in horse #10), the lowest level detectable in our assay, to 102.4/ml (in horse #9). Horse #14 did not develop a detectible viremia during the test period. However, this horse was infected by the virus, as evidenced by Nt antibody detected after day 12.
Anamnestic Nt antibody response was not observed in vaccinated horses as evidenced by the gradual increase in Nt titer during the experiment. Pre-existing Nt antibody in the vaccinated horse prior to mosquito challenge could suppress initial virus infection and replication. Without virus replication, the challenge virus antigen provided by infected mosquitoes may not contain a sufficient antigen mass to stimulate anamnestic immune response in the vaccinated horse. All vaccinated horses were euthanized at 14 days after virus challenge. Gross pathological and histopathological lesions indicative of WN viral infection were not observed.
Example 12 Preparation of Recombinant Plasmids Containing Coding Sequences for Yellow Fever Virus (YFV) or St. Louis Encephalitis Virus (SLEV) prM and E Proteins
A strategy similar to constructing the pCDJE2-7 recombinant plasmid was used to prepare YFV and SLEV recombinant plasmids. Genomic RNA was extracted from 150 μL of YFV strain TRI-788379 or SLE strain 78V-6507 virus seeds using Q1Aamp™ Viral RNA Kit (Qiagen, Santa Clarita, Calif.). The viral RNA was used as a template for amplification of YFV or SLEV prM and E gene coding regions. Primers YFDV389 (nucleotide sequence, SEQ ID NO:4; amino acid sequence, SEQ ID NO:5), cYFDV2452 (SEQ ID NO:6), SLEDV410 (nucleotide sequence, SEQ ID NO:7; amino acid sequence, SEQ ID NO:8) and cSLEDV2449 (SEQ ID NO:9) were used to generate the corresponding recombinant nucleic acids as described above for the preparation of the JEV and WNV recombinant plasmids. RT-PCR amplified cDNA, digested with KpnI and NotI enzymes, was inserted into the KpnI-NotI site of a eukaryotic expression plasmid vector, pcDNA3 (Invitrogen). Both strands of the cDNA were sequenced and verified for identity to sequences from YFV strain TRI-788379 or SLEV strain 78V-6507. Recombinant plasmids pCDYF2 and pCDSLE4-3, which contained the nucleotide sequences of the prM and E coding regions for YFV or SLEV, respectively, were purified using an EndoFree™ Plasmid Maxi Kit (Qiagen), and used for in vitro transformation or mouse immunization.
YFV or SLEV specific antigens were expressed in COS-1 cells transformed by pCDYF2 or pCDSLE4-3, respectively. The level of expressed proteins was similar to a YFV- or SLEV-infected COS-1 cell control. As in the JEV model, COS-1 cell lines transformed by vectors bearing genes for the viral antigens were obtained which constitutively express YFV or SLEV antigenic proteins. Epitope mapping by IFA using a panel of YFV or SLEV E-specific Mabs indicated that the authentic E protein was expressed by the pCDYF2- or pCDSLE4-3-transformed COS-1 cells. A preliminary study indicated that 100% of three week-old female, ICR mice seroconverted after intramuscular inoculation with a single dose of 100 μg/100 μL of pCDSLE4-3 plasmid in deionized water.
Example 13 Preparation of Recombinant Plasmids Containing Coding Sequences for St. Louis Encephalitis Virus prM and E Antigens with JEV Signal Sequence
Genomic RNA was extracted from 150 μL of Vero cell culture medium infected with MSI-7 strain of St. Louis encephalitis virus using the QIAamp™ Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in 80 μl of nuclease-free water, and used as a template for the amplification of St. Louis encephalitis virus prM and E gene coding sequences. Primer sequences were obtained from the work of Trent et al. (Virology 156: 293-304 (1987)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR). Restriction site AfeI was engineered at the 5′ terminus of the cDNA by using amplimer SLE463 (SEQ ID NO:30). An in-frame translation termination codon, followed by a NotI restriction site was introduced at the 3′ terminus of the cDNA by using amplimer cSLE2447 (SEQ ID NO:31). The RT-PCR product was purified by a QIAquick™ PCR Purification Kit (Qiagen).
The double-stranded amplicon, produced by use of the two amplimers above (SEQ ID NO:30 and SEQ ID NO:31), was digested with AfeI and NotI enzymes to generate a 2004 fragment of DNA (463 to 2466 nt), and inserted into the AfeI and NotI sites of a pCBJESS-M vector to form pCBSLE (nucleotide sequence, SEQ ID NO:21; amino acid sequence, SEQ ID NO:22). The pCBJESS-M was derived from the pCBamp plasmid, that contained the cytomegalovirus early gene promoter and translational control element and an engineered, modified JE signal sequence element (SEQ ID NO:27). The JE signal sequence element comprises the modified JE signal sequence at −4 (Cys to Gly) and −2 (Gly to Ser) position in the original pCBJESS plasmid.
Automated DNA sequencing using an ABI prism 377 Sequencer (Applied Biosystems/Perkin Elmer, Foster City, Calif.) was used to confirm that the recombinant plasmid had a correct prM and E sequence as defined by Trent et al. (Virology 156: 293-304 (1987)).
Example 14 Preparation of Recombinant Plasmids Containing Coding Sequences for Yellow Fever Virus (YFV) prM and E Proteins with JEV Signal Sequence
Genomic RNA was extracted from 150 μL of Vero cell culture medium infected with 17D-213 strain of yellow fever virus using the QIAamp™ Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in 80 μl of nuclease-free water, and used as a template for the amplification of yellow fever virus prM and E gene coding sequences. Primer sequences were obtained from the work of dos Santos et al. (Virus Research 35: 35-41 (1995)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR). Restriction site AfeI was engineered at the 5′ terminus of the cDNA by using amplimer YF482 (SEQ ID NO:28). An in-frame translation termination codon, followed by a NotI restriction site was introduced at the 3′ terminus of the cDNA by using amplimer cYF2433 (SEQ ID NO:29). The RT-PCR product was purified by a QIAquick™ PCR Purification Kit (Qiagen).
The double-stranded amplicon, produced by use of the two amplimers above (SEQ ID NO:28 and SEQ ID NO:29), was digested with AfeI and NotI enzymes to generate a 1971 fragment of DNA (482 to 2452 nt), and inserted into the AfeI and NotI sites of a pCBJESS-M vector to form pCBYF (nucleotide sequence, SEQ ID NO:23; amino acid sequence, SEQ ID NO:24). The pCBJESS-M was derived from the pCBamp plasmid, that contained the cytomegalovirus early gene promoter and translational control element and an engineered JE signal sequence element (SEQ ID NO:27). The JE signal sequence element comprises the modified JE signal sequence at −4 (Cys to Gly) and −2 (Gly to Ser) position of JESS in the pCBJESS plasmid.
Automated DNA sequencing using an ABI prism 377 Sequencer (Applied Biosystems/Perkin Elmer, Foster City, Calif.) was used to confirm that the recombinant plasmid had a correct prM and E sequence as defined by dos Santos et al. (Virus Research 35: 35-41 (1995)).
Example 15 Preparation of Recombinant Plasmids Containing Coding Sequences for Powassan Virus prM and E Antigens with JEV Signal Sequence
Genomic RNA was extracted from 150 μL of Vero cell culture medium infected with LB strain of Powassan virus using the QIAamp™ Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in 80 μl of nuclease-free water, and used as a template for the amplification of Powassan virus prM and E gene coding sequences. Primer sequences were obtained from the work of Mandl et al. (Virology 194: 173-184 (1993)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR). Restriction site AfeI was engineered at the 5′ terminus of the cDNA by using amplimer POW454 (SEQ ID NO:25). An in-frame translation termination codon, followed by a NotI restriction site was introduced at the 3′ terminus of the cDNA by using amplimer cPOW2417 (SEQ ID NO:26). The RT-PCR product was purified by a QIAquick™ PCR Purification Kit (Qiagen).
The double-stranded amplicon, produced by use of the two amplimers above (SEQ ID NO:25 and SEQ ID NO:26), was digested with AfeI and NotI enzymes to generate a 1983 bp fragment of DNA (454 to 2436 nt), and inserted into the AfeI and NotI sites of a pCBJESS-M vector to form pCBPOW (nucleotide sequence, SEQ ID NO: 19; amino acid sequence, SEQ ID NO:20). The pCBJESS-M was derived from the pCBamp plasmid, that contained the cytomegalovirus early gene promoter and translational control element and an engineered JE signal sequence element (SEQ ID NO:27). The JE signal sequence element comprises the modified JE signal sequence at −4 (Cys to Gly) and −2 (Gly to Ser) position of JESS in the pCBJESS plasmid.
Automated DNA sequencing using an ABI prism 377 Sequencer (Applied Biosystems/Perkin Elmer, Foster City, Calif.) was used to confirm that the recombinant plasmid had a correct prM and E sequence as defined by Mandl et al. (Virology 194:173-184, (1993)).
Example 16 Preparation of Plasmids Containing Coding Sequences for Dengue Serotype 2 Structural Proteins
Procedures such as those carried out for other flaviviruses (see Examples 1, 9 and 12-15) are to be followed to prepare vectors including nucleic acid TU's for dengue serotype 2 antigens. According to the examples, the amplimers used for construction of the vectors may be chosen to engineer the normal dengue virus signal sequence or they may be chosen so as to engineer a signal sequence from another flavivirus, such as a modified Japanese encephalitis virus signal sequence.
A plasmid containing the dengue serotype 2 gene region from prM to E is to be constructed. The dengue serotype 2 prM and E genes (Deubel et al., Virology 155:365-377 (1986); Gruenberg et al., J. Gen. Virol. 69: 1301-1398 (1988); Hahn et al., Virology 162:167-180 (1988)) are to be ligated into a plasmid such as pcDNA3, and then excised and cloned into vectors such as pCBamp, pCEP4, pREP4, or pRc/RSV (supplied by Invitrogen, Carlsbad, Calif.) to enable expression. If necessary, a dengue serotype 2 virus-specific sequence encoded in a cDNA sequence may be amplified using a procedure such as the polymerase chain reaction (PCR). Alternatively, if the viral RNA is the source of the gene region, a DNA sequence may be amplified by a RT-PCR procedure. A DNA fragment including an initiation codon at the 5′ end, and a termination codon at the 3′ end is to be cloned into an expression vector at an appropriate restriction nuclease-specific site, in such a way that the cytomegalovirus (CMV) immediate early (1E) promoter, an initiation codon, and a terminator, are operably linked to the dengue serotype 2 virus sequence.
Example 17 Vaccination of Mice Using a Dengue Serotype 2 DNA Vaccine
The dengue serotype 2 nucleic TU vaccine encoding the gene region from prM to E prepared in Example 16 is to be suspended in a suitable pharmaceutical carrier, such as water for injection or buffered physiological saline, and injected intramuscularly into groups of weanling mice. Control groups receive a comparable plasmid preparation lacking the dengue serotype 2 specific genes. The generation of dengue serotype 2-specific antibodies, and/or of dengue serotype 2-specific immune system cytotoxic cells, is to be assessed at fixed intervals thereafter, for example at weekly intervals. At about two to four months after administration of the nucleic acid TU vaccine, mice are to be challenged with dengue serotype 2 virus. Levels of viremia are to be assessed at appropriate intervals thereafter, such as every second day. Passive protection by maternal antibody is to be assessed as indicated in Example 8.
Example 18 Design and Construction of Improved Signal Peptides
Signal peptides can determine the translocation and orientation of inserted protein, hence, the topology of prM and E proteins. The most common feature of signal peptides of eukaryotes consists of an 8 to 12 stretch of hydrophobic amino acids called the h-region (von Heijne, “Signal sequences. The limits of variation” J. Mol. Biol. 184: 99-105 (1985)). The region between the initiator Met and the h-region, which is known as the n-region, usually has one to five amino acids, and normally carries positively charged amino acids. Between the h-region and the cleavage site is the c-region, which consists of three to seven polar but mostly uncharged amino acid residues. During viral polyprotein synthesis, modulation of the signalase cleavage site from a cryptic to cleavable conformation at the junction of C and prM proteins depends on prior removal of the C protein by the viral protease complex, NS2B/NS3 (Lobigs, “Flavivirus premembrane protein cleavage and spike heterodimer secretion require the function of the viral proteinase NS3,” Proc. Natl. Acad. Sci. USA. 90: 6218-6222 (1993)). Thus, it is critical to consider the effectiveness of the viral signal sequence when prM and E proteins are to be expressed alone by an expression plasmid.
Signal peptide differences in various plasmid constructs can account, at least in part, for the difference in protein translocation, cleavage site presentation and correct topology, thus, prM and E secretion and VLP formation. The modulation or optimization of these attributes can be improved by selection or use of signal sequences with properties that impart the desired characteristics. This can be accomplished by use of machine-learning computer programs using, for example, a hidden Markov model (HMM) trained on eukaryotes (see Henrik Nielsen et al., “Prediction of signal peptides and signal anchors by a hidden Markov model,” In Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology (ISMB 6), AAAI Press, Menlo Park, Calif., pp. 122-130 (1998); Nielsen et al., “Machine learning approaches to the prediction of signal peptides and other protein sorting signals,” Protein Engineering 12: 3-9 (1999); Nielsen et al., “A neural network method for identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites,” Int. J. Neural Sys. 8: 581-599 (1997); “From sequence to sorting: Prediction of signal peptides,” Henrik Nielsen, Ph.D. thesis. Defended at Department of Biochemistry, Stockholm University, Sweden (May 25, 1999); each of which is incorporated herein by reference, particularly for the teaching related to the optimization of signal sequences using computer-enabled algorithms).
An example of the type of program used is that found at http://www.cbs.dtu.dk/services/SignalP-2.0/as of Apr. 3, 2002. The HMM described in the referred to and incorporated references was applied to calculate the signal peptide probability of the prM signal peptide sequences in different plasmid constructs (Table 7). SignalP-HMM searches correctly predicted the signal peptidase cleavage sites in all constructs. However, considerable differences in cleavage probability (ranging between 0.164 and 1.000) and in signal peptide probability (ranging between 0.165 to 1.00) were observed (Table 7). This is not surprising, as the cleavage site and signal peptide probability are known to also be influenced by the positively charged amino acids in the n-region, the length of the hydrophobic amino acid in the h-region and amino acid composition in the c-region in the constructs (Chang et al., “Flavivirus DNA vaccines: current status and potential,” Annals of NY Acad. Sci. 951: 272-285 (2001); Sakaguchi et al., “Functions of Signal and Signal-Anchor Sequences are Determined by the Balance Between the Hydrophobic Segment and the N-Terminal Charge,” Proc. Natl. Acad. Sci. USA 89: 16-19 (1992)).
Three JE virus plasmid constructs, each derived from different strain of JE virus, showed different vaccine potentials (Lin et al., “DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice,” J. Virol. 72: 191-200 (1998); Konishi et al., “Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes,” J. Virol. 72: 4925-4930 (1998); Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)). The signal peptide sequences in these constructs are different in the length of n-region which may or may not contain charged amino acids (Table 7). The n-region containing positively charged amino acids forms a short loop in the cytoplasmic side that causes the h-region (transmembrane helix) to be inserted in a tail orientation, exposing the signalase cleavage site. In our study, secreted VLPs containing prM/M and E proteins could be purified from culture medium of the pCDJE2-7 transformed cell line, JE4B, or pCBJE1-14 transiently transformed COS-1 cells. The gradient-purified VLPs and virions have identical immunological and biochemical properties. Processing efficiency from prM to mature M protein, the hallmark of flavivirus morphogenesis, is also similar between VLPs and virion particles. Thus, prM and E proteins expressed by pCDJE2-7 and pCBJE1-14 can be expressed as type II transmembrane proteins in the orientation similar to that of virion prM and E (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)). In contrast, the prM protein of pcDNA3JEME could be expressed as a type II membrane protein with its transmembrane h-region inserted in a head orientation because of the absence of positively charged amino acids in its n-region (Konishi et al., “Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes,” J. Virol. 72: 4925-4930 (1998)). Efficient protein synthesis in combination with the expressed protein having the correct topology, particularly of the expressed prM and E, can enhance VLP formation and secretion, and thus promote the immunogenicity of the DNA vaccine (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)).
The use of computer-based computations, as described above, has been applied to optimize the design of expression plasmid. In particular, the predictive power of the SignalP-HMM program was applied to design the WN virus expression plasmid (Table 2) (Davis et al., “West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays,” J. Virol. 75: 4040-4047 (2001)). The pCBWN plasmid consists of a short version of JE virus signal peptide followed by WN virus prM-E gene sequence. Vaccine potential of this construct was amply demonstrated, as a single i.m. injection of pCBWN DNA not only induced a protective immunity but also prevented WN virus infection in mice and horses.
As discussed earlier, and as demonstrated in Examples 13-15, virus-encoded signal sequence from the same virus as the antigen-coding regions is not necessarily the optimal signal peptide available. Further, non-modified signal sequence is not necessarily optimal. For example, the signal peptide encoded in the pCBJE1-14 plasmid can be improved, as measured by the signal sequence probability by shortening n-region, by altering c-region sequence, or by the combination of both modifications (FIG. 6). By way of illustration, a shortened version of JE virus signal peptide has been used for the expression of WN virus prM and E genes as described herein and in papers incorporated herein by reference for the teaching (Davis et al., “West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays,” J. Virol. 75: 4040-4047 (2001)). Dose titration studies by single i.m. inoculation indicated that the pCBWN was at least 2-4 fold more immunogenic than pCBJE1-14 in mice.
Example 19 Multivalent Vaccines
Multivalent and/or combination vaccines designed to immunize against multiple flaviviruses can also be produced. In preparation of a multivalent vaccine, monovalent vaccine components are prepared that include elements related to pathogens of interest, such as YF, different serotypes of DEN, JE, WN, SLE and TBE (RSSE and CEE) viruses or any other combination of flaviviruses. Design and production of DNA constructs as described in the other examples and in the specification are carried out as described. Combinations of appropriate vaccines can be made to provide multivalent or combination vaccines protective against multiple pathogens. Preliminary data from our group has demonstrated that i.m. injection of the combined pCBJE1-14 and pCBWN DNA vaccines induced JE virus- and WN virus-specific Nt antibodies in mice (Table 8). Each monovalent component, even if constructed using identical transcriptional and translational regulators, should preferably be tested in an analogous model system to ensure its vaccine potential. A combination vaccine cocktail can then be formulated. These vaccine cocktails can be tailored specifically for particular geographic regions. For example, a vaccine cocktail for tropical and subtropical Asia should include four serotypes of DEN, WN and JE virus vaccines. Similarly useful vaccine cocktails for Africa and Latin America should include four serotypes of DEN, WN and YF virus vaccines and four serotypes of DEN, Rocio and YF virus vaccines, respectively.
Example 20 Preparation and Testing of Recombinant Dengue Virus Type 2 Vaccines
a. Summary of example. A series of plasmids that encode the premembrane (prM) and envelope (E) proteins of the dengue virus type 2 (DEN-2) were constructed. These plasmids included an authentic DEN-2 prM-E construct (pCBD2-14-6) (SEQ ID NO:42) encoding the protein described by SEQ ID NO:43, a 90% DEN-2 E-10% Japanese encephalitis (JE) virus E chimeric construct (pCB9D2-1J-4-3) (SEQ ID NO:44) that encodes the protein described by SEQ ID NO:45 and an 80% DEN-2 E-20% JE E chimeric construct (pCB8D2-2J-2-9-1) (SEQ ID NO:46) that encodes the protein described by SEQ ID NO:47. Monoclonal antibody (MAb) reactivity indicated that all three plasmids expressed E protein epitopes that reacted with a panel of domain 1, 2 and 3 antibodies. However, only the pCB8D2-2J-2-9-1 construct (SEQ ID NO:46) secreted high levels of prM, M (matured prM) and E into the media of the plasmid-transformed COS-1 cells. The major portion of the prM and E protein expressed by COS-1 cells transformed with pCBD2-14-6 plasmid (SEQ ID NO:42) and by COS-1 cells transformed with pCB9D2-4-3 plasmid (SEQ ID NO:44) remained membrane-bound. Replacement of 20% of the sequence encoding the E protein of DEN-2 E with sequence encoding the corresponding JE E protein sequence had no effect on MAbs reactivity.
In testing, groups of mice received two intramuscular immunization of selected plasmids at 0 and 3-wks, and the immune response was evaluated by determining specific neutralizing and ELISA antibody. The plasmid expressing secreted prM and E, which can form subviral-particles (SVPs), was superior to other constructs in stimulating an antibody response. Ninety percent neutralization titers ranging from 1:40 to >1:1000 were observed from the 7 of 9 serum specimens of pCB8D2-2J-2-9-1 immunized mice.
b. Importance of DEN-2 virus and vaccines. Dengue (DEN) fever is an acute infection that occurs in subtropical and tropical areas. It is one of the most important flaviviral diseases of humans. As noted earlier, there are four distinct DEN serotypes (DEN-1, DEN-2, DEN-3 and DEN-4) of dengue virus. Infection with any of these is usually either asymptomatic or only causes a self-limited febrile illness known as dengue fever (DF). However, in a small percentage of cases, dengue virus infection results in a much more serious disease, life-threatening dengue hemorrhage fever or dengue shock syndrome (DHF/DSS). Thus, while there are approximately 100 million cases of the relatively mild DF world-wide annually which are of limited concern, there are also an estimated 500,000 hospitalized DHF/DSS cases reported annually. To protect against this disease, a safe and effective DEN vaccine effective against all four serotypes is required for administration to children and non-immune adults in the DEN endemic and epidemic regions.
Safe vaccines must minimize the potential risk of serious infection by virulent viruses. Such virulent viruses can arise by gene reversion or recombination of some types of vaccines derived from attenuated vaccine viruses. Such occurrences did arise in the poliovirus eradication campaign (Guillot et al., “Natural Genetic Exchanges between Vaccine and Wild Poliovirus Strains in Humans,” J. Virol. 74: 8434-8443 (2000); Liu et al., “Molecular Evolution of a Type 1 Wild-Vaccine Poliovirus Recombinant during Widespread Circulation in China,” J. Virol. 74: 11153-11161 (2000)). Further, genomic sequencing of an American strain of yellow fever virus, TRINID79A, demonstrates that there is extensive similarity between this strain and the attenuated yellow fever vaccine virus, FNV (Chang et al., “Nucleotide sequence variation of the envelope protein gene identifies two distinct genotypes of yellow fever virus,” J. Virol. 69: 5773-5780 (1995); Pisano et al., “Complete nucleotide sequence and phylogeny of an American strain of yellow fever virus, TRINID79A,” Arch. Virol. 144: 1837-1843 (1999)). While not conclusive in and of itself, the similarity strongly suggests that TRINID 79A is derived from the FNV vaccine virus.
The use of DNA-based vaccines is a novel and promising immunization approach for the development of flavivirus vaccines (as described herein, in Chang et al., “Flavivirus DNA vaccines: current status and potential,” Ann. NY Acad. Sci. 951: 272-285 (2001), and in references cited therein). In this example, a number of DEN-2 vaccines were produced and the immune response in mice after i.m. immunization of DEN-2 constructs were correlated with the efficiency of prM/M and E secretion. One construct that led to the secretion of significant amounts of prM/M and E antigens was shown to be capable of stimulating high titers of neutralizing antibodies in plasmid-vaccinated mice.
c. Materials and Methods.
i. Cell culture and virus strains. COS-1 cells (ATCC, Manassas, Va.; 1650-CRL) were grown at 37° C. with 5% CO2 in Dulbecco's modified Eagle minimal essential medium (DMEM, GIBCO, Grand Island, N.Y.) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Hyclone Laboratories, Inc., Logan, Utah), 1 mM sodium pyruvate, 1 mM non-essential amino acids, 30 ml/liter 7.5% NaHCO3, 100 units/ml of penicillin, and 100 μg/ml of streptomycin. Vero and C6/36 cells were grown under the same conditions used for COS-1 cells. DEN-2 virus, strain-16681, was used for cDNA cloning, IgG ELISA and the plaque reduction neutralization test (PRNT). Virus was propagated in the C6/36 cell culture. Virus used for immunological or biochemical studies was purified by precipitation with 7% polyethylene glycol (PEG-8000; Fisher Scientific, Fair Lawn, N.J.) followed by ultracentrifugation on 30% glycerol-45% potassium-tartrate gradients (Obijeski et al., “Segmented genome and nucleocapsid of La Crosse virus,” J. Virol. 20:664-675 (1976)).
ii. Plasmid construction. Genomic RNA was extracted from 150 μl of C6/36 cell culture medium infected with DEN-2 16681 strain using the QIAamp™ Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was resuspended in 80 μl of diethyl pyrocarbonate-treated water (DEPC, Sigma, ST. Louis, Mo.) and then used as a template in reverse transcriptase-PCR(RT-PCR) amplification of DEN-2 virus prM and E genes. Primer sequences (Table 9) were designed based on published sequences (Gadkari et al., “Critical evaluation of Kyasanur Forest disease virus neutralizing antibodies found in bats (a preliminary report),” Indian J. Med. Res. 64: 64-67 (1976); Kinney et al., “Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53,” Virology 230: 300-308 (1997)). The recognition and cleavage site for restriction enzyme KasI was incorporated at the 5′ terminus of the cDNA amplicon. An in-frame termination codon, followed by a NotI restriction site, was introduced at the 3′terminus of the cDNA amplicon. The DEN-2 virus cDNA amplicon was digested with KasI and NotI enzymes, and was then inserted into the KasI and NotI sites of a pCBJESS vector to form the 100% DEN-2 E plasmid, pCBD2-14-6 (SEQ ID NO:42).
To construct the 90% and 80% DEN-2 E plasmids, the 100% DEN-2 plasmid, pCBD2-14-6 (SEQ ID NO:42), and the JE plasmid, pCBJE1-14 (SEQ ID NO:17), were used as the PCR templates to amplify DEN-2 and JE DNA sequence, respectively. Sets of primers used in amplification reactions to obtain the DEN-2 and JE gene fragments are listed in Table 9. T7 and SP6 priming sites are found in the pCBamp plasmid, derived from original pCDNA-3 plasmid (Invitrogen, Carlsbad, Calif.), and can be utilized as desired or as required. PCR amplified DNA fragments for the 90% DEN-2-10% JE E protein gene were digested with BxtXI restriction endonuclease, ligated using T4 DNA ligase, digested with KasI and NotI enzyme, and inserted into the KasI and NotI sites of the pCBJESS vector to obtain the plasmid, pCB9D2-1J-4-3 (SEQ ID NO:44). PCR amplified DNA fragments for the 80% DEN-2-20% JE E gene were digested with BsmBI, ligated with T4 DNA ligase, digested with KasI and NotI enzyme, and inserted into the KasI and NotI sites of the pCBJESS vector to obtain the plasmid, pCB8D2-2J-2-9-1 (SEQ ID NO:46). Schematic representations of the three plasmid constructs are shown in FIG. 7. The 90% DEN-2-10% JE E and the 80% DEN-2-20% JE E protein junction regions, respectively, are shown in Table 9.
Automated DNA sequencing was performed on an ABI Prism 377 Sequencer (Applied Biosystems/Perkin Elmer, Foster City, Calif.) according to the manufacture's recommended procedures. Recombinant plasmids with the correct prM and E sequences were identified using sequence analysis.
iii. Transient expression of DEN-2 recombinant antigen in COS-1 cells by electroporation. COS-1 cells were electroporated separately with each DEN-2 plasmid or green fluorescent protein expression plasmid control (pEGFP, Clonetech, San Francisco, Calif.) using the protocol described elsewhere in the examples and in Chang et al., (“A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)). Electroporated cells were seeded onto 75 cm2 culture flasks, and kept at 37° C. and 5% CO2. Six hours following electroporation the growth media were replaced with a maintenance media containing 2% fetal bovine serum. Tissue culture medium and cells were harvested separately 48 hours following electroporation for antigen characterization.
iv. Epitope mapping using DEN-2 E-specific monoclonal antibodies. Forty-eight hours following electroporation, adherent cells were trypsinized, resuspended in PBS containing 5% goat serum, spotted on a 12 well spot-slide and air dried. Cells adhered to the spot-slide were fixed with acetone for 10 minutes at −20° C. and allowed to air dry. E-protein specific monoclonal antibodies (MAb) were used to detect protein expression by the indirect immunofluorescence antibody assay (IFA), as described previously (Table 10; Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)).
v. Characterization of the recombinant DEN-2 virus antigen. Tissue culture medium was harvested 48 hours following electroporation. Antigen-capture (Ag-capture) ELISA was used to detect secreted DEN-2 virus antigen in the culture medium of transiently transformed COS-1 cells. The MAb 4G2 and horseradish peroxidase-conjugated MAb 6B6C-1 were used to capture the DEN virus antigens and detect captured antigen, respectively (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000); Hunt et al., “A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen,” J. Virol. Methods. 97: 133-149 (2001)).
Forty-eight hours following electroporation, transformed cells for each plasmid were trypsinized and resuspended in PBS as aliquots containing 5×106 cells. These cell samples were processed for membrane protein extraction using the Mem-PER mammalian membrane protein extraction reagent kit (Pierce, Rockford, Ill.) following the manufacturer's suggested protocol. Both hydrophobic and hydrophilic proteins are isolated. This procedure was developed for enrichment of integral membrane protein found in the hydrophobic phase. Both hydrophobic and hydrophilic fractions were analyzed by Ag-capture ELISA for DEN-2 recombinant antigen.
Recombinant antigen in the medium was concentrated by precipitation with 10% polyethylene glycol (PEG)-8000. The precipitant was resuspended in TNE buffer (50 mM Tris, 100 mM NaCl, 10 mM EDTA, pH 7.5) to 1/100% of the original volume, clarified by centrifugation, and stored at 4° C. Recombinant antigen concentrated by PEG precipitation and resuspended in TNE buffer was extracted with 4.0% ethanol to remove residual PEG (Hunt et al., “A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen,” J. Virol. Methods. 97: 133-149 (2001)). Ethanol-extracted antigens, hydrophobic membrane proteins from the transformed cells and gradient-purified DEN-2 virions were analyzed on a NuPAGE, 4-12% Bis-Tris gradient gel in an Excel Plus Electrophoresis Apparatus™ (Invitrogen Corp., Carlsbad, Calif.), followed by electroblotting onto nitrocellulose membranes using a Excel Plus Blot Unit (Invitrogen Corp.). DEN-2 virus-specific protein was detected by western blot using DEN-2 virus specific MAbs 1A6A-8 (E specific) and 1A2A-1 (capsid specific), as well as rabbit antiserum specific for DEN-2 prM and mouse serum specific for a peptide composed of amino acid 1-34 of the DEN-2 M protein, and normal mouse ascitic fluid was used as negative control (Murray et al., “Processing of the dengue virus type 2 proteins prM and C-prM,” J. Gen. Virol. 74 (Pt 2): 175-182 (1993); Roehrig et al., “Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica,” Virology 246: 317-328 (1998)).
vi. Mouse vaccination. Groups of ten, three-wk-old female ICR out-bred mice were used in the study. Mice were i.m. injected with pCBD2-14-6, pCB9D2-1J-4-3, pCB8D2-2J-2-9-1 or pEGFP on week-0 and week-3 at a dose of 100 μg in a volume of 100 μl per mouse. The plasmid DNA was purified from XL-1 blue cells with EndoFree Plasmid Giga Kits™ (Qiagen) and resuspended in PBS, pH 7.5, at a concentration of 1.0 μg/μl. Mice that received 100 μg of pEGFP were used as plasmid-vaccinated controls. Mice were bled every 3 wks following injection, and the DEN-2 virus specific antibody response was evaluated by use of indirect ELISA and PRNT.
vii. Serological tests. Pre- and post-vaccination serum specimens were tested for antibody binding ability to purified DEN-2 virion by ELISA, for neutralizing (Nt) antibody by PRNT, and for antibodies that recognize purified DEN-2 virus proteins by Western blotting. PRNT was performed with Vero cells, as previously described (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)), using DEN-2 (strain-16681) and JE (strain-Nakayama) virus. Endpoints were determined at a 90% plaque-reduction level (Hunt et al., “A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen,” J. Virol. Methods. 97: 133-149 (2001)).
d. Results.
i. Transient expression of DEN-2 virus recombinant antigen. Expression of the prM and E genes of DEN-2 virus or a chimeric E gene from a combination of DEN-2 and JE virus sequences (80% DEN-20% JE or 90% DEN-10% JE) was accomplished by separate transformations of each of the three recombinant DEN-2 DNA plasmids into COS-1 cells. The basic plasmid design was based on results from previous studies with JE virus and WN virus recombinant plasmids in which plasmid-transformed cells expressed, and secreted authentic viral proteins into the cell culture fluid (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000); Davis et al., “West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays,” J. Virol. 75: 4040-4047 (2001)). Transient expression of DEN-2 recombinant proteins was initially assessed by Ag-capture ELISA of cell culture supernatants and by IFA of acetone-fixed, transformed COS-1 cells (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000)). The point of optimum antigen expression was determined to be 48 hours following electroporation.
ii. Epitope mapping of the E protein expressed by transiently-transformed COS-1 cells. The DEN-2 protein expressed by each of the recombinant plasmids was evaluated by IFA using a panel of murine MAbs with known reactivity to DEN-2 virus (Table 10; Henchal et al., “Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies,” Am. J. Trop. Med. Hyg. 34: 162-169 (1985); Roehrig et al., “Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica,” Virology 246: 317-328 (1998)). The MAb panel included antibodies reactive with each of the three antigenic domains of the E protein of flaviviruses as well as prM and C proteins. (Mandl et al., “Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model,” J. Virol. 63: 564-571 (1989); Rey et al., “The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution,” Nature 375: 291-298 (1995)). The MAbs specific for flavivirus antigenic Domains 2 and 3 showed nearly identical qualitative reactivity with DEN-2 virus and each of the three plasmid-expressed proteins. One of the Domain 1-specific MAbs, 1B4C-2, also showed a similar reactivity pattern with all expressed proteins. However, two of the Domain 1-specific MAbs, 2B3A-1 and 9A4D-1, were much less reactive with E protein expressed by plasmids pCBD2-14-6 and pCB9D2-1J-4-3 as shown by endpoint titration (values in parentheses, Table 10). Comparison of the endpoint titers revealed the apparent poor expression of epitopes C3 and C4 in constructs containing 100% DEN-2 E and 90% DEN-2 E-10% JE E. MAb 2H2, specific for prM, had the same reactivity with antigen expressed by all three plasmids. Anti-C MAb 1A2A-1 reacted well with DEN-2 virus and had low level, non-specific reactivity with the plasmid-expressed viral proteins, which included prM and E, but not C.
iii. Comparison of secreted protein and membrane-bound protein produced by each of the three DEN-2 recombinant plasmids. Similar amounts of cell culture fluid were harvested from COS-1 cells 48 hours post-transformation for each recombinant DEN-2 plasmid. Secreted recombinant antigen found in the culture fluid was concentrated 100-fold by PEG precipitation, followed by ethanol extraction to remove PEG which interfered with subsequent analysis by polyacrylamide gel electrophoresis. The relative amount of secreted antigen expressed by each plasmid was determined by Ag-capture ELISA analysis of both PEG-precipitated and ethanol-extracted cell culture fluid preparations (Table 11). Secreted antigen was detected only from cells transfected with pCB8D2-2J-2-9-1 (SEQ ID NO:34), which contained 80% DEN-2 E and 20% JE E genes. The recombinant plasmids containing either 100% DEN-2 E or 90% DEN-2 E-10% JE E genes produced no ELISA-detectable antigen in the culture fluid, despite efforts to concentrate expressed protein.
Western blot analysis was also used to evaluate the production of secreted antigen by each of the DEN-2 recombinant plasmids. For comparison purposes, equivalent volumes of PEG-precipitated, ethanol-extracted cell culture supernatant were run on NuPAGE gradient gels, electroblotted to nitrocellulose, and analyzed using MAbs or polyclonal antisera capable of reacting with all DEN-2 structural proteins (FIG. 8A). Western blot analysis showed greater sensitivity in detecting recombinant antigen than Ag-capture ELISA since DEN-2-specific proteins were detected in the culture fluid from two of the plasmids, pCB8D2-2J-2-9-1 and pCB9D2-1J-4-3 (SEQ ID NOS:46 and 44, respectively). Plasmid pCB8D2-2J-2-9-1 (SEQ ID NO:46) expressed the greatest amount of secreted antigen which was shown to be composed of E, prM, and M proteins. Relatively less secreted antigen was produced by pCB9D2-1J-4-3 (SEQ ID NO:44) and barely detectable levels were found for the pCBD2-14-6 (SEQ ID NO:42) preparation, which appeared to contain relatively less expressed E protein, especially if the non-specific reactivity of the E-specific MAb, 1A6A-8, on the control pEGFP was taken into consideration (FIG. 8A, lanes a, b for 14-6 and GFP).
Since E, prM, and M are membrane-associated proteins throughout their intracellular synthesis, any assessment of the expression of these proteins by the three recombinant DEN-2 plasmids should include an evaluation of cell membrane preparations from plasmid-transformed cells. The Mem-PER Mammalian Membrane Protein Extraction Reagent kit (Pierce) was used to isolate the integral membrane proteins from equivalent numbers of cells transformed by each of the recombinant plasmids. Hydrophobic proteins were separated from hydrophilic proteins by phase partitioning. Preliminary analysis by Ag-capture ELISA indicated that the hydrophilic protein fraction was non-reactive; however, the hydrophobic protein fractions from COS-1 cells transformed with each of the recombinant DEN-2 plasmids had similar titers in ELISA tests (Table 11). These results indicated that recombinant antigen encoded by all three plasmids was expressed following transformation, but that the recombinant antigens expressed were not all secreted at the same level.
Confirmation of the Ag-capture results for the hydrophobic protein fractions was accomplished by western blot (FIG. 8B). Equivalent volumes of hydrophobic protein fractions from each of the plasmid-transformed cells were diluted according to the manufacturer's recommendations for SDS-polyacrylamide gel electrophoresis in order to reduce band and lane distortion. Immunoblotting with E-, prM-, C-, and M-specific MAbs or polyclonal antisera demonstrated that all three recombinant DEN-2 plasmids induced the production of similar amounts of recombinant antigen composed of E and prM. No M protein was detected, either because it was not processed from prM or because the levels were too low to be detected. Despite efforts to reduce band distortion, high levels of detergent in the hydrophobic protein samples apparently caused E and prM to run in a slightly aberrant manner (slower migration) compared to samples without such high concentrations of detergents (compare E and prM migration in FIGS. 8A and 8B).
iv. Comparison of the immune response in mice vaccinated with three different DEN-2 recombinant DNA plasmids. Three-week old ICR mice were immunized by i.m. injection with 100 μg of pCB8D2-2J-2-9-1 (SEQ ID NO:46), pCB9D2-1J-4-3 (SEQ ID NO:44), pCBD2-14-6 (SEQ ID NO:42), or pEGFP on weeks 0 and 3. Mice were bled 3, 6, and 9 weeks after the primary immunization. Individual and pooled sera were tested by indirect ELISA, using screening dilutions of 1:100 and 1:400 at 3 and 6 weeks post-vaccination and endpoint titrations at 9 weeks post-vaccination. Nine-week sera were also tested by PRNT with both DEN-2 and JE viruses. The ELISA results showed that after one immunization (3-week sera), all mice given pCB8D2-2J-2-9-1 had seroconverted, whereas only 50% of pCB9D2-1J-4-3 and 20% of pCBD2-14-6-vaccinated mice reacted with DEN-2 virus (Table 12). By 9 weeks post-vaccination, all mice vaccinated with either pCB8D2-2J-2-9-1 or pCBD2-1J-4-3 demonstrated anti-DEN-2 ELISA reactivity; however, the geometric mean titers differed significantly (titers of 1:20,000 versus 1:708, respectively). Only 40% of pCBD2-14-6-immunized mice had anti-DEN-2 ELISA titers greater than 1:100. A western blot of pooled 9-week sera from pCB8D2-2J-2-9-1-immunized mice on purified DEN-2 virus showed that the immunodominant response was to the E glycoprotein. Slight reactivity reactivity to prM and M were also detected.
More significantly, in terms of evaluating the vaccine potential of the three DEN-2 plasmids, the induction of virus-neutralizing antibody in 7 of 9 mice immunized with pCB8D2-2J-2-9-1 (SEQ ID NO:46) was observed based on a 90% plaque-reduction endpoint (Table 10). However, if a 50% neutralization endpoint is used, then all 9 of 9 sera have PRNT titers of 3 1:40. Ninety percent neutralization titers ranged from 1:40 to >1:1000 for the 7 sera with neutralizing activity. None of the mice immunized with pCB9D2-1J-4-3 produced neutralizing antibody, and only 1 of 10 sera from pCBD2-14-6-vaccinated mice neutralized virus, but at a titer of only 1:8.
Since two of the recombinant plasmids, namely pCB9D2-1J-4-3 (SEQ ID NO:44) and pCB8D2-2J-2-9-1 (SEQ ID NO:46) contained JE virus E-gene sequences, all sera were also evaluated for the presence of JE virus neutralizing activity. However, no such activity was detected at the 90% neutralization endpoint for mice in any of the immunization groups. Not surprisingly, mice immunized with the control plasmid pEGFP exhibited no reactivity to either DEN-2 or JE viruses.
e. Discussion. The same steps used earlier for the JE and WN vaccines was initially used to construct a recombinant DEN-2 plasmid, pCBD2-14-6 (SEQ ID NO:42), consisting of the authentic DEN-2 prM and E gene region. Antigenic mapping of DEN-2 proteins expressed by COS-1 cells transformed by this plasmid, using a panel of MAb by IFA, indicated the prM and E protein had a compatible fluorescent intensity and a similar MAb reactivity as virus infected cells (Table 10). However, these COS-1 cells transformed by the plasmid encoding an authentic DEN-2 prM and E region failed to secrete detectable DEN-2 antigen into the culture fluid (as measured by antigen-capture ELISA). In addition, vaccination using the plasmid encoding an authentic DEN-2 prM and E region failed to stimulate anti-DEN-2 virus neutralizing antibody in i.m. immunized-mice (Table 13). Interestingly, transformation of cells by pCBD2-14-6 resulted in a punctuated-globular fluorescent staining that suggested that the C-terminus of the E protein of DEN-2 may contribute to that protein's membrane retention signal. This IFA staining pattern was not observed in either the JE or WN construct-transformed cells (Chang et al., “A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice,” J. Virol. 74: 4244-4252 (2000); Davis et al., “West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays,” J. Virol. 75: 4040-4047 (2001)). Therefore, in light of the observation made in accordance with the teachings of the present application, two additional plasmids, pCB9D2-1J-4-3 (SEQ ID NO:44) and pCB8D2-2J-2-9-1 (SEQ ID NO:46), in which appropriate manipulation of the DNA sequence was made for 10% or 20% of C-terminal E of DEN-2 to be replaced with the corresponding region of JE virus E protein, respectively. Relative effectiveness of the different constructs in stimulating detectable anti-DEN-2 ELISA antibody in vaccinated mice is shown in Table 13.
These results are consistent with the model that interactions between prM and E can influence the processes of particle assembly and secretion. Support for this model can be found in a study of tick-borne encephalitis virus that putatively suggests that interactions between prM and the ectodomain of E are involved in prM-mediated intracellular transport of prM-E, thus, secretion of virus-like particle (Allison et al., “Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E,” J. Virol. 73: 5605-5612 (1999)).
In the present example, replacing a C-terminal portion of DEN-2 E protein with JE E protein, corresponding to TBE H1pred to TM2, resulted in DEN-2 prM protein and chimeric E protein secretion. However, in contrast, replacement of TM1 and TM2, in TBE, caused only a minor improvement in antigen secretion. The major portion of the prM and E protein expressed by either COS-1 transformed pCBD2-14-6 and pCB9D2-4-3 plasmid remained membrane-bound (Table 13). These results indicated that an unidentified membrane retention sequence is located in the C-terminal stem region of DEN-2 E protein. Substitution of this C-terminal stem region with sequence from the JE virus removes or renders ineffective this retention sequence.
It has been asserted by others that the prM protein is essential for maintaining proper conformation and secretion of E protein during prM-E maturation (Aberle et al., “A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms,” J. Immunol. 163: 6756-6761 (1999), Allison et al., “Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form,” J. Virol. 69:5816-5820 (1995)). Further, it has also been demonstrated that the ectodomain of the E protein interacts with prM. This interaction has been estimated to involve amino acid sequence within amino acid residues 200-327 of E in the Murray Valley encephalitis virus (Guirakhoo et al., “The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein,” Virology 191: 921-931 (1992)).
Proper prM and E interactions and retained integrity of the E protein's structure are likely maintained in the protein expressed by all three DEN-2 constructs, at least insofar as they are required for immunoreactivity. Furthermore, the replacement of the C-terminus 20% E in the pCB8D2-2J-2-9-1 resulted in a protein that maintained 395 amino acids of authentic DEN-2 E. Any such modification is expected to have minimal influence on E and prM-E interactions and their influence on the antigenic nature of the chimeric E protein. As replacing the C-terminus region of DEN-2 E with JE stem-anchor sequence had no effect on MAbs reactivity (Table 10), retention of the DEN-2 sequence so replaced can only be optional in attaining a DEN-2 specific immunological response.
Previously, it has been shown that a plasmid construct encoding a secreted subviral particle of tick-borne encephalitis virus prM and E protein was superior, in terms of the extent and functionality of the antibody response and in terms of response to virus challenge, to other constructs that encoded C-terminally truncated soluble E-dimer that was secreted, full-length E that was not secreted, or a truncated E that was not efficiently secreted (Aberle et al., “A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms,” J. Immunol. 163: 6756-6761 (1999)). However, here we have demonstrated that the vaccine potency of DEN-2 DNA is correlated with the secretion of prM/M and E (Table 13). The morphology and physical character of secreted prM and E were not demonstrated in this study. However, the prM and E, secreted by the pCB8D2-2J-2-9-1 construct, does likely form a viral-like particle. It is believed that the presentation of multiple protective antigens on the particle surface improves vaccine potency of this construct.
Previous attempts for the development of DEN-2 virus DNA vaccine has resulted in varying degrees of success (Kochel et al., “Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice,” Vaccine 15: 547-552 (1997); Konishi et al., “A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice,” Vaccine 18: 1133-1139 (2000)). To improve the level of effectiveness, differing strategies have been adopted. For example, coimmunization of the immuno-stimulatory CpG motif containing pUC19 plasmid, plasmid expressing murine GM-CSF in the vaccine regimen, or replacing C-terminus 43 amino acid of E with lysosome-associated membrane retention sequence improved the antibody response to the DEN-2 vaccine has been used (Porter et al., “Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses,” Arch. Virol. 143: 997-1003 (1998); Raviprakash et al., “Synergistic Neutralizing Antibody Response to a Dengue Virus Type 2 DNA Vaccine by Incorporation of Lysosome-Associated Membrane Protein Sequences and Use of Plasmid Expressing GM-CSF,” Virology 290: 74-82 (2001)). Unmethylated CpG motifs directly activates macrophages, natural killer cells and lymphocytes to secrete cytokines and chemokines, and supports the development of immune responses mediated by Th1 cytokines (Manders et al., “Immunology of DNA vaccines: CpG motifs and antigen presentation,” Inflamm. Res. 49: 199-205 (2000)). However, inclusion of the CpG might bias the host's cytokine profile and thereby contribute to the both the development of Th-1-mediated organ-specific autoimmune disorders and interfere with immune homeostasis (Smith et al., “The regulation of DNA vaccines,” Curr. Opin. Biotech. 12: 299-303 (2001)). There is also evidence in mice that excess levels of cytokine, although increasing the response of certain T-helper cells, can decrease or shutdown the response of other actors in the immune response, leading to generalized immunosuppression or chronic inflammation (Robertson et al., “Assuring the quality, safety, and efficacy of DNA vaccines,” Mol. Biotechnol. 17: 143-149 (2001)). Correspondingly, the safety and efficacy of flavivirus DNA immunization could be benefited by manipulation of an expression plasmid to enhance transcription and translation and targeting prM and E proteins for secretion that promote correct polyprotein processing and assembly (Chang et al., “Flavivirus DNA vaccines: current status and potential,” Ann. NY Acad. Sci. 951: 272-285 (2001)). Future improvements could be focused on enhancing DNA uptake by antigen presenting cells or by muscle cells (Rodriguez et al., “Enhancing DNA immunization,” Virology 268: 233-238 (2000)).
TABLE 1
Transient expression of JE prM and E proteins by various recombinant plasmids
in two transferred cell lines.
IFA intensity/
percentage of
antigen-
Vector Recombinant positive cells*
Promotor Intron Poly (A) ORI Plasmid COS-1 COS-7
pCDNA3 CMV No BGH SV40 pCDJE2-7 3+/40  3+/35
pCBamp CMV No BGH No pCBJE1-14 3+/45 nd
pC1Bamp CMV Yes BGH No pC1BJES14 3+/39 nd
pCEP4 CMV No SV40 OriP pCEJE 2+/4  2+/3
pREP4 RSV No SV40 OriP pREJE 1+/3  1+/2
pRe/RSV RSV No BGH SV40 pRCJE 1+/3  1+/3
pCDNA3 CMV No BGH SV40 pCDNA3/CAT — —
*Various cell lines were transformed with pCDNA3/CAT (negative control), pCDJE2-7, pCBJE1-14, pC1BJES14, pCEJEm pREJE, or pRCJE, Cells ere trypsinized 48 hours later and tested by an indirect immunofluorescent antibody assay (IFA) with JE virus-specific HIAF. Data are presented as the intensity (scale of 1+ to 4+) and the percentage of IFA positive cells. The pCDNA3/CAT transformed cells were used as the negative control.
TABLE 2
Characterization of proteins expressed by a pCDJE2-7 stably
transformed clone (JE-4B) of COS-1 cells with JE virus-reactive
antibodies.
Biological Immunofluorescent
Activity of Mab intensity of cells
Mab or Biological JEV
antiserum Specificity Function infected 4B
Mab:
MC3 JEV Specific 2+ 2+
2F2 JEV Specific HI, N 4+ 4+
112 JEV Specific 4+ 4+
503 JEV Specific N 4+ 3+
109 Subgroup HI 2+ 1+
N.04 Subgroup HI, N 3+ 4+
201 Subgroup 1+ 1+
203 Subgroup 4+ 3+
204 Subgroup 2+ 2+
301 Subgroup HI 2+ 2+
504 Flavivirus 4+ 4+
6B6C-1 Flavivirus 2+ 2+
3B4C-4 VEE — —
H1AF:
Anti-JEV 4+ 3+
Anti-WEE — —
PBS — —
TABLE 3
Persistence of the immune response in mice immunized with pCDJE2-7 or JE-VEX vaccine.
ELISA Titer (log10) PRNT90% Titer
3 wks 6 wks 9 wks 23 wks 40 wks 60 wks* 3 wks 6 wks 9 wks
1x pCDJE2-7 2.6-3.2 3.8-5.0 3.8-4.4 >3.2 >3.2 2.4, 2.4, 3.8, <20  20 40-160
4.4
2x pCDJE2-7 2.6-3.8 4.4 3.8-4.4 >3.2 >3.2 2.6, 3.8, 3.8 <20 20-40 40-160
2x JE-VAX 2.6-3.8 4.4-5.0 3.8-5.6 >3.2 >3.2 <2, <2, <2, 4.4 <20 20-40 20-160
2x <2 <2 <2 ND ND <2 <20 <20 <20
pCDNA3/CAT
Mice were inoculated with 1 or 2, 100 μg/dose plasmid DNA, or ⅕ human dose of JE-VAX vaccine. Sera were collected for testing prior to the second immunization.
*Individual serum titers.
TABLE 4
The age-dependent percent seropositive rate in mice following
vaccination with various JEV vaccines.
3-day old 3-week old
3 weeks PV 7 weeks PV 3 weeks PV 7 weeks PV
JE-VAX 0 0 100 100
pCDNA3/CAT 0 0 0 0
pCDJE2-7 40 60 90 90
pC1BJES14 10 60 80 100
pCBJE1-14 80 100 100 100
TABLE 5
Protection from JEV challenge in 8 week old mice following vaccination
at 3 days old with various JEV vaccines.
Days post-challenge
Pre-challenge JEV survival rate (%)
Vaccine seroconversion 6 7 8 9 21
JE-VAX 0 100 100 60 40 40
pCDNA3/CAT 0 100 80 30 30 30
pCDJE2-7 60 100 100 100 100 100
pC1BJES14 60 100 100 100 100 100
pCBJE1-14 100 100 100 100 100 100
TABLE 6
Evaluation of the ability of maternal antibody from JEV-nucleic acid-
vaccinated female mice to protect their pups from fatal JEV encephalitis.
JEV challenged pups
Vaccinated mother Challenge age
Vaccine PRNT90% (days) No. survival1 ELISA2
1 x pCDJE2-7 40 4 0/11
2 x pCDJE2-7 80 4 12/12  12/12
2 x JE-VAX 20 3 0/16
2 x pCDNA-3/CAT <10 5 0/14
1 x pCDJE2-7 20 15 5/11 5/5
2 x pCDJE2-7 40 14 8/12 7/8
2 x JE-VAX 80 13 5/5  5/5
2 x pCDNA-3/CAT <10 14 0/14
Mice were inoculated intramuscularly with 1 or 2, 100 μg dose of plasmid DNA, or subcutaneously with two, ⅕ human dose of JE-VAX vaccine. Sera were collected 9 weeks post-vaccination for PRNT testing prior to mating with non-immune male.
1No Survivors/total for each litter.
2Number of JEV ELISA-antibody-positive animals (titer ≧1:400)/No. of survivors; sera were collected for testing 12 weeks after challenge.
TABLE 7
Characteristic of the signal peptides and their vaccine of potentials
among flavivirus DNA vaccine constructs
Signal peptide
probabilitya Immunization
Plasmid Signal peptide sequence preceding prM protein SP AP Csite protocol/protection
pSLE1 ?L D TIN RR PS KKR GGT R SLLGLAALIGLASS/ 0.702 0.292 0.352 im × 2/Partial
LQLLSTYQG (SEQ ID NO:32)
pJME 0.998 0.000 0.778 im × 2/Partial
MWLASLAVVIACAGA/M K LSNFQG K
(SEQ ID NO: 33)
pCJEME MN E GSIMWLASLAVVIACAGA/M K LSNFQG K 0.985 0.012 0.785 im × 2/100%
(SEQ ID NO: 34)
pCBJE1-14 MG RK QN KR GGN E GSIMWLASLAVVTACAGA/ 0.791 0.199 0.623 im × 1/100%
M K LSNFQG K  (SEQ ID NO: 35)
pcDNA3prM-E MS KKR GGS E TSVLMVIFMLIGFAAA/L K LSNFQG K 0.721 0.277 0.622 im × 4/Partial
(SEQ ID NO: 36) gg × 2-4/100%
pCBWN MG KR SAGSIMWLASLAVVIACAGA/VTLSNFQG K 0.976 0.024 0.526 im × 1/100%
(SEQ ID NO: 37)
p1012D2ME MNVL R GF RKE IGRMLNILN RRRR TAGMIIMLIPTVMA/ 0.165 0.778 0.164 id × 2/None
F H LTT R NG E  (SEQ ID NO: 38)
SV-PE MVGLQ KR G KRR SATDWMSWLLVITLLGMTLA/ 0.943 0.056 0.899 im or gg × 2/100%
ATV RKER GD (SEQ ID NO: 39)
pWRG7077- MGWLLVVVLLGVTLA/ATV RKER GD (SEQ ID 1.000 0.000 0.912 gg × 2/100%
RSSE NO: 40)
pWRG7077- MSWLLVITLLGMTIA/ATV RKER GD (SEQ ID 0.999 0.000 0.821 gg × 2/100%
CEE NO: 41)
aThe SignalP HMM program was applied to calculate signal peptide (SP), anchor peptide (AP) and signalase cleavage site (C site) probabilities. Single amino acid codes were used, and charged amino acids were highlighted by underline-bold letters. The signalase cleavage site separating SP and prM is indicated by “/”. DNA vaccines were inoculated by intramuscluar (im), intradermal (id), or gene gun (gg) method.
TABLE 8
Neutralizing antibody (Nt) responses in mice immunized with different doses of the
combined WN and JE virus DNA vaccines.
pCBWN + pCBJE1-14 pCB
Dose per plasmid (μg) 100 + 100 40 + 40 20 + 20 10 + 10 Control 100
Percentage of mice with Nt:
WN virus/JE virus: 100/100 100/70  70/0  60/0  0/0
Range of PRNT90 titer:
WN virus: 1:320-1:80  1:80-1:20  1:80-<1:10  1:20-<1:10 <1:10
JE virus: 1:40-1:10  1:10-<1:10 <1:10 <1:10 <1:10
Groups of ten, three-week-old female ICR out-bred mice were i.m. injected with a single dose of Combined plasmid DNAs as indicated. The serum specimens collected 12-week after immunization were assayed by the plaque-reduction neutralization test (PRNT). The end-point titers against JE and WN virus were calculated based on the 90% percent plaque reduction using JE virus (strain SA-14) and West Nile virus (strain NY-6480), respectively.
TABLE 9
Oligonucleotides used to construct DEN-2 virus prM-E expression
plasmids, and the junction region of chimeric DEN-2 and JE E indicated.
100% DEN-2 prM-E:
D2KasI-438a 5′ TGTGCA
Figure US08221768-20120717-P00001
TTCCATTTAACCACACGTAACG		 (SEQ ID NO: 48)
CD2NotI-2402 5′ TCGA
Figure US08221768-20120717-P00002
TCAACTAATTAGGCCTGCACCATGACTC		 (SEQ ID NO: 49)
90% DEN-2E & 10% JE E:
T7 5′ CTTATCGAAATTAATACGACTCACTATAGG (SEQ ID NO: 50)
CD2BstXI-2244 5′ ATAGATTGCT
Figure US08221768-20120717-P00003
AA C ACT
Figure US08221768-20120717-P00004
TGG		 (SEQ ID NO: 51)
JE-2281 5′ ACTCCATAGGAAAAGCCGTTCACC (SEQ ID NO: 52)
CSP6 5′ GCGAGCTCTAGCATTTAGGTGACACTATAG (SEQ ID NO: 53)
                DEN-2
Figure US08221768-20120717-P00005
  
Figure US08221768-20120717-P00006
JE
90-10 Junction: Leu His Gln Val Phe Gly Gly Ala Phe Arg Thr (SEQ ID NO: 55)
CTC CAC CAA GTG TTT GGT GGT GCC TTC AGA ACA (SEQ ID NO: 54)
80% DEN-2E & 20% JE E:
T7 5′ CTTATCGAAATTAATACGACTCACTATAGG (SEQ ID NO: 56)
CD2BsmBI-2097 5′ GAATT
Figure US08221768-20120717-P00007
ACTTCCTTTCTTAAACCAGTTGAGCTTC		 (SEQ ID NO: 57)
JEBsmBI-2175 5′ GGAATT
Figure US08221768-20120717-P00008
GGAAGCACGCTGGGCAAGG		 (SEQ ID NO: 58)
CSP6 5′ GCGAGCTCTAGCATTTAGGTGACACTATAG 3′ (SEQ ID NO: 59)
                DEN-2
Figure US08221768-20120717-P00005
  
Figure US08221768-20120717-P00006
JE
80-20 Junction: Asn Trp Lys Lys Gly Ser Thr Leu Gly Lys Ala (SEQ ID NO: 61)
AAC TGG TTT AAG AAA GGA AGC ACG CTG GGC GCC (SEQ ID NO: 60)
aRestriction enzyme sites encoded in oligonucleotides were highlighted by the bold, italic and underline.
TABLE 10
Characterization of DEN-2 E glycoprotein epitopes expressed by the recombinant DEN-2
plasmids as determined by the indirect fluorescent antibody assay (IFA).
Controlsa
Antibody DEN-2 Normal Plasmid constructa
MAb (Epitope)b Antigenic Domainc PRNTd infected cells cells pCBD2-14-6 pCB9D2-1J-4-3 pCB8D2-2J-2-9-1
4G2 (A1) 2 +/− 4+ — 4+ 4+ 4+
4E5 (A2) 2 Yes 3+ — 3-4+ 3-4+ 2-3+
1B7 (A5) 2 Yes 3-4+ — 4+ 4+ 2-3+
1B4C-2 (C1) 1 No 3-4+ (8000)  — 2-3+ (4000) 2-3+ (4000) 2-3+ (8000) 
2B3A-1 (C3) 1 No 3-4+ (≧3200) —  3+ (100)  2+ (100) 2-3+ (≧3200)
9A4D-1 (C4) 1 No 3-4+ — 2-3+ (400)  1-3+ (400)    3+ (≧12800)
3H5 (B2) 3 Yes 4+ — 4+ 4+ 4+
10A4D-2 (B3) 3 Yes 2-3+ — 3-4+ 3-4+ 2-3+
1A1D-2 (B4) 3 Yes 4+ — 3-4+ 4+ 3-4+
9D12-6 Yes 2-4+ 2-3+ 2-3+ 3-4+
2H2 prM No 4+ — 4+ 3-4+ 3-4+
1A2A-1 Capsid No 2-3+ — 1+ 2+ 1-2+
aIFA substrates were acetone-fixed COS-1 cells, either infected with DEN-2 16681, uninfected controls, or transformed with a DEN-2 recombinant plasmid.
bMonoclonal antibodies were used at a predetermined optimum dilution based on reactivity with DEN-2 16681 virus. For some MAbs, endpoint titers, shown in parentheses, are reported and for others, only qualitative values are reported based on a scale from 1+ to 4+, with 3-4+ considered positive, 2+ equivocal, and 1+ negative.
cAntigenic domains based on the E-glycoprotein of TBE virus (Mandl et al., “Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model,” J. Virol. 63: 564-571 (1989); Rey et al., “The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution,” Nature 375: 291-298 (1995)).
dPlaque-reduction neutralization activity at a 1:100 dilution of ascitic fluid, using a 90% plaque-reduction endpoint, except for 4G2 and 9D12-6, for which a 50% neutralization endpoint is reported (Henchal et al., “Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies,” Am. J. Trop. Med. Hyg. 34: 162-169 (1985); Roehrig et al., “Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica,” Virology 246: 317-328 (1998)).
TABLE 11
Detection of secreted and membrane-bound DEN-2 recombinant
protein by antigen-capture ELISA.
Endpoint
Plasmid Sample type ELISA titer
pCBD2-14-6 PEG-precipitated culture fluida <1:10
pCBD2-14-6 PEG-precipitated, ethanol- <1:20
extracted culture fluidb
pCBD2-14-6 Hydrophobic membrane protein  1:160
preparationc
pCB9D2-1J-4-3 PEG-precipitated culture fluida <1:10
pCB9D2-1J-4-3 PEG-precipitated, ethanol- <1:20
extracted culture fluidb
pCB9D2-1J-4-3 Hydrophobic membrane protein  1:80
preparationc
pCB8D2-2J-2-9-1 PEG-precipitated culture fluida  1:640
pCB8D2-2J-2-9-1 PEG-precipitated, ethanol-  1:80
extracted culture fluidb
pCB8D2-2J-2-9-1 Hydrophobic membrane protein  1:80
preparationc
pEGFP PEG-precipitated culture fluida <1:10
pEGFP PEG-precipitated, ethanol- <1:10
extracted culture fluidb
pEGFP Hydrophobic membrane protein <1:10
preparationc
aCulture supernatant from plasmid-transformed cells was precipitated with 10% polyethylene glycol (PEG) and resuspended in 1/100th of orginal volume.
bPEG-precipitated culture supernatant was extracted with 4% ethanol to remove PEG and the pellet was resuspended in ⅕ of the volume extracted.
cHydrophobic membrane fractions were prepared as described in Materials and Methods.
TABLE 12
Immunogenicity of three DEN-2 recombinant plasmids in ICR mice.
ELISA on DEN-2 virus PRNT on PRNT on JE
Screen
3 Screen 6 DEN-2 virusa virusa
wks, p.v.c wks, p.v.c Endpoint titer Endpoint titer Endpoint titer
Plasmid DNAb Mouse # 1:100 1:400 1:100 1:400 9 wks, p.v. 9 wks, p.v. 9 wks, p.v.
pCB8D2-2J-2-9-1 Pool, NDd ND + + 64,000 ND ND
1, 2, 4-10
1 + + + + 64,000 >1000 <2
2 + + + + 32,000 >1000 <2
4 + + + + 16,000  200 <2
5 + + + + 4,000  <10 <2
6 + + + + 16,000  200 <2
7 + − + + 64,000  100 <2
8 + − + + 8,000   40 <2
9 + + + + 6,400   <2 <4
10  + + + + 64,000 >1000 <2
pCB9D2-1J- Pool, 1-10 ND ND + + 1,000 ND  <2e
4-3 1 − − + − 400  <10 ND
2 + − + + 200  <10 ND
3 + + + + 4,000   <2 ≦4
4 + − + − 200  <10 ND
5 − − + + 400  <10 ND
6 + + + + 4,000   <2  2
7 − +/− − − 100  <10 ND
8 − − − − 200  <10 ND
9 + − + − 4,000   <2 <2
10  − − + + 4,000   <2 <2
pCBD2- Pool, 1-10 ND ND + − 200   <2f  <2g
14-6 1 − − − − 400  <10 ND
2, 3, 6-9 − − − − <100 ND ND
4 + + + + 1,000   <2 <2
5 − − + − 2,000   8 <2
10  + − − − <100 ND ND
pEGFP Pool, 1-10 − ND − ND <100   <2 <2
aPRNT, plaque-reduction neutralization test, 90% neutralization endpoint.
bMice were immunized intramuscularly with 100 μg plasmid DNA on weeks 0 and 3.
cELISA screens used sera diluted 1:100 and 1:400.
dND, not done.
ePool, 1, 2, 4, 5, 7, 8.
fPool, 2, 3, 6-10.
gPool, 1-3, 6-10.
TABLE 13
Summary of the characteristics of three DEN-2 recombinant plasmids.
Ag-capture ELISA titer on
ELISA titer DEN-2b DEN-2
Hydrophobic Pooled PRNTc
IFAa Secreted membrane No. sera No. sera
Plasmid +/− Globular/Diffuse antigen protein prep sera ≧1:100 titer ≧1:10
pCB8D2- + Diffuse  1:640 1:80 9/9 1:64000 7/9d
2J-2-9-1
pCB9D2- + Globular <1:10 1:80 10/10 1:1000  0/10
1J-4-3
pCBD2- + Globular <1:10  1:160  3/10 1:200  0/10
14-6
aIndirect fluorescent antibody assay (IFA) staining characteristics, + or −, and diffuse or globular pattern.
bAnti-DEN-2 ELISA titer of sera from mice immunized with the recombinant plasmids. Sera were collected 9 weeks post-vaccination (weeks 0 and 3). Number of mice with titer of ≧1:100/total number of mice is shown, including the endpoint ELISA titer of the pooled serum sample.
cNumber of mice with plaque-reduction neutralization titers (PRNT, 90% reduction) ≧1:10/ total number of mice. Sera were collected 9 weeks post-vaccination.
dOf the 7 mice with neutralizing antibody, 3 mice had PRNT titers of >1:1000, 3 had titers of ≧1:100 < 1:1000, and one had a titer of 1:40.

Claims (30)

1. An immunogenic polypeptide expressed from a nucleic acid comprising a transcriptional unit encoding a Japanese encephalitis virus (JEV) prM signal sequence fused to the N-terminus of an immunogenic flavivirus antigen, wherein the antigen comprises flavivirus M and E proteins, and the antigen is of a second flavivirus or the antigen is a chimeric antigen comprising an amino acid sequence from JEV and a second flavivirus, and wherein the transcriptional unit directs the synthesis of the antigen.
2. The immunogenic polypeptide of claim 1, wherein the immunogenic flavivirus antigen is of a second flavivirus selected from the group consisting of yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, St. Louis encephalitis virus, Powassan virus and West Nile virus.
3. The immunogenic polypeptide of claim 1, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus and an M protein and an E protein of West Nile virus.
4. The immunogenic polypeptide of claim 1, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus and an M protein and an E protein of yellow fever virus.
5. The immunogenic polypeptide of claim 1, wherein the transcriptional unit encodes prM a signal sequence of Japanese encephalitis virus and an M protein and an E protein of St. Louis encephalitis virus.
6. The immunogenic polypeptide of claim 1, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus and an M protein and an E protein of Powassan virus.
7. The immunogenic polypeptide of claim 1, comprising a polypeptide sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 22 and SEQ ID NO: 24.
8. The immunogenic polypeptide of claim 1, wherein the transcriptional unit comprises a control sequence disposed appropriately such that it operably controls the synthesis of the antigen.
9. The immunogenic polypeptide of claim 8, wherein the control sequence is the cytomegalovirus immediate early promoter.
10. An isolated cell expressing the immunogenic polypeptide of claim 1.
11. A composition comprising the immunogenic polypeptide of claim 1 and a pharmaceutically acceptable carrier.
12. A method of eliciting an immune response in a subject against infection by a flavivirus, comprising administering to the subject an effective amount of the composition of claim 11.
13. The method of claim 12, wherein the second flavivirus is selected from the group consisting of yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, St. Louis encephalitis virus, Powassan virus and West Nile virus.
14. The method of claim 12, wherein the flavivirus antigen is both the M protein and the E protein, and wherein a cell within the body of the subject, after incorporating the nucleic acid within it, secretes subviral particles comprising the M protein and the E protein.
15. The method of claim 12, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus, and an M protein and an E protein of West Nile virus.
16. The method of claim 12, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus, and an M protein and an E protein of yellow fever virus.
17. The method of claim 12, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus, and an M protein and an E protein of St. Louis encephalitis virus.
18. The method of claim 12, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus, and an M protein and an E protein of Powassan virus.
19. The method of claim 12, comprising administering the composition to the subject in a single dose.
20. The method of claim 12, wherein the composition is administered via a parenteral route.
21. A method of detecting a flavivirus antibody in a sample, comprising:
contacting the sample with the immunogenic polypeptide of claim 1 under conditions whereby an antigen/antibody complex can form; and
detecting antigen/antibody complex formation, thereby detecting a flavivirus antibody in the sample.
22. The immunogenic polypeptide of claim 1, wherein the prM signal sequence comprises the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 27.
23. The immunogenic polypeptide of claim 1, wherein the immunogenic flavivirus antigen is a chimeric antigen comprising amino acid sequence from JEV and a second flavivirus, wherein the second flavivirus is selected from yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, St. Louis encephalitis virus, Powassan virus and West Nile virus.
24. The immunogenic polypeptide of claim 23, wherein the immunogenic flavivirus antigen comprises a chimeric E protein.
25. The immunogenic polypeptide of claim 23, wherein the immunogenic flavivirus antigen comprises an M protein from the second flavivirus and a chimeric E protein comprising amino acid sequence from Japanese encephalitis virus and the second flavivirus.
26. The immunogenic polypeptide of claim 25, wherein the chimeric E protein comprises a carboxy terminal portion from Japanese encephalitis virus, wherein the carboxy terminal portion is 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50% or 75% of the chimeric E protein.
27. The immunogenic polypeptide of claim 26, wherein the carboxy terminal portion is at least 10% of the chimeric E protein.
28. The immunogenic polypeptide of claim 27, wherein the carboxy terminal portion is at least 20% of the chimeric E protein.
29. The immunogenic polypeptide of claim 25, wherein the second flavivirus is a dengue virus.
30. The immunogenic polypeptide of claim 25, wherein the second flavivirus is a St. Louis encephalitis virus.
US12/580,080 1998-06-04 2009-10-15 Chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence Expired - Lifetime US8221768B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/580,080 US8221768B2 (en) 1998-06-04 2009-10-15 Chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8790898P 1998-06-04 1998-06-04
PCT/US1999/012298 WO1999063095A1 (en) 1998-06-04 1999-06-03 Nucleic acid vaccines for prevention of flavivirus infection
US09/826,115 US7227011B2 (en) 1998-06-04 2001-04-04 Nucleic acid vaccines for prevention of flavivirus infection
US70153601A 2001-06-18 2001-06-18
US10/500,796 US7662394B2 (en) 1998-06-04 2002-04-04 Nucleic acids encoding chimeric Flavivirus immunogens comprising the Japanese encephalitis virus (JEV) PRM signal sequence
PCT/US2002/010764 WO2002081754A1 (en) 2001-04-04 2002-04-04 Nucleic acid vaccines for prevention of flavivirus infection
US12/580,080 US8221768B2 (en) 1998-06-04 2009-10-15 Chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2002/010764 Division WO2002081754A1 (en) 1998-06-04 2002-04-04 Nucleic acid vaccines for prevention of flavivirus infection
US10500796 Division 2002-04-04
US10/500,796 Division US7662394B2 (en) 1998-06-04 2002-04-04 Nucleic acids encoding chimeric Flavivirus immunogens comprising the Japanese encephalitis virus (JEV) PRM signal sequence

Publications (2)

Publication Number Publication Date
US20100040643A1 US20100040643A1 (en) 2010-02-18
US8221768B2 true US8221768B2 (en) 2012-07-17

Family

ID=25245753

Family Applications (6)

Application Number Title Priority Date Filing Date
US09/826,115 Expired - Lifetime US7227011B2 (en) 1998-06-04 2001-04-04 Nucleic acid vaccines for prevention of flavivirus infection
US10/500,796 Expired - Lifetime US7662394B2 (en) 1998-06-04 2002-04-04 Nucleic acids encoding chimeric Flavivirus immunogens comprising the Japanese encephalitis virus (JEV) PRM signal sequence
US11/424,138 Expired - Lifetime US7632510B2 (en) 1998-06-04 2006-06-14 Methods of inducing flavivirus immune responses through the administration of recombinant flaviviruses comprising an engineered japanese encephalitis virus signal sequence
US11/424,127 Expired - Fee Related US7521177B2 (en) 1998-06-04 2006-06-14 Flavivirus detection methods employing recombinant antigens comprising a Japanese encephalitis (JEV) signal sequence
US12/508,946 Expired - Fee Related US8232379B2 (en) 1998-06-04 2009-07-24 Nucleic acids encoding chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence
US12/580,080 Expired - Lifetime US8221768B2 (en) 1998-06-04 2009-10-15 Chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US09/826,115 Expired - Lifetime US7227011B2 (en) 1998-06-04 2001-04-04 Nucleic acid vaccines for prevention of flavivirus infection
US10/500,796 Expired - Lifetime US7662394B2 (en) 1998-06-04 2002-04-04 Nucleic acids encoding chimeric Flavivirus immunogens comprising the Japanese encephalitis virus (JEV) PRM signal sequence
US11/424,138 Expired - Lifetime US7632510B2 (en) 1998-06-04 2006-06-14 Methods of inducing flavivirus immune responses through the administration of recombinant flaviviruses comprising an engineered japanese encephalitis virus signal sequence
US11/424,127 Expired - Fee Related US7521177B2 (en) 1998-06-04 2006-06-14 Flavivirus detection methods employing recombinant antigens comprising a Japanese encephalitis (JEV) signal sequence
US12/508,946 Expired - Fee Related US8232379B2 (en) 1998-06-04 2009-07-24 Nucleic acids encoding chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence

Country Status (12)

Country Link
US (6) US7227011B2 (en)
EP (3) EP1383931A4 (en)
JP (2) JP4448281B2 (en)
KR (1) KR100913984B1 (en)
CN (2) CN101002936A (en)
BR (1) BRPI0208301B8 (en)
CA (1) CA2443323C (en)
HK (1) HK1062836A1 (en)
MX (1) MXPA03008838A (en)
NZ (1) NZ529106A (en)
WO (1) WO2002081754A1 (en)
ZA (1) ZA200307580B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10898566B2 (en) 2016-09-19 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zika virus vaccines
US10947277B2 (en) 2016-06-13 2021-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
FR2823222B1 (en) * 2001-04-06 2004-02-06 Merial Sas VACCINE AGAINST NILE FEVER VIRUS
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
US20050031641A1 (en) * 2001-04-06 2005-02-10 Loosmore Sheena May Recombinant vaccine against West Nile Virus
NZ570270A (en) * 2001-07-27 2010-08-27 Wyeth Corp West nile vaccine for equidae
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US7351547B2 (en) * 2002-10-31 2008-04-01 Health Research, Inc. Diagnostic test for West Nile virus
WO2004016586A2 (en) * 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2004044220A2 (en) * 2002-11-08 2004-05-27 The Administrators Of The Tulane Educational Fund Flaviviris fusion inhibitors
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2004112694A2 (en) 2003-05-23 2004-12-29 Chiron Corporation Immunogenic reagents from west nile virus
US7060280B2 (en) * 2003-06-11 2006-06-13 Academia Sinica Immunization against flavivirus
US7585621B2 (en) 2003-09-09 2009-09-08 Idexx Laboratories, Inc. Detection of West Nile virus infection and vaccination
US7074555B2 (en) 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
WO2005108560A2 (en) * 2004-05-04 2005-11-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of west nile virus virus-like particles
WO2006017206A2 (en) * 2004-07-12 2006-02-16 Tengen Biomedical Company Flavivirus vaccine
EP1784487B1 (en) 2004-07-27 2011-08-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of cross-reactive epitopes of flavivirus envelope glycoprotein
WO2006029300A2 (en) * 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
EA015907B1 (en) * 2004-10-20 2011-12-30 Санофи Пастер Байолоджикс Ко. Recombinant flavivirus and use thereof
WO2006107655A2 (en) * 2005-04-01 2006-10-12 Wyeth Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
CA2878579C (en) 2005-04-08 2018-01-23 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
JP5193856B2 (en) 2005-06-24 2013-05-08 インターベツト・インターナシヨナル・ベー・ベー Inactivated chimeric vaccine and related methods of use
US7455842B2 (en) * 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
US20070190617A1 (en) * 2006-02-13 2007-08-16 Chang-Jer Wu DNA vaccine for Japanese encephalitis virus
US20080044808A1 (en) * 2006-08-15 2008-02-21 Qian-Li Song West nile virus antigen and assay
WO2008127307A2 (en) * 2006-11-09 2008-10-23 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using prime-boost approach
PT2308514E (en) 2007-03-23 2013-09-06 To Bbb Holding B V Conjugates for targeted drug delivery across the blood-brain barrier
JP2008263964A (en) * 2007-03-29 2008-11-06 Yamaguchi Univ Cell line derived from bat
EP2003144A1 (en) * 2007-06-15 2008-12-17 Institut Pasteur Method for the diagnosis or the screening of an arbovirus infection, reagents useful in said method and their applications
WO2009024534A2 (en) * 2007-08-17 2009-02-26 Intercell Ag Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses
US8138318B2 (en) * 2007-09-13 2012-03-20 Abbott Laboratories Hepatitis B pre-S2 nucleic acid
US8835620B2 (en) * 2008-01-11 2014-09-16 Vgx Pharmaceuticals, Llc Vaccines against multiple subtypes of dengue virus
US8715999B2 (en) * 2008-02-08 2014-05-06 Valneva Austria Gmbh Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines
MX2010011373A (en) * 2008-04-22 2010-11-12 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof.
CN101333246B (en) * 2008-07-30 2011-04-13 中国农业科学院哈尔滨兽医研究所 Neutral B cell antigen epitope polypeptide of encephalitis b virus E protein and uses thereof
NZ603854A (en) * 2008-08-29 2015-03-27 Boehringer Ingelheim Vetmed West nile virus vaccine
CN101607983B (en) * 2009-07-29 2012-06-13 中国农业科学院哈尔滨兽医研究所 Encephalitis B virus PrM/M protein B cell antigen epitope polypeptide and applications
CA3150404A1 (en) 2009-07-31 2011-02-03 Pnuvax Inc. High yield yellow fever virus strain with increased propagation in cells
US20110182976A1 (en) * 2010-01-28 2011-07-28 National Taiwan Ocean University Lipoplex-patch based dna vaccine
US8993744B2 (en) 2010-05-21 2015-03-31 University of Pittsburgh—of the Commonwealth System of Higher Education Universal dengue virus sequences and methods of use
AR079970A1 (en) * 2010-07-23 2012-02-29 Xcellerex Inc HIGH PERFORMANCE VIRUSES OF THE YELLOW FEVER VIRUS WITH INCREASED PROPAGATION IN THE CELLS
WO2012065105A2 (en) * 2010-11-12 2012-05-18 Thomas Monath Chimeric flavivirus vaccines
ES2842595T3 (en) 2011-03-14 2021-07-14 Boehringer Ingelheim Animal Health Usa Inc Equine rhinitis vaccine
EP2768847A4 (en) 2011-10-20 2015-11-11 Us Gov Health & Human Serv Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
US8920804B2 (en) 2011-12-22 2014-12-30 Inbios International, Inc. Methods and materials for the detection of dengue virus infection
PE20150356A1 (en) * 2012-07-24 2015-03-20 Sanofi Pasteur VACCINE COMPOSITIONS FOR THE PREVENTION AGAINST INFECTION BY DENGUE VIRUS
TW201620546A (en) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 Vaccine compositions
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
CN104630160B (en) * 2015-01-23 2018-04-27 中国农业科学院哈尔滨兽医研究所 Express the recombinant Newcastle disease LaSota vaccine strains of west nile fever virus PrM/E albumen
BR112017028212A2 (en) 2015-07-03 2018-09-11 Sanofi Pasteur concomitant vaccination against dengue and yellow fever
TW201718638A (en) * 2015-07-21 2017-06-01 現代治療公司 Infectious disease vaccines
US20180028643A1 (en) * 2016-06-21 2018-02-01 Brock Adam Kingstad-Bakke Zika virus vaccines using virus-like particles
BE1025121B1 (en) * 2016-11-17 2018-11-05 Glaxosmithkline Biologicals Sa ANTIGENIC CONSTRUCTS OF ZIKA VIRUS
WO2018152526A1 (en) 2017-02-20 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
EP3530668A1 (en) * 2018-02-22 2019-08-28 Euroimmun Medizinische Labordiagnostika AG A novel assay for the diagnosis of viral infections
WO2019162454A1 (en) * 2018-02-22 2019-08-29 Euroimmun Medizinische Labordiagnostika Ag Assay for the diagnosis of viral infections
CN113429479B (en) * 2018-04-04 2023-03-10 中国科学院微生物研究所 High-sensitivity yellow fever virus humanized monoclonal antibody and application thereof
CN108904793B (en) * 2018-07-29 2021-03-30 首都医科大学附属北京友谊医院 DNA vaccine for preventing epidemic encephalitis B and construction method thereof
CA3124373A1 (en) * 2018-12-20 2020-06-25 The Wistar Institute Of Anatomy And Biology Vaccines against powassan virus, and methods of using same
CA3162377A1 (en) * 2019-12-18 2021-06-24 Joel MASLOW Powassan viral antigens and related compositions, and uses thereof to vaccinate and treat patients
KR102216078B1 (en) * 2020-04-22 2021-02-16 국방과학연구소 Expression vector for gene of antigen delivery for use as genetic vaccine and genetic vaccine
US20230272405A1 (en) * 2020-06-22 2023-08-31 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53133627A (en) 1977-04-25 1978-11-21 Nippon Seibutsu Kagaku Kenkiyu High purity deactivated vaccine for japanese encephalitis
JPS634895A (en) 1986-06-24 1988-01-09 Mitsubishi Electric Corp Device for supplying ozone refining water
JPS63105682A (en) 1986-10-23 1988-05-10 Mitsubishi Kasei Corp Cdna derived from dengue virus 3 type
US4810492A (en) 1986-06-05 1989-03-07 The Research Foundation For Microbial Diseases Of Osaka University Flavivirus antigen
WO1990001946A1 (en) 1988-08-20 1990-03-08 The United States Of America, Represented By The Secretary, United States Department Of Commerce Recombinant vaccinia virus for prevention of disease caused by flavivirus
US5021347A (en) 1987-09-16 1991-06-04 Nippon Zeon Co., Ltd. Recombinant vaccinia virus expressing E-protein of Japanese encephalitis virus
WO1992002548A1 (en) 1990-08-10 1992-02-20 Institut Pasteur Recombinant baculovirus expressing proteins e and ns1 of flaviviridae viruses and flaviviridae-related viruses
WO1992003545A1 (en) 1990-08-15 1992-03-05 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
WO1993006214A1 (en) 1991-09-19 1993-04-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5229293A (en) 1988-05-12 1993-07-20 Nippon Zeon Co Ltd. Recombinant baculovirus
JPH05276941A (en) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd Production of noninfectious structure particle containing surface antigen protein of virus belonging to family flavivirus
JPH07265093A (en) 1994-03-30 1995-10-17 Chemo Sero Therapeut Res Inst Production of surface antigen protein of japanese encephalitis virus using mammalian cell
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
WO1998037911A1 (en) 1997-02-28 1998-09-03 Oravax, Inc. Chimeric flavivirus vaccines
WO1999006068A2 (en) 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
WO1999063095A1 (en) 1998-06-04 1999-12-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
US6074865A (en) 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6165477A (en) 1995-05-24 2000-12-26 Hawaii Biotechnology Group, Inc. Subunit immonogenic composition against dengue infection
US6258788B1 (en) 1997-11-20 2001-07-10 The United States Of America As Represented By The Secretary Of The Army DNA vaccines against tick-borne flaviviruses
WO2002072036A2 (en) 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
WO2002083903A2 (en) 2001-02-28 2002-10-24 Brown University Research Foundation West nile virus epitopes and uses thereof
US6696281B1 (en) * 1997-02-28 2004-02-24 Acambis, Inc. Chimeric flavivirus vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (en) 1968-10-17 1970-08-24
FR2614219B1 (en) 1987-04-23 1993-07-09 Materiels Annexes Dialyse PROCESS FOR THE MANUFACTURE OF GRANULES FOR THE PREPARATION OF DIALYSIS SOLUTIONS AND INSTALLATION FOR ITS IMPLEMENTATION.
US4783502A (en) 1987-12-03 1988-11-08 Ppg Industries, Inc. Stable nonaqueous polyurethane microparticle dispersion
JPH0425408A (en) 1990-05-21 1992-01-29 Hitachi Ltd Method of automatic continuous operation control of pelletizing system
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53133627A (en) 1977-04-25 1978-11-21 Nippon Seibutsu Kagaku Kenkiyu High purity deactivated vaccine for japanese encephalitis
US4810492A (en) 1986-06-05 1989-03-07 The Research Foundation For Microbial Diseases Of Osaka University Flavivirus antigen
JPS634895A (en) 1986-06-24 1988-01-09 Mitsubishi Electric Corp Device for supplying ozone refining water
JPS63105682A (en) 1986-10-23 1988-05-10 Mitsubishi Kasei Corp Cdna derived from dengue virus 3 type
US5021347A (en) 1987-09-16 1991-06-04 Nippon Zeon Co., Ltd. Recombinant vaccinia virus expressing E-protein of Japanese encephalitis virus
US5229293A (en) 1988-05-12 1993-07-20 Nippon Zeon Co Ltd. Recombinant baculovirus
WO1990001946A1 (en) 1988-08-20 1990-03-08 The United States Of America, Represented By The Secretary, United States Department Of Commerce Recombinant vaccinia virus for prevention of disease caused by flavivirus
WO1992002548A1 (en) 1990-08-10 1992-02-20 Institut Pasteur Recombinant baculovirus expressing proteins e and ns1 of flaviviridae viruses and flaviviridae-related viruses
WO1992003545A1 (en) 1990-08-15 1992-03-05 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
WO1993006214A1 (en) 1991-09-19 1993-04-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
JPH05276941A (en) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd Production of noninfectious structure particle containing surface antigen protein of virus belonging to family flavivirus
JPH07265093A (en) 1994-03-30 1995-10-17 Chemo Sero Therapeut Res Inst Production of surface antigen protein of japanese encephalitis virus using mammalian cell
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6165477A (en) 1995-05-24 2000-12-26 Hawaii Biotechnology Group, Inc. Subunit immonogenic composition against dengue infection
US6074865A (en) 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
WO1998037911A1 (en) 1997-02-28 1998-09-03 Oravax, Inc. Chimeric flavivirus vaccines
US6696281B1 (en) * 1997-02-28 2004-02-24 Acambis, Inc. Chimeric flavivirus vaccines
WO1999006068A2 (en) 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
US6258788B1 (en) 1997-11-20 2001-07-10 The United States Of America As Represented By The Secretary Of The Army DNA vaccines against tick-borne flaviviruses
WO1999063095A1 (en) 1998-06-04 1999-12-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
WO2002083903A2 (en) 2001-02-28 2002-10-24 Brown University Research Foundation West nile virus epitopes and uses thereof
WO2002072036A2 (en) 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides

Non-Patent Citations (118)

* Cited by examiner, † Cited by third party
Title
"Update: Surveillance for West Nile Virus in Overwintering Mosquitoes—New York, 2000," Morb. Mortal. Wkly. Rep., 49(09):178-179 (Mar. 10, 2000).
"Update: West Nile Virus Activity—Northeastern United States, 2000," Morb. Mortal. Wkly. Rep., 49(36):820-822 (Sep. 15, 2000).
Aberle et al., "A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms," J Immunology 163:6756-6761 (1999).
Allison et al., "Synthesis and Secretion of Recombinant Tick-Borne Encephalitis Virus Protein E in Soluble and Particulate Form," J Virology 69(9):5816-5820 (Sep. 1995).
Alvarez et al., "A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients," Hum. Gene Ther. 8:229-242 (Jan. 20, 1997).
Anderson et al., "Isolation of West Nile Virus from Mosquitoes, Crows, and a Cooper's Hawk in Connecticut," Science 286(5448):2331-2333 (Dec. 17, 1999).
Arroyo, J., et al., "Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (chimerivax-je)," Journal of Virology, The American Society for Microbiology, US, vol. 75, No. 2, Jan. 2001, pp. 934-942, XP002967301.
Asnis et al., "The West Nile Virus Outbreak of 1999 in New York: The Flushing Hospital Experience," Clin. Infect. Dis. 30: 413-418 (2000).
Azevedo et al., "Main features of DNA-based immunization vectors," Braz. J. Med. Biol. Res. 32(2):147-153 (1999).
Bray et al., "Mice Immunized with Recombinant Vaccinia Virus Expressing Dengue 4 Virus Structural Proteins with or without Nonstructural Protein NSI are Protected Against Fatal Dengue Virus Encephalitis," J. Virol. 63(6):2853-2856 (Jun. 1989).
Cavener and Ray, "Eukaryotic start and stop translation sites," Nucleic Acids Research, 19(12):3185-3192 (1991).
Chang et al., "A Single Intramuscular Injection of Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice," J. Virol. 74(9):4244-4252 (May 2000).
Chang et al., "Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus," Virology, 306:170-180 (2003).
Chang et al., "Flavivirus DNA Vaccines," Annals New York Academy of Sciences, 951:272-285 (2001).
Chang et al., "Recent advancement in flavivirus vaccine development," Expert Rev. Vaccines, 3(2):199-220 (2004).
Chang, G.-J. J, et al., 2003, Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus, Virol. 306:170-180. *
Chen et al., "Construction of Intertypic Chimeric Dengue Viruses Exhibiting Type 3 Antigenicity and Neurovirulence for Mice," J Virology, 69(8):5186-5190 (Aug. 1995).
Clarke et al., "Techniques for Hemagglutination and Hemagglutination-Inhibition With Arthropod-Borne Viruses," Amer. J. Trop. Med. and Hyg., 7:561-573 (1958).
Colombage et al., "DNA-Based and Alphavirus-Vectored Immunisation with PrM and E Proteins Elicits Long-Lived and Protective Immunity against the Flavivirus, Murray Valley Encephalitis Virus," Virology 250:151-163 (1998).
Davis et al., "West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses in Vitro a Noninfectious Recombinant Antigen That Can be Used in Enzyme-Linked Immunosorbent Assays," J. Virol. 75(9):4040-4047, 2001 (published on-line Apr. 4, 2001).
Deubel et al., "Nucleotide Sequence and Deduced Amino Acid Sequence of the Nonstructural Proteins of Dengue Type 2 Virus, Jamaica Genotype: Comparative Analysis of the Full-Length Genome," Virology 165:234-244 (1988).
Deubel et al., "Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Type 2 Virus, Jamaica Genotype," Virology 155:365-377 (1986).
Dmitriev et al., "Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis," J. Biotechnol. 44:97-103 (1996).
Duarte dos Santos et al., "Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213," Virus Res. 35:35-41 (1995).
Falgout et al., "Immunization of Mice with Recombinant Vaccinia Virus Expressing Authentic Dengue Virus Nonstructural Protein NSI Protects Against Lethal Dengue Virus Encephalitis," J. Virol. 64(9):4356-4363 (1990).
Falgout et al., "Proper Processing of Dengue Virus Nonstructural Glycoprotein NSI Requires the N-Terminal Hydrophobic Signal Sequence and the Downstream Nonstructural Protein NS2a," J. Virol. 63(5):1852-1860 (May 1989).
Fonseca et al., "Recombinant vaccinia viruses co-expressing dengue-1 glycoprotein prM and E induce neutralizing antibodies in mice," Vaccine 12(3):279-285 (1994).
Garmendia et al., "Recovery and Identification of West Nile Virus from a Hawk in Winter," J. Clin. Microbiol. 38(8):3110-3111 (Aug. 2000).
Gruenberg et al., "Partial Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Virus Type 2, New Guinea C and PUO-218 Strains," J. Gen. Virol., 69:1391-1398 (1988).
Guirakhoo et al., "Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus is Immunogenic and Protective in Nonhuman Primates," J. Virol., 74(12):5477-5485 (2000).
Hahn et al., "Nucleotide Sequence of Dengue 2 RNA and Comparison of the Encoded Proteins with Those of Other Flaviviruses," Virology 162:167-180 (1988).
Hashimoto et al., "Molecular Cloning and Complete Nucleotide Sequence of the Genome of Japanese Encephalitis Virus Beijing-1 Strain," Virus Genes 1(3):305-317 (1988).
Heinz et al., "Flaviviruses." In Immunochemistry of Viruses II: The Basis for Serodiagnosis and Vaccines. (edited by von Regenrnortel and Neurath) Elsevier Science Publishers, Chapter 14, pp. 89-305 (1990).
Henchal et al., "Dengue Virus-Specific and Flavivirus Group Determinants Identified With Monoclonal Antibodies by Indirect Immunofluorescence," Amer. J. Trop. Med. Hyg. 31:830-836 (1982).
Hennessy et al., "Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study," Lancet 347:1583-1586 (Jun. 8, 1996).
Ho et al., "DNA vaccination induces a long-term antibody response and protective immunity against pseudorabies virus in mice," Arch Virol, 143:115-125 (1998).
Hubàlek et al., "West Nile Fever-a Reemerging Mosquito-Borne Viral Disease in Europe," Emerg. Infect. Dis., 5(5):643-650 (1999).
Hunt and Calisher, "Relationships of Bunyamwera Group Viruses by Neutralization," Amer. J. Trop. Med. Hyg., 28(4):740-749 (1979).
Hunt et al., "A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen," J. Virological Methods, 97:133-149 (2001).
Jacobs et al., "High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model," J. Virol., 66(4):2086-2095 (Apr. 1992).
Jacobs, "A novel recombinant adenovirus vector expressing a flavivirus non-structural protein protects against lethal flavivirus challenge," Clinical Science, 85:117-122 (1993).
Jia et al., "Genetic analysis of West Nile New York 1999 encephalitis virus," Lancet, 354:1971-1972 (Dec. 4, 1999).
Johnson et al., "Detection of Anti-Arboviral Immunoglobulin G by Using a Monoclonal Antibody-Based Capture Enzyme-Linked Immunosorbent Assay," J. Clin. Microbiol., 38(5):1827-1831 (May 2000).
Kimura-Kuroda and Yasui, "Antigenic Comparison of Envelope Protein E between Japanese Encephalitis Virus and Some Other Flaviviruses Using Monoclonal Antibodies," J. Gen. Virol., 67:2663-2672 (1986).
Kimura-Kuroda and Yasui, "Topographical Analysis of Antigenic Determinants on Envelope Glycoprotein V3 (E) of Japanese Encephalitis Virus, Using Monoclonal Antibodies," J. Virol., 45(1):124-132 (Jan. 1983).
Kitchener et al., "Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in health Australian adults," Vaccine, 24:1238-1241 (2006).
Klinman et al., "CpG motifs as immune adjuvants," Vaccine, 17 :19-25 (1999).
Kochel et al., "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," Vaccine, 15(5):547-552 (1997).
Köhler et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, 256:495-497 (Aug. 7, 1975).
Konishi et al., "A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice," Vaccine 18:1133-1139 (2000).
Konishi et al., "Avipox virus-vectored Japanese encephalitis virus vaccines: use a vaccine candidates in combination with purified subunit immunogens," Vaccine, 12(7):633-638 (1994).
Konishi et al., "Comparison of Protective Immunity Elicited by Recombinant Vaccinia Viruses That Synthesize E or NS1 of Japanese Encephalitis Virus," Virology, 185:401-410 (1991).
Konishi et al., "Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles," J. Virol. 75(5):2204-2212 (Mar. 2001).
Konishi et al., "Induction of Protective Immunity against Japanese Encephalitis in Mice by Immunization with a Plasmid Encoding Japanese Encephalitis Virus Premembrane and Envelope Genes," J Virology, 72(6):4925-4930 (Jun. 1998).
Konishi et al., "Japanese Encephalitis DNA Vaccine Candidates Expressing Premembrane and Envelope Genes Induce Virus-Specific Memory B Cells and Long-Lasting Antibodies in Swine," Virology, vol. 268:49-55, 2000.
Konishi et al., "Mice Immunized with a Subviral Particle Containing the Japanese Encephalitis Virus prM/M and E Proteins Are Protected from Lethal JEV Infection," Virology, 188:714-720 (1992).
Konishi et al., "The Anamnestic Neutralizing Antibody Response is Critical for Protection of Mice from Challenge following Vaccination with a Plasmid Encoding the Japanese Encephalitis Virus Premembrane and Envelope Genes," J. Virology 73(7):5527-5534 (Jul. 1999).
Kozak, "An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs," Nucleic Acids Research, 15(20):8125-8148 (1987).
Kozak, "An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs," Nucleic Acids Research, 15(20):8125-8148 (1987).
Kozak, "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," J. Mol. Biol., 196:947-950 (1987).
Kozak, "Circumstances and Mechanisms of Inhibition of Translation by Secondary Structure in Eucaryotic mRNAs," Mol. Cell. Biol., 9(11):5134-5142 (Nov. 1989).
Kozak, "Point Mutations Define a Sequence Flanking the AUG Initiator Codon That Modulates Translation by Eukaryotic Ribosomes," Cell, 44:283-292 (Jan. 31, 1986).
Kuno et al., "Phylogeny of the Genus Flavivirus," J. Virol., 72(1):73-83 (Jan. 1998).
Laemmli, "Cleavage of Structural Proteins during the Assembly of the Head of Bateriophage T4," Nature, 277:680-685 (Aug. 15, 1970).
Lai et al., "Immunization of Monkeys with Baculovirus Recombinant-expressed Dengue Envelope and NSI Glycoproteins Induces Partial Resistance to Challenge with Homotypic Dengue Virus," In Vaccines 90: Modern Approaches to New Vaccines including Prevention of AIDS, Cold Spring Harbor Laboratory, Cold Springs Harbor, NY, pp. 119-124 (1990).
Lanciotti et al., Origin of the West Nile Virus Responsible for an Outbreak of Encephalitis in the Northeastern United States, Science, 286:2333-2337 (Dec. 17, 1999).
Lin et al., "DNA Immunization with Japanese Encephalitis Virus Nonstructural Protein NS1 Elicits Protective Immunity in Mice," J. Virol., 72(1):191-200 (Jan. 1998).
Mackow et al., "The Nucleotide Sequence of Dengue Type 4 Virus: Analysis of Genes Coding for Nonstructural Proteins," Virology, 159:217-228 (1987).
Mandl et al., "Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic Elements in Tick-Borne Versus Mosquito-Borne Flaviviruses," Virology, 194:173-184 (1993).
Martin et al., "Standardization of Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assays for Routine Diagnosis of Arboviral Infections," J. Clin. Microbiol., 38(5):1823-1826 (May 2000 ).
Mason et al., "Japanese Encephalitis Virus-Vaccinia Recombinants Produce Particulate Forms of the Structural Membrane Proteins and Induce High Levels of Protection against Lethal JEV Infection," Virology, 180:294-305 (1991).
Mason et al., "Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NS1," Virology, 161:262-267 (1987).
Mir et al., "High-efficiency gene transfer into skeletal muscle mediated by electric pulses," Proc. Nat. Acad. Sci. USA, 96:4262-4267 (Apr. 1999).
Monath, "Dengue and Yellow Fever-Challenges for the Development and Use of Vaccines," N. Engl. J. Med., 357(22):2222-2225 (Nov. 2007).
Monath, "Flaviviruses," Virology (R.N. Fields, ed.), 763-814 (1990).
Nitayaphan et al., "Nucleotide Sequence of the Virulent SA-14 Strain of Japanese Encephalitis Virus and Its Attenuated Vaccine Derivative, SA-14-14-2," Virology, 177:541-552 (1990).
Osatomi and Sumiyoshi, "Complete Nucleotide Sequence of Dengue Type 3 Virus Genome RNA," Virology, 176:643-647 (1990).
Osatomi et al., "Nucleotide Sequence of Dengue Type 3 Virus Genomic RNA Encoding Viral Structural Proteins," Virus Genes, 2(1):99-108 (1988).
Phillpotts et al., "Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus," Arch. Virol. 141:743-749 (1996).
Phillpotts, R. J., et al., 1996, Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus, Arch. Virol. 141:743-749. *
Pincus et al., "Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis," Virology, 187:290-297 (1992).
Pletnev A.G. et al., "Construction and Characterization of Chimeric Tick-Borne Encephalitis/Dengue Type 4 Viruses," Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, U.S. vol. 89, No. 21, Nov. 1, 1992, pp. 10532-10536.
Pletnev, A. G., et al., 1992, Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses, Proc. Natl. Acad. Sci. USA 89:10532-10536. *
Porter et al., "Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG Immune-stimulatory motifs on antibody responses," Arch. Virol. 143:997-1003 (1998).
Purdy et al., "Secretion of Noninfectious Dengue Virus-Like Particles and Identification of Amino Acids in the Stem Region Involved in Intracellular Retention of Envelope Protein," Virology, vol. 333:239-250, 2005.
Ramelow et al., "Detection of tick-borne encephalitis virus RNA in ticks (Ixodes ricinus) by the polymerase chain reaction," J. Virol. Meth., 45:115-9 (1993).
Raviprakash et al., "Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein," Vaccine 18:2426-2434 (2000).
Rice et al., "Nucleotide Sequence of Yellow Fever Virus: Implications for Flavivirus Gene Expression and Evolution," Science, 229:726-733 (Aug. 23, 1985).
Roehrig et al., "Identification of Epitopes on the E Glycoprotein of Saint Louis Encephalitis Virus Using Monoclonal Antibodies," Virology, 128:118-126 (1983).
Roehrig et al., "Synthetic Peptides Derived from the Deduced Amino Acid Sequence of the E-Glycoprotein of Murray Valley Encephalitis Virus Elicit Antiviral Antibody," Virology, 171:49-60 (1989).
Rothman, "Dengue: defining protective versus pathologic immunity," J. Clin. Invest., 113(7):946-951 (Apr. 2004).
Sato et al., "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization," Science, 273(5273):352-354 (Jul. 19, 1996).
Schalich et al., "Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions," J. Virol., 70:4549-4557 (Jul. 1996).
Schimaljohn et al., "Naked DNA Vaccines Expressing the prM and E Genes of Russian Spring Summer Encephalitis Virus and Central European Encephalitis Virus Protect Mice from Homologous and Heterologous Challenge," J. Virology 71(12):9563-9569 (Dec. 1997).
Seeger et al., "The cloned genome of ground squirrel hepatitis virus is infectious in the animal," Proc Natl Aca Sci U.S.A., 81(18):5849-4852 (Sep. 1984).
Sela, The Choice of Carrier. Synthetic Vaccines vol. I (edited by Amon) CRC Press Inc, Boca Raton, FL., pp. 83-92 (1987).
Simmons et al., "Short Report: Antibody Responses of Mice Immunized with a Tetravalent Dengue Recombinant Protein Subunit Vaccine," Am. J. Trop. Med. Hyg. 65(2):159-161 (2001).
Smithburn et al., "A Neurotropic Virus Isolated From the Blood of a Native of Uganda," Am. J. Trop. Med. Hyg., 20:471-492 (1940).
Stephenson, "Understanding dengue pathogenesis: implications for vaccine design," Bull. World Health Org., 83:308-314 (Abstract only).
Stocks and Lobigs, "Posttranslational signal peptidase cleavage at the flavivirus C-prM junction in vitro," J. Virol., 69(12):8123-8126 (1995).
Stocks, C. E., and M. Lobigs, 1998, Signal peptidase cleavage at the flavivirus C-prM junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prM, J. Virol. 72(3):2141-2149. *
Sumiyoshi et al., "Complete Nucleotide Sequence of the Japanese Encephalitis Virus Genome RNA," Virology, 161:497-510 (1987).
Tardei et al., "Evaluation of Immunoglobulin M (IgM) and IgG Enzyme Immunoassays in Serologic Diagnosis of West Nile Virus Infection," J. Clin. Microbiol. 38(6):2232-2239 (Jun. 2000).
Trent et al., "Partial Nucleotide Sequence of St. Louis Encephalitis Virus RNA: Structural Proteins. NS1 ns2a and ns2b," Virology, 156:293-304 (1987).
Tsai et al., Japanese Encephalitis Vaccines. In Vaccines (2nd edition) (edited by Plotkin and Mortimer), W.B. Saunders Co., Philadelphia, PA, Chapter 24, pp. 671-713 (1994).
Tsai et al., Japanese Encephalitis Vaccines. In Vaccines (3rd edition) (edited by Plotkin and Orenstein), W.B. Saunders Co., Philadelphia, PA, Chapter 27, pp. 672-710 (1999).
Venugopal et al., "Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins," Vaccines, 13(11):1000-1005 (1995).
Wang et al., "Immune Response to Neonatal Genetic Immunization," Virology, 228:278-284 (1997).
Wang et al., "Immunization of Mice Against West Nile Virus with Recombinant Envelope Protein," J. Immunol. 167:5273-5277 (2001).
Wolff et al., "Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle," Hum Mol Genet, 1(6):363-369 (Sep. 1992).
Yang et al., "A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A," Nature, 382:319-324 (Jul. 25, 1996).
Yasui et al., "Analysis of Japanese encephalitis (JE) virus genome and implications for recombinant JE vaccine," Southeast Asian J. Trop. Med. Public Health, 21(4):663-669 (1990).
Yasui, K., et al., 1990, Analysis of Japanese encephalitis (JE) virus genome and implications for recombinant JE vaccine, SE Asian J. Trop. Med. Pub. Health 21(4):663-669. *
Zhang et al., "Immunization of Mice with Dengue Structural Proteins and Nonstructural Protein NSI Expressed by Baculovirus Recombinant Induces Resistance to Dengue Virus Encephalitis," J. Virol., 62(8):3027-3031 (Aug. 1988).
Zhang et al., "Passive Protection of Mice, Goats, and Monkeys Against Japanese Encephalitis With Monoclonal Antibodies," J. Med. Virol., 29:133-138 (1989).
Zhao et al., "Cloning Full-Length Dengue Type 4 Viral DNA Sequences: Analysis of Genes Coding for Structural Proteins," Virology, 155:77-88 (1986).
Zhao et al., "Expression of Dengue Virus Structural Proteins and Nonstructural Protein NS1 by a Recombinant Vaccinia Virus," J. Virol., 61(12):4019-4022 (Dec. 1987).
Zou & Brown, "Translation of the reovirus M1 gene initiates from the first AUG codon in both infected and transfected cells," Virus Research 40:75-89, 1996.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947277B2 (en) 2016-06-13 2021-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
US11578103B2 (en) 2016-06-13 2023-02-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding Zika virus-like particles and their use in Zika virus vaccines and diagnostic assays
US10898566B2 (en) 2016-09-19 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zika virus vaccines

Also Published As

Publication number Publication date
NZ529106A (en) 2005-03-24
CA2443323C (en) 2013-01-15
EP2332572B1 (en) 2014-01-08
MXPA03008838A (en) 2004-10-15
US7662394B2 (en) 2010-02-16
US20070166701A1 (en) 2007-07-19
CA2443323A1 (en) 2002-10-17
US20100040643A1 (en) 2010-02-18
CN1304575C (en) 2007-03-14
EP1935991A2 (en) 2008-06-25
EP1383931A1 (en) 2004-01-28
EP1383931A4 (en) 2004-12-22
KR20030092051A (en) 2003-12-03
BRPI0208301A8 (en) 2018-11-27
US20100003273A1 (en) 2010-01-07
US7521177B2 (en) 2009-04-21
EP1935991A3 (en) 2008-09-10
CN1500152A (en) 2004-05-26
US20070166329A1 (en) 2007-07-19
WO2002081754A1 (en) 2002-10-17
HK1062836A1 (en) 2004-11-26
ZA200307580B (en) 2005-03-30
US8232379B2 (en) 2012-07-31
US7227011B2 (en) 2007-06-05
BRPI0208301B1 (en) 2019-12-24
JP2010017185A (en) 2010-01-28
BRPI0208301B8 (en) 2021-05-25
CN101002936A (en) 2007-07-25
EP2332572A1 (en) 2011-06-15
EP1935991B1 (en) 2012-11-07
JP2004532023A (en) 2004-10-21
US20030022849A1 (en) 2003-01-30
US7632510B2 (en) 2009-12-15
JP4448281B2 (en) 2010-04-07
BR0208301A (en) 2004-03-09
KR100913984B1 (en) 2009-08-25
US20050163804A1 (en) 2005-07-28
JP5236597B2 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
US8221768B2 (en) Chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence
US20120093862A1 (en) Nucleic acid vaccines for prevention of flavivirus infection
Davis et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays
DE3886363T3 (en) NANBV diagnostics
Chang et al. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus
JPH06511149A (en) Immunoreactive hepatitis C virus polypeptide compositions
Melnick Poliovirus and other enteroviruses
AU2010202127B2 (en) Nucleic acid vaccines for prevention of flavivirus infection
AU2002307147B2 (en) Nucleic acid vaccines for prevention of flavivirus infection
AU2002307147A1 (en) Nucleic acid vaccines for prevention of flavivirus infection

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHANG, GWONG-JEN J.;REEL/FRAME:023385/0664

Effective date: 20040309

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY